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1. Childhood malignancies 
1.1. Introduction 
During the past decades, remarkable advances have been achieved in the treatment and 
survival of children with cancer. Despite these important advances, cancer remains the 
second leading cause of death in children, after mortality related to accidents.  
The types, distribution, prognosis and responsiveness to therapy of the malignancies 
occurring in the pediatric age group differ markedly from those that occur in adult populations. 
Primary epithelial tumors, originating from cells covering internal and external body surfaces, 
predominate in adults (e.g. cancer of the colon, lung and breast). By contrast, childhood 
tumors are usually of mesenchymal origin or derive from the hematopoietic or central nervous 
systems.  
Acute leukemia is the most common cancer in children younger than 15 years of age, followed 
by tumors of the central nervous system (CNS), lymphoma and neuroblastoma (Figure 1). 
 
 
 
Figure 1: Distribution of cancer in children younger that 15 years of age in Belgium 
(Based on data from the National Cancer Registry, 1998) 
 
 
0 20 40 60
Number of patients
Neuroblastoma
Lymphoma
CNS tumors
Acute
leukemia
 
Introduction 
4 
1.2. Acute Lymphoblastic Leukemia 
1.2.1. Clinical features 
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. It accounts 
for one fourth of all childhood cancers and approximately 75% of all childhood leukemias.1 The 
clinical incidence of ALL in the United States is estimated at 3 to 4 per 100.000 Caucasian 
children younger than 15 years of age.2-4 ALL is more common among whites than blacks, but 
a racial predilection has not been demonstrated.5 Boys have higher incidence rates than girls 
with a male-to-female ratio of 1.3.4 Childhood ALL has a peak incidence between 2 and 6 
years in white children.2,3 
 
Various constitutional chromosomal abnormalities are associated with childhood leukemia. 
Children with Down’s syndrome have a 15-fold greater risk of developing leukemia than 
normal children.2,6 In addition, patients with fragile chromosomes, as in Bloom’s syndrome, 
Fanconi’s anemia and ataxia telangiectasia, are at high risk to develop ALL.2,7,8 The frequency 
of leukemia is higher than expected in families of leukemia patients and the concordance of 
acute leukemia in monozygotic twins under the age of 7 is estimated at 25%.9,10 Both in utero 
exposure to diagnostic X-rays and postnatal exposure to therapeutic doses of ionizing 
radiation can mediate the development of ALL.11-13 However, the actual percentage of 
leukemias directly attributable to radiation is probably small. So far, no association between 
chronic exposure to electromagnetic fields or chemicals and ALL has been found.2 Some 
reports have suggested that prenatal or postnatal exposure to viruses is associated with a 
higher risk of ALL.14-17 However, no definitive link between viral infections and the occurrence 
of ALL has been established. Congenital immunodeficiency diseases and abnormalities of the 
immune system are occasionally observed in pediatric ALL patients.  
 
The molecular basis for leukemic transformation in humans is unknown. It has been 
suggested that acute leukemia develops as a result of spontaneous mutations in a single 
hematopoietic progenitor cell leading to dysregulated growth and arrested differentiation.18 
Proposed molecular mechanisms for leukemic induction include activation of oncogenes or 
creation of fusion genes with oncogenic properties and/or loss or inactivation of tumor 
suppressor genes. 
 
A complete morphologic, immunologic and genetic examination of bone marrow aspirates is 
necessary to establish the diagnosis of ALL. Most centers require 20% to 30% leukemic cells 
in the bone marrow before the diagnosis is confirmed.2,3  
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Initial blood counts show a broad spectrum of abnormal findings. Approximately 20% of 
children present with leukocyte counts greater than 50.103/µl. Neutropenia (< 500 
granulocytes/µl) and thrombocytopenia (< 100.103 platelets/µl) are common phenomena and 
approximately 80% of the patients present with anemia (hemoglobin < 10g/dl). A variety of 
other abnormal laboratory findings may be encountered. Increased serum uric acid levels 
reflect increased anabolism and catabolism of purines, hypercalcemia may result from 
leukemic infiltration in the bone, and elevated serum lactate dehydrogenase (LDH) and 
phosphorus levels are associated with tumor cell lysis. Approximately 5% to 10% of de novo 
ALL patients present with an anterior mediastinal mass which can be detected on chest 
radiographs. Bone radiography may disclose bone involvement. Cerebrospinal fluid should be 
examined because it contains leukemic blasts in 3% to 5% of leukemic patients.  
 
1.2.2. Classification 
Formerly, ALL was classified into three categories (L1, L2 and L3) according to the system 
proposed by the French-American-British (FAB) cooperative group.19 This FAB system was 
based solely on morphological and cytochemical findings. The discovery of new genetic 
aberrations, predicting clinical behavior and outcome, necessitated the development of a new 
classification scheme. The World Health Organization (WHO) defined a new system based on 
genetic, cytochemical and morphological information.20 ALLs are divided into two major 
categories: precursor B-cell lymphoblastic leukemia (B-ALL) and precursor T-cell 
lymphoblastic leukemia (T-ALL).  
1.2.2.1. Morphology 
Precursor B-ALL lymphoblasts in bone marrow smears or imprints vary from small cells with 
scant cytoplasm, condensed nuclear chromatin and indistinct nucleoli to larger cells with 
moderate amounts of cytoplasm, dispersed nuclear chromatin and multiple, variably prominent 
nucleoli.20 In 10% of the cases, azurophilic granules are present.  
T-ALL cells are cytomorphologically quite similar to precursor B lymphoblasts. In smears, 
precursor T-ALL cells are of medium size with high nuclear/cytoplasmic ratio. There may be a 
considerable difference in size, ranging from small lymphoblasts with very condensed nuclear 
chromatin and indistinct nucleoli to larger blasts with finely dispersed chromatin and relatively 
prominent nucleoli.20  
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1.2.2.2. Cytochemistry 
Lymphoblasts are negative for myeloperoxidase and Sudan Black-B, but may react with 
periodic acid Schiff (PAS) or non-specific esterase.20 T-ALL cells often show focal acid 
phosphatase activity in bone marrow smears or imprints. 
1.2.2.3. Immunophenotype 
Precursor B-ALL cells express terminal deoxynucleotidyl transferase (TdT) and HLA-DR 
antigens.20 They are almost always positive for CD19, cytoplasmic (c) CD79a, CD10 and 
CD22. CD20 is expressed in a minority of cases and CD45 may be absent. The myeloid 
associated antigens CD13 and CD33 are frequently expressed as aberrant markers. Based on 
their immunophenotype, precursor B-ALL blasts are divided into three subgroups: early 
precursor B-ALL, common B-ALL and pre-B-ALL (Figure 2). Early precursor B-ALL blasts 
express CD34, CD19, cCD79a, CD22 and nuclear TdT. The more mature common B-ALL 
cells are CD10 positive and the most differentiated pre-B-ALL cells express cytoplasmic µ 
chains. Surface immunoglobulin is characteristically absent.  
Precursor T-ALL cells are TdT positive and variably express CD1a, CD2, CD3, CD4, CD5, 
CD7 and CD8.20 Of these, CD7 and cCD3 are most frequently positive. CD4 and CD8 are 
often co-expressed on the blasts and CD10 may be positive. In addition to CD117, myeloid 
markers CD13 and/or CD33 are occasionally present. T lymphoblasts may present clonal 
rearrangements of the T-cell receptor genes. Immunoglobulin gene rearrangements are also 
observed in T-ALL cells. Precursor T-ALL is classified into three subtypes which represent 
different stages of intrathymic differentiation (Figure 2): immature T-ALL, common T-ALL and 
mature T-ALL. 
1.2.2.4. Genetics 
At the moment, genetic abnormalities can be identified in approximately 65% to 70% of 
pediatric ALL patients.20,21 They are prognostically important and are used to modify treatment. 
Patients with hyperdiploid chromosome numbers (between 51 and 65 chromosomes or DNA-
index between 1.16 and 1.6) have a good prognosis.22-25 In addition, t(12;21)(p13;q22) is also 
associated with favorable outcome.26-28 This rearrangement results in the fusion of the TEL 
gene (12p13), a member of the ETS-like family of transcription factors, and the transcription 
factor-encoding AML1 gene (21q22). The t(12;21) is detected in about 20% to 30% of children 
with precursor B-ALL.29,30  
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Other cytogenetic findings, including t(9;22)31-34, t(4;11)35-39, t(1;19)40-42, and hypodiploidy43,44, 
are associated with poor prognosis. The t(9;22) transposes the 3’ portion of the cytoplasmic 
tyrosine kinase gene ABL (9q34) to the 5’ region of BCR (22q11.2), generating a chimeric 
tyrosine kinase oncogene.45 The translocation is present in 3% to 5% of pediatric ALL patients.  
 
Cytogenetic abnormalities involving the MLL gene on 11q23 are frequently observed in 
childhood ALL. The most common is t(4;11)(q21;q23). This translocation is usually found in 
early precursor B-ALL patients. Translocation t(1;19), found in 25% of children with pre-B-ALL, 
results in the fusion of the transcription activator-encoding gene E2A (19p13.3) with the 
homeobox gene PBX1 (1q23).46,47  
Genetic abnormalities including del(6q)48,49, del(9p)50, del(12p)51,52, and hyperdiploidy (less 
than 51 chromosomes)53-55 are associated with an intermediate prognosis. 
 
 
Figure 2: Immunophenotype of acute lymphoblastic leukemia 
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In contrast to precursor B-ALL, the recurrent chromosomal alterations observed in precursor 
T-ALL have not been helpful in providing significant prognostic information.56,57 In about one 
third of the T-ALL patients translocations involving the α and δ T-cell receptor loci at 14q11.2, 
the β locus at 7q35 or the γ locus at 7p14-15 have been detected.58,59 Partner genes include 
the transcription factors MYC (8q24.1), TAL1 (1p32), RBTN1 (11p15), RBTN2 (11p13), and 
HOX11 (10q24) and the cytoplasmic tyrosine kinase LCK (1p34.3-35).60,61 In 5% of the T-ALL 
patients, the TAL1 gene is dysregulated by a deletion in its 5’ regulatory region.62 The deletion 
del(9p), resulting in loss of the tumor suppressor gene CDKN2A (INK4A/p16), is frequently 
observed in T-ALL patients.63  
 
1.2.3. Prognostic factors and therapy 
The ability to identify subsets of patients who have a better or worse prognosis than average 
has contributed to the success of modern ALL treatment programs. Various clinically 
significant features, including initial leukocyte count, age at diagnosis, sex, cytogenetic 
aberrations, immunophenotype, and response to therapy, have been identified.1,2,64 (Table 1) 
It is important to realize that the impact of prognostic factors depends on the efficacy of the 
therapy. Some parameters have lost their clinical relevance (e.g. race) due to the major 
improvements in the treatment of ALL patients. 
 
Children are divided into different risk groups based on these prognostic parameters. Low risk 
patients are treated with less intensive and toxic chemotherapy, whereas high risk patients 
receive a more aggressive treatment. So far, no single classification system is universally 
accepted but the initial leukocyte count and age at diagnosis form the basis for most methods 
of prognostic stratification.  
 
Although specific approaches to therapy might differ from center to center, all modern 
treatment regimens comprise four major elements: remission induction, 
intensification/consolidation, CNS-directed therapy and continuation of therapy.1,2,65-67 
Induction therapy typically includes administration of a glucocorticoid (dexamethasone or 
prednisone), vincristine, and L-asparaginase. The leukemic blasts of ALL patients are usually 
sensitive to chemotherapy at the time of diagnosis. Consequently, complete remission 
(defined as the absence of clinical signs and symptoms, the recovery of normal blood cell 
counts, and the recovery of normocellular bone marrow with less than 5% blast cells) will be 
achieved in 97% to 98% of children.  
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Table 1 
Factors associated with prognosis for children with ALL 
 
 
 
 
 
Favorable Prognosis 
 
 
Unfavorable Prognosis 
 
 
Initial Leukocyte Count 68-71 
 
 
≤ 50.103/µl 
 
 
> 50.103/µl 
 
 
Age at Diagnosis 69,72,73 
 
 
 
2-10 years 
 
 
 
< 2 years (especially 
infants) 
> 10 years 
 
 
Sex 74-77 
 
Female 
 
 
Male 
 
Cytogenetic Aberrations 
 
9 Ploidy 22-25,43,44,53-55  
 
 
 
9 Chromosomal rearrangements 
26-28,31-42  
 
 
 
Hyperploidy 
 
 
 
t(12;21) 
 
 
 
Hypoploidy 
Pseudodiploidy 
Tetraploidy 
 
t(9;22), t(4;11), t(1;19) 
 
Immunophenotype78-82 
 
 
 
Early Precursor B-ALL 
CD10+ 
 
T-ALL (especially CD3+) 
Pre-B-ALL 
 
 
Response to Treatment/MRD83-90 
 
Early response 
(< 1000 blast in peripheral 
blood after one week of 
prednisolone treatment. 
Cytomorphologic 
remission at day 35) 
 
Late response 
 
 
 
The intensification or consolidation therapy aims at the destruction of residual lymphoblasts to 
a level comparable with cure. During this consolidation period, patients receive either 
increased doses of agents used previously or entirely new agents with minimal cross-
resistance. The importance of preventive CNS therapy was first demonstrated by investigators 
at St. Jude Children’s Research Hospital.91 CNS-directed therapy is essential because 
leukemia in the CNS reduces the chance of cure and increases morbidity related to the need 
for intensive remission-retrieval therapy. Most children with ALL are treated with methotrexate 
or triple-agent chemotherapy (methotrexate, corticoids, and cytarabine). ALL patients require 
prolonged continuation treatment. The most common continuation therapy relies on the daily 
administration of 6-mercaptopurine and weekly administration of methotrexate. The general 
rule in modern protocols is to discontinue all therapy in patients in whom continuous complete 
remission has been achieved for 2 years.  
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Long-term event-free survival rates for newly diagnosed children with ALL have improved 
markedly during the past 30 years. However, 20% to 30% of the pediatric ALL patients relapse 
and cannot be cured with modern therapy.92-99 Intrinsic or acquired resistance to a wide variety 
of structurally and functionally unrelated chemotherapeutic compounds is one of the most 
important causes of treatment failure in childhood ALL. A variety of cellular mechanisms can 
give rise to multidrug resistance (MDR), but best studied is the transmembrane protein-
mediated efflux of cytotoxic compounds which leads to a decreased cellular drug accumulation 
and toxicity. The clinical significance of multidrug resistance-related proteins in childhood ALL 
and the laboratory techniques used to study these efflux pumps are discussed in more detail 
in Chapter 2. 
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1.3. Neuroblastoma 
1.3.1. Clinical features 
Neuroblastoma is the most common extracranial solid tumor in children and accounts for 8% 
to 10% of all childhood malignancies.100 The clinical incidence of neuroblastoma in the 
Western world is estimated at 1 per 100.000 children younger than 15 years of age.101,102 The 
median age at diagnosis is 22 months and 97% of all neuroblastoma patients are less than 10 
years old. The tumor is slightly more common in boys than in girls with a male-to-female ratio 
of 1.3/1.103 
 
The etiology of neuroblastoma is unknown. So far, no clear association between the incidence 
of neuroblastoma and prenatal or postnatal exposure to drugs, chemicals, electromagnetic 
fields or radiation has been found.104-106 A few families with more than one affected sibling 
have been reported, but a genetic basis has not yet been demonstrated.107,108 
 
Neuroblastomas are neuroectodermal tumors which arise from primitive, pluripotent, 
sympathetic cells or sympathogonia. These embryonic cells originate from the neural crest 
and form, after migration and differentiation, the different normal tissues of the sympathetic 
nervous system (Figure 3).109 As a consequence, most neuroblastomas occur within the 
adrenal gland (35%) or along the sympathetic nervous system chain ganglia (abdomen (30%), 
thorax (20%)).100 The location of the primary tumor has some impact on outcome. Children 
with a primary tumor in the thorax or pelvis have a better prognosis than those with adrenal 
tumors.110  
 
The diagnosis of neuroblastoma is established by pathologic examination of tumor tissue by 
light microscopy.111 Alternatively, the diagnosis is made based on the detection of 
neuroblastoma cells in bone marrow aspirates or trephine biopsies in combination with the 
demonstration of increased urinary catecholamine metabolites (e.g. homovanillic acid (HVA) 
and vanillylmandelic acid (VMA)). Plain radiography, bone scintigraphy, ultrasound, computed 
tomography (CT-scan), magnetic resonance imaging (MRI-scan) and meta-
iodobenzylguanidine (MIBG) scintigraphy are used to determine the extend of the disease. 
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Figure 3: Distribution of the sympathetic nervous system. The sympathetic ganglia extend 
from the neck to the pelvis, including the adrenal medulla. Sympathetic tissue is represented 
in grey. (Reproduced from ref.112) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The evaluation of bone marrow smears is not only important for clinical staging and risk 
assessment at diagnosis, it can also be used to monitor therapeutic response during 
treatment. Conventional cytology of bone marrow smears is still the only accepted technique 
for the detection of disseminated neuroblastoma cells. However, the sensitivity of this method 
is limited since a tumor cell number below 0.1 % cannot be detected by conventional 
cytomorphology.113,114 Therefore, more sensitive and specific detection techniques are urgently 
needed. New laboratory methods used to screen for residual neuroblastoma cells, will be 
discussed in Chapter 3. 
 
1.3.2. Classification 
In the past, three major staging systems were used to classify neuroblastoma patients in 
different risk groups: (1) system proposed by Evans (Children’s Cancer Study Group);115 (2) 
system used by the Pediatric Oncology Group;116 and (3) system utilized by the American 
Joint Committee on Cancer.117 The differences between these staging systems were 
substantial and made the comparison of results from clinical trials and biological studies 
impossible. Therefore, a new staging system, based on the Evans classification, was 
formulated by Brodeur and colleagues.111,118 This International Neuroblastoma Staging System 
(INSS) is generally accepted and classifies patients based on clinical, radiographic and 
surgical evaluation (Table 2).  
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The most important prognostic parameters are disease stage and age of the patient at 
diagnosis.119 Children over the age of one year have a worse prognosis than infants (< 1 year) 
and there is a progressive decline in outcome with increasing stage of disease. The 
exceptions to this are infants with stage 4S disease. Their outcome is similar to that of patients 
with stage 1 or 2 disease.  
 
1.3.3.  Histopathology 
Peripheral neuroblastic tumors belong to the group of “small blue round cell” neoplasms of 
childhood. Other members of this group are lymphoblastic lymphomas, Ewing’s sarcomas, 
primitive neuroectodermal tumors, rhabdomyosarcomas and other undifferentiated small cell 
soft tissue sarcomas.100  
Historically, peripheral neuroblastic tumors have been divided into three basic morphologic 
categories, based on the presence of neuroblasts and/or gangliocytic differentiated cells: 
neuroblastoma, ganglioneuroblastoma, and ganglioneuroma.100 Recently, a new prognostically 
significant and biologically relevant classification system has been proposed by the 
International Neuroblastoma Pathology Committee (INPC).120 This INPC classification system 
is exclusively based on morphologic changes and focuses not only on the gangliocytic 
differentiation of neuroblasts, but also on the relative amount of Schwannian cell stroma, as 
originally proposed by Shimada.121 Peripheral neuroblastic tumors are divided into four basic 
 
Table 2 
International Neuroblastoma Staging System111,118 
 
 
Stage 
 
 
Description 
 
1 
 
 
2A 
 
 
2B 
 
 
3 
 
 
 
4 
 
 
4S 
 
Localized tumor confined to the area of origin; complete gross excision, with or without microscopic 
residual disease; identifiable ipsilateral and contralateral lymph nodes negative microscopically 
 
Unilateral tumor with incomplete gross excision; identifiable ipsilateral and contralateral lymph nodes 
negative microscopically 
 
Unilateral tumor with complete or incomplete gross excision; positive ipsilateral regional lymph nodes; 
identifiable contralateral lymph nodes negative microscopically 
 
Tumor infiltrating across the midline with or without regional lymph node involvement; or unilateral 
tumor with contralateral regional lymph node involvement; or midline tumor with bilateral lymph node 
involvement 
 
Dissemination of tumor to distant lymph nodes, bone, bone marrow, liver, or other organs (except as 
defined in stage 4S) 
 
Localized primary tumor as defined for stage 1 or 2 with dissemination limited to liver, skin, or bone 
marrow 
 
Introduction 
14 
morphological categories and their subtypes: 1) neuroblastoma (Schwannian stroma-poor), 
undifferentiated, poorly differentiated, and differentiating; 2) ganglioneuroblastoma, intermixed 
(Schwannian stroma-rich); 3) ganglioneuroma (Schwannian stroma-dominant); and 4) 
ganglioneuroblastoma, nodular (composite Schwannian stroma-rich/stroma-dominant and 
stroma-poor). 
Neuroblastomas are composed of uniform, small, round cells with scant cytoplasm and an 
often granular (“salt and pepper”) chromatin structure.100 Depending on the presence of 
neuropil and gangliocytic differentiated tumor cells, undifferentiated, poorly differentiated and 
differentiating subtypes are recognized. Scattered Schwann cells can be detected in delicate 
fibrovascular septa. The tumor cells may form Homer Wright rosettes (clusters of neuroblasts 
around a core of neuropil). The fully differentiated and benign counterpart of neuroblastoma is 
ganglioneuroma. It is composed of mature ganglion cells embedded in bulky stroma 
composed of Schwann cells. The differentiation of ganglioneuroblastomas is intermediate to 
neuroblastomas and ganglioneuromas. They present with large areas of Schwannian cell 
stroma which surrounds islands of stroma-poor neuroblastic tissue, either as small scattered 
foci (intermixed type) or as grossly visible nodules (nodular type).  
Based on patient age and morphological features (e.g. grade of neuroblastic differentiation, 
presence or absence of Schwannian stroma and mitosis-karyorrhexis index (MKI)) peripheral 
neuroblastic tumors are classified into favorable histology or unfavorable histology.122,123 
Poorly differentiated and differentiating neuroblastomas with low and intermediate MKI below 
1,5 years of age, and differentiating neuroblastoma with low MKI between 1,5 and 5 years of 
age are categorized as favorable. All other neuroblastomas are considered unfavorable. 
Nodular ganglioneuroblastomas are categorized according to the histology of the neuroblastic 
nodule based on the same criteria as for neuroblastomas. Intermixed ganglioneuroblastomas 
and ganglioneuroma are considered favorable.  
 
1.3.4. Genetics 
1.3.4.1. Ploidy 
The DNA content of neuroblastoma cells can be used to predict response to treatment and 
outcome of patients, especially in infants less than 1 year of age with advanced stage disease. 
Based on their ploidy, neuroblastomas can be divided into two distinct subgroups. The 
majority of the neuroblastoma cell lines, xenografts and advanced stage tumors have near-
diploid or near-tetraploid chromosome numbers, whereas favorable neuroblastomas, 
especially those from infants, are characterized by a hyperdiploid or near-triploid DNA 
content.124,125 Virtually all near-diploid or near-tetraploid tumors show various genomic 
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aberrations, including amplifications, deletions, and unbalanced translocations as a result of 
genomic instability. This is not the case in hyperdiploid or near-triploid tumors. These tumors 
have a basic defect in the machinery of mitosis and chromosome segregation and are 
characterized by whole chromosome gains with few if any structural rearrangements.125 
Look and coworkers were the first to describe a relationship between hyperdiploidy and better 
response to chemotherapy in infants with unresectable neuroblastoma.126 In a subsequent 
Pediatric Oncology Group study, hyperdiploidy was clearly associated with long term survival 
in infants whereas diploidy predicted early treatment failure.127 However, there was no 
relationship between ploidy and clinical outcome in children over two years of age. 
In general, patients with near-triploid tumors usually have favorable clinical and biological 
prognostic factors and excellent survival rates, whereas unfavorable prognostic factors and a 
poor outcome were observed in patients who had near-diploid or near-tetraploid tumors.128,129  
1.3.4.2. MYCN amplification 
The amplification of MYCN, a proto-oncogene located on the distal short arm of chromosome 
2 (2p24.1), is one of the most intriguing and striking genetic aberrations found in 
neuroblastoma. The extra MYCN copies are located on extrachromosomal double minutes 
(dmins) or homogeneously staining regions (HSRs) involving different chromosomes.100 
Amplification values in neuroblastoma may range from 10 to more than 500-fold but values 
around 50 to 100-fold are generally seen in tumors.130  
Brodeur and coworkers were the first to study the frequency and significance of MYCN 
amplification in neuroblastoma.131 MYCN amplification was found in 25% of primary tumors 
from untreated patients and was strongly associated with advanced disease, rapid tumor 
progression and poor outcome.131,132  
MYCN amplification is virtually always associated with very high MYCN expression 
levels.133,134 However, the independent prognostic significance of high MYCN mRNA or protein 
levels remains unclear. 
The amplified DNA encompassing MYCN is quite large (500 to 1 000 kb). Therefore, it has 
been suggested that additional genes, located near MYCN, might be co-amplified. However, 
so far no other, consistently co-amplified gene has been identified. In approximately 40% to 
50% of MYCN-positive neuroblastomas, the RNA helicase gene DDX1 is co-amplified.135 
Similarly, a gene termed NAG (neuroblastoma amplified gene) can be co-amplified with 
MYCN.136 However, the extend to which these co-amplified genes contribute to the 
neuroblastoma phenotype remains a matter for debate.  
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1.3.4.3. Deletion of the short arm of chromosome 1 
Deletion of the short arm of chromosome 1 is a common cytogenetic abnormality in 
neuroblastoma. Loss of heterozygosity (LOH) is found in 30% to 50% of primary tumors.137-139 
Several regions of deletion have been identified. A common deleted region is located at the 
distal end of chromosome 1p (1p36.2 to 1p36.3).140 Schleiermacher and colleagues141 
reported three cases with interstitial deletions of 1p32 only and Takeda and coworkers142 
divided their tumors with 1p deletion into two groups: those with large terminal deletions which 
encompassed the region from 1pter to 1p32 and those with smaller interstitial deletions in 
1p36. They found a relationship between large terminal 1p deletions, MYCN amplification and 
unfavorable outcome. Caron and colleagues confirmed these results.143 These findings 
suggest that at least two neuroblastoma suppressor genes are located on 1p (one at 1p36.3 
and another one at 1p35-p36.1).  
Although there is a strong correlation between 1p deletion and high-risk features such as age 
above 1 year at diagnosis, metastatic disease and MYCN amplification, the independent 
prognostic significance of 1p LOH remains unclear. A retrospective Children’s Cancer Group 
study indicated that 1p36 LOH was an independent predictor of event-free survival but not of 
overall survival.144 These findings suggest that 1p LOH analysis may be used to identify low- 
or intermediate-risk patients who are likely to relapse. 
1.3.4.4. Gain of the long arm of chromosome 17 
Unbalanced translocations resulting in gain of 17q material and partial loss of the partner 
chromosome are the most common genetic aberrations in primary neuroblastomas. The most 
frequent partner is chromosome 1p but other partner chromosomes may also be involved.145-
147 Gain of 17q21-qter is found in 50% to 75% of primary tumors and is associated with a poor 
prognosis.148-154 The smallest region of gain is a 25 Mb region at 17q23.1-17qter.155 This 
region contains probably one or multiple genes that contribute to neuroblastoma 
tumorigenesis when present in increased copy number. So far, no candidate genes have been 
identified. 
 
1.3.5. Therapy and Prognosis 
Neuroblastomas are often described as enigmatic and unpredictable because of their 
heterogeneous biologic, genetic, and morphologic characteristics.100 Some neuroblastomas 
are highly malignant and respond poorly to current treatment whereas others regress 
spontaneously or mature to benign ganglioneuroma.156 Based on age, stage and MYCN 
status, physicians are able to predict, to some extent, the biological course of the disease.119 
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Three different risk groups are defined. Patients with stage 1, 2 and 4S disease without MYCN 
amplification are included in the low-risk group (36% of all patients). They require minimal 
therapy and are usually treated with surgery only. Their prognosis is very good with a 5-year 
survival rate of approximately 96%. The group of the intermediate-risk patients includes 
patients with stage 3 neuroblastoma and infants with stage 4 disease without MYCN 
amplification (10% of all children). These patients are treated with conventional chemotherapy 
in combination with surgery and have a 74% survival rate. The third group includes high-risk 
stage 4 patients over the age of one year, regardless of their MYCN status in addition to 
children with MYCN-amplified stage 1, 2, 3 and 4S disease (54% of all patients). When 
chemotherapy, surgical resection of the primary tumor, myeloablative therapy with 
hematopoietic stem cell rescue and therapy with 13-cis-retinoic acid are combined, a survival 
rate of approximately 30% to 40% is obtained.157 
 
Recently, a new model for improved risk assessment and therapy stratification has been 
proposed by Vandesompele and colleagues.158 Based on comparative genomic hybridization 
data from 231 untreated neuroblastomas, three major clinicogenetic subgroups have been 
identified. Subgroup 1 consists of infants with a low stage near-triploid tumor with numerical 
aberrations and favorable histology. These patients have an excellent outcome. The second 
group represents older children with a near-diploid/tetraploid stage 4 tumor, characterized by 
unfavorable histology, partial 17q gain, 11q loss and/or 3p deletion. These children have a 
poor overall 5-year survival of approximately 40%. Patients belonging to subgroup 3 have a 
comparable survival rate. They present with a near-diploid/tetraploid high stage tumor, 
displaying unfavorable histology, partial 17q gain, 1p loss and MYCN amplification. Patients 
belonging to subgroup 2 are generally older compared to children from subgroup 3 (median 
age at diagnosis of 41 months compared to 26 months). 
 
Gene expression profiling can also be used to identify genetic signatures predictive of clinical 
outcome.159-163 Several research groups compared expression profiles from tumors with 
favorable and unfavorable characteristics in order to identify differentially expressed genes 
which could be new prognostic markers or therapeutic targets in aggressive 
neuroblastoma.159-161 Krasnoselsky and colleagues identified a specific subset of cell cycle 
and/or chromosome segregation genes that distinguish stage 4 tumors from all lower stage 
neuroblastomas.163 Wei et al. identified 19 genes (e.g. MYCN, CD44, DLK1, SLIT3 and 
ROBO2) which predicted outcome for 98% of the studied neuroblastoma patients. However, 
integration of these findings into clinical risk prediction algorithms requires independent testing 
in large groups of uniformly treated patients.  
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2. Aims of this thesis 
Although the prognosis of children diagnosed with ALL or neuroblastoma has improved 
markedly during the past four decades, a considerable number of children relapses and 
cannot be cured with current chemotherapy. One of the major goals of researchers, working in 
the field of pediatric hematology-oncology, is the identification of new prognostic parameters 
which can be used to classify children into different risk groups. Low risk patients are treated 
with less intensive and toxic chemotherapy, whereas high risk patients receive a more 
aggressive treatment. Recently, two approaches have become popular: 1) screening for 
transmembrane protein-mediated multidrug resistance (MDR) in childhood ALL and 2) minimal 
residual disease (MRD) analysis in neuroblastoma. However, the clinical relevance of these 
prognostic parameters remains controversial due to the lack in sensitive and specific detection 
methods. Consequently, we decided to develop, optimize and standardize new detection 
techniques for the assessment of MDR and MRD. In addition, the clinical relevance of these 
parameters in childhood malignancies was studied. Briefly, the aims of the thesis are: 
 
9 Review current data on the clinical significance of multidrug resistance-related 
proteins in childhood ALL. 
 
9 Evaluation of the prognostic significance of P-glycoprotein (P-gp) expression and 
activity in childhood ALL. 
 
9 Development of a highly sensitive functional flow cytometric assay to measure P-gp 
activity in pediatric ALL patients. 
 
9 Development and standardization of an immunocytochemical staining method for 
detection of disseminated neuroblastoma cells (in collaboration with the SIOPEN Bone 
Marrow Subcommittee).  
 
9 Development of multiparameter flow cytometric assays to screen for occult 
neuroblastoma cells. Comparison of the flow cytometric results with those of an 
immunocytochemical reference assay. 
 
9 Development of molecular methods to detect rare tumor cells and study of the 
prognostic significance of MRD in neuroblastoma. 
 
9 Review current knowledge about the detection techniques used to study MRD in 
neuroblastoma. 
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1.  Introduction 
While most children with ALL achieve complete remission with current therapeutic regimens, 
approximately 20% to 30% of them relapse and succumb to resistant disease. Various 
cellular mechanisms can give rise to multidrug resistance (MDR), but best studied is the 
transmembrane protein-mediated efflux of cytotoxic compounds which leads to a decreased 
intracellular drug accumulation and toxicity.  
P-glycoprotein (P-gp) is the best-characterized MDR pump.164 In addition, several other drug 
resistance-related proteins have been identified, including multidrug resistance-associated 
protein 1 (MRP1)165, breast cancer resistance protein (BCRP)166 and lung resistance protein 
(LRP)167.  
Despite profound research, the clinical relevance of cellular resistance, mediated by MDR-
related transport proteins, remains unclear. The comparison of data is hampered by the lack 
in standardized detection techniques. In addition, most assays used for clinical diagnosis are 
not sensitive enough to detect low-level resistant cells. Consequently, highly sensitive and 
specific tests are urgently needed in order to guarantee the accurate measurement of weak 
activity of MDR-related proteins. 
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2. Clinical relevance of multidrug resistance in childhood 
ALL 
2.1. Paper 1 
 
THE PROGNOSTIC SIGNIFICANCE OF MULTIDRUG RESISTANCE-RELATED 
PROTEINS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA 
 
Swerts K., De Moerloose B., Dhooge C., Laureys G., Benoit Y. and Philippé J. 
 
European Journal of Cancer (Submitted) 
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The prognostic significance of multidrug resistance-related 
proteins in childhood acute lymphoblastic leukemia 
 
Swerts K., De Moerloose B., Dhooge C., Laureys G., Benoit Y. and Philippé J. 
 
European Journal of Cancer (Submitted) 
 
 
ABSTRACT 
 
An important problem in the treatment of children with acute lymphoblastic leukemia (ALL) is 
pre-existent or acquired resistance to structurally and functionally unrelated 
chemotherapeutic compounds. Various cellular mechanisms can give rise to multidrug 
resistance (MDR). Best studied is the transmembrane protein-mediated efflux of cytotoxic 
compounds which leads to decreased cellular drug accumulation and toxicity. Several MDR-
related efflux pumps have been characterized, including P-glycoprotein (P-gp), multidrug 
resistance-associated protein 1 (MRP1), breast cancer resistance protein (BCRP) and lung 
resistance protein (LRP). P-gp expression and/or activity has been associated with 
unfavorable outcome in pediatric ALL patients whereas MRP1 does not seem to play a major 
role. BCRP and LRP might contribute to drug resistance in B-lineage ALL but larger studies 
are needed to confirm these results.  
The present review summarizes the current knowledge concerning multidrug resistance-
related proteins and focuses on the clinical relevance and prognostic value of these efflux 
pumps in childhood ALL. 
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INTRODUCTION 
 
The prognosis of children diagnosed with acute lymphoblastic leukemia (ALL) has improved 
markedly during the past decades. However, approximately 25% of the affected children 
relapse and cannot be cured with current chemotherapy [1]. Intrinsic or acquired resistance 
to a wide variety of structurally and functionally unrelated chemotherapeutic compounds is 
one of the most important causes of treatment failure in childhood ALL. A variety of cellular 
mechanisms can give rise to multidrug resistance (MDR), including enhanced expression of 
cellular transporters, reduced drug uptake, alterations in detoxifying mechanisms, enhanced 
DNA repair processes, downregulation of drug targets, changes in cell cycle regulation and 
alterations in apoptotic pathways [2,3]. 
Classical multidrug resistance is associated with transmembrane protein-mediated efflux of 
cytotoxic compounds leading to a decreased cellular drug accumulation and toxicity. Several 
MDR-related drug efflux pumps have been characterized. Most of them belong to the 
superfamily of ATP-binding cassette (ABC) transporters.  
P-glycoprotein (P-gp) is the best-characterized MDR pump [4]. Various neoplastic agents 
such as anthracyclines, mitoxantrone, taxanes, vinca alkaloids and epipodophyllotoxins are 
P-gp substrates. During the past 10 years, several new drug resistance-related proteins have 
been identified. One of these is the multidrug resistance-associated protein 1 (MRP1), an 
ATP-dependent efflux pump which extrudes glutathione conjugated compounds out of the 
cell [5]. Currently, the MRP family consists of nine MRP homologues (MRP1-MRP9). The 
breast cancer resistance protein (BCRP) is evolutionary distinct from the other ABC 
transporters [6]. BCRP is a half-molecule and formation of homo- or heterodimers is 
essential for its function as an active transporter [7,8]. Anthracyclines, topoisomerase I 
inhibitors, topoisomerase II inhibitors, cell-cycle inhibitors and methotrexate are BCRP 
substrates. Another MDR-related protein named lung resistance protein (LRP) is involved in 
the nuclear-cytoplasmic transport and/or sequestration of cytotoxic compounds. LRP is 
identified as the major vault protein (MVP) and confers resistance against vincristine, 
doxorubicin and etoposide [9]. Unlike P-gp, MRP and BCRP, LRP is not a member of the 
ABC transporter family. In the present review, current knowledge concerning the clinical 
relevance and prognostic value of multidrug resistance-related proteins in childhood ALL will 
be summarized.  
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P-GLYCOPROTEIN 
 
Juliano and Ling were the first to isolate P-glycoprotein (P-gp) from resistant Chinese-
hamster ovary cells [4]. P-gp is encoded by the MDR1 gene, located on the long arm of 
chromosome 7 (7q21.1) [10,11]. It is a 170 kDa protein which consists of two structurally 
homologous domains, each containing six hydrophobic transmembrane segments and a 
highly conserved ATP binding site [12,13]. The two times two domain organization is most 
likely the result of an internal gene duplication [14]. The presence of two ATP binding sites 
defines P-gp as a member of the ATP binding cassette (ABC) superfamily of transport 
proteins [15].  
The mechanism by which P-gp decreases the intracellular accumulation of anthracyclines, 
mitoxantrone, taxanes, epipodophyllotoxins and vinca alkaloids, is poorly understood. There 
are at least three possible mechanisms of action. The first hypothesis assumes that 
amphiphatic and lipophilic substrates are removed from the cytoplasm through a channel 
formed by the transmembrane segments [16,17]. Furthermore, a “vacuum cleaner” model 
has been suggested in which P-gp transports compounds from either the inner or the outer 
leaflet of the lipid bilayer into the external medium [18,19]. Alternatively, P-gp might function 
as a “flippase”, transporting drugs from the inner to the outer leaflet of the bilayer after which 
the compounds will leave the plasma membrane by diffusion [20,21].  
P-gp is expressed in various normal tissues with secretory or barrier functions including lung, 
placenta, testes, adrenal gland, kidney, liver, pancreas, colon, jejunum and brain [22-24]. In 
addition, P-gp is expressed by hematopoietic precursors and lymphocytes [25,26]. These 
findings suggest that P-gp plays a major role in the excretion and/or transport of cytotoxic 
xenobiotics.  
P-gp mediated multidrug resistance can be reversed by various inhibitors. Competitive 
binding experiments showed that most modulators compete with cytotoxic substrates for P-
gp binding sites [27]. Such agents include calcium channel blockers (e.g. verapamil), 
calmodulin inhibitors (e.g. pimozide), immunosuppressive agents (e.g. cyclosporine A, PSC 
833), quinolones (e.g. chloroquine and quinine), indole alkaloids (e.g. reserpine), antibiotics 
(e.g. erythromycin), detergents (e.g. cremophor EL), steroids and anti-estrogens (e.g. 
tamoxifen) [28,29]. Other agents such as MDR1 anti-sense oligonucleotides, interference 
RNA and protein kinase C inhibitors (e.g. staurosporine), modulate P-gp activity through the 
transcriptional regulation of the MDR1 gene [30-32]. In addition, P-gp specific monoclonal 
antibodies such as MRK16, UIC2 and HYB-241 can be used to inhibit the P-gp mediated 
drug efflux [33-35]. Thus far, clinical trials with P-gp antagonists have yielded disappointing 
results [36-38].  
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Various techniques have been developed to study P-gp expression and function. MDR1 
mRNA can be detected and/or quantified by reverse transcriptase PCR (RT-PCR) [39]. P-gp 
expression can also be determined using different monoclonal antibodies. Some recognize 
internal P-gp epitopes (e.g. C219 and JSB-1), others interact with external antigens (e.g. 
MRK16, 4E3 and UIC2) [40,41]. Monoclonal antibodies binding to external epitopes are 
preferred because they are superior in detecting low and variable levels of P-gp [42]. The P-
gp activity is usually studied using functional flow cytometric assays. The intracellular 
accumulation of P-gp substrates such as rhodamine 123, JC-1, 3,3’-diethyloxacarbocyanine 
iodide (DiOC2) or daunorubicin, is measured in the presence or absence of a P-gp specific 
inhibitor [43-45].  
Several contradictory reports about the clinical importance of P-gp in childhood acute 
leukemia have been published [39,46-78]. Table 1 summarizes the reported data.  
Approximately 30% of all diagnostic ALL samples are P-gp positive. Some authors reported 
more P-gp positive patients at relapse [49,53,58,62] whereas others were unable to find a 
significant difference in the number of P-gp positive samples taken at initial diagnosis or at 
relapse [57,68]. When P-gp expression levels in initial ALL samples were compared to those 
in relapse samples, several authors reported a higher P-gp expression at relapse, i.e. 
especially at multiple relapses [48,55,56]. However, these results were not confirmed by 
others [39,46,61].  
Tafuri et al. found an increased P-gp activity in samples from relapsed ALL patients [56]. 
However, Pieters and coworkers evaluated the daunorubicin and vincristin accumulation in 
the presence or absence of a P-gp inhibitor and found no difference in P-gp function between 
initial and relapse samples [50].  
The P-gp expression did not differ between infant or older ALL patients [75,76]. Some 
authors found a significantly higher P-gp expression and/or function in T-ALL compared to B-
ALL samples [62,73].  
In some studies no relationship between P-gp status and event free survival (EFS) or overall 
survival (OS) was found [63,69,70,77,78]. However, most authors were able to demonstrate 
a significant association between P-gp expression and/or function and clinical outcome in 
childhood ALL. Brophy et al., Tafuri et al. and Kanerva et al. investigated the relationship 
between the response rate and P-gp expression [39,56,62]. Brophy and Tafuri reported a 
correlation between clinical response and absence of P-gp expression. By contrast, Kanerva 
did not find a relation between early response and P-gp status. 
Goasguen and coworkers found no difference in the first complete remission rate between P-
gp positive or P-gp negative patients [52]. However, relapses occurred more frequently in 
children with P-gp positive blasts and the survival rate was significantly higher in P-gp 
negative patients. The EFS-curve followed the same trend but did not reach statistical 
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significance. In accordance with Goasguen, Sauerbrey et al. found a significantly lower 
probability of remaining in continuous complete remission and a tendency for an increased 
relapse rate in P-gp positive patients [54]. Volm and coworkers published that P-gp positive 
patients had a significant lower median relapse-free survival [60]. In a study published by 
Dhooge and coworkers, a significant correlation between EFS and P-gp status was found 
[65]. The OS-curve followed the same trend but reached borderline statistical significance. 
These results were confirmed by Casale et al. [74]. De Moerloose et al. reported that the 
combination of P-gp expression and activity was a statistically significant parameter 
predicting relapse in childhood ALL [72]. Plasschaert and coworkers evaluated the P-gp 
expression and activity in 69 samples from pediatric and adult ALL patients and found an 
association between P-gp activity and EFS or OS in T-ALL patients [73]. By contrast, no 
impact of P-gp activity on EFS or OS was found in B-ALL patients.  
In conclusion, the clinical importance of P-gp in childhood ALL remains unclear. One of the 
reasons for the variability in published data is the lack in standardized detection techniques. 
Moreover, the variety in detection methods hampers the comparison of data. Although this 
problem has been studied by a number of international workshops, implementation of 
consensus recommendations has been difficult [79-83]. Large and well controlled clinical 
studies, using standardized detection techniques, are indispensable to determine the 
prognostic significance of P-gp in childhood ALL.  
 
MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1 
 
The multidrug resistance-associated protein (MRP1), which Cole et al. isolated from the 
doxorubicin resistant small cell lung cancer cell line H69AR, is also a member of the ATP-
binding cassette transporter protein family [5]. The MRP1 gene, mapped on chromosome 16 
(16p13.1), encodes a 190 kDa N-glycosylated hydrophobic anion pump localized on both the 
plasma and intracytoplasmic membranes, including the endoplasmic reticulum and Golgi 
apparatus [84]. 
The amino acid homology between MRP1 and P-gp is 15 %. Compared to P-gp, MRP1 has 
an additional N-terminal membrane spanning domain which is linked via a cytoplasmic loop 
to a P-gp-like core [85].  
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Table 1: Clinical importance of P-pg in childhood ALL 
(DOX: doxorubicin; DNR: daunorubicin; VCR: vincristin; FC: flow cytometry; I ALL: Initial ALL; R ALL: Relapsed 
ALL; IC: immunocytochemistry; RT-PCR: reverse transcription polymerase chain reaction; ISH: in situ 
hybridization; Acc: accumulation; Rho123: rhodamine 123; Mod: modulator; EFS: event-free survival; OS: overall 
survival; c: children; a: adults; WBC: white blood cell; CCR: continuous complete remission) 
 
Author Samples Conclusions
Ubezio et al., 1989 [46] 5 I ALL MDR1 gene expression level and intracellular DOX concentration did not differ between initial and relapse samples
RNA blot 5 R ALL
P-gp function:
DOX Acc by FC
Mizuno et al., 1991 [47] P-gp expression: 9 I ALL P-gp was not detected in any of the samples
FC 4 R ALL
Gekeler et al., 1992 [48] MDR1 gene expression: 7 I ALL No difference in MDR1 mRNA levels between initial and relapsed ALL
RNA slot blot 14 1st R ALL Significant increase in MDR1 expression levels in multiple relapsed ALL
11 ≥ 2nd R ALL
Kingreen et al., 1992 [49] P-gp expression: 48 I ALL At Dx: 6% P-gp expression; At relapse: 23% P-gp expression
IC 47 R ALL No relation between between P-gp expression and clinical outcome in the relapsed patients
Pieters et al., 1992 [50] P-gp expression: 28 I ALL P-gp was not detected in any of the tested samples
IC 14 R ALL DNR and VCR accumulation did not differ between resistant and sensitive cells
P-gp function: Resistance modifiers did not enhance the in vitro cytotoxicity of DNR or VCR
DNR/VCR Acc + Mod
In vitro drug resistance:
MTT assay
Fenneteau et al., 1993 [51] P-gp expression: 35 I ALL c At Dx: 4% P-gp expression
IC 16 I ALL a
Goasguen et al., 1993 [52] P-gp expression: 36 I ALL At Dx: 33% P-gp expression
IC The rate of first complete remission did not differ between P-gp positive and P-gp negative patients
Survival rate was significantly higher in P-gp negative compared to P-gp positive patients
EFS curve followed this trend
Brophy et al., 1994 [39] MDR1 gene expression: Cell lines from: No difference in P-gp expression level between initial and relapsed ALL
RT-PCR and slot blot 16 I ALL Complete clinical response to therapy correlated with absence of MDR1 expression
P-gp expression: 20 R ALL
IC and ISH
Dhooge et al., 1994 [53] P-gp expression: 33 I ALL At Dx: 12% P-gp expression; At relapse: 55% P-gp expression
IC 11 R ALL 4 out of 6 relapsed patients with P-gp expression experienced a rapid unfavorable outcome
Sauerbrey et al., 1994 [54] P-gp expression: 104 I ALL At Dx: 35% P-gp expression
IC P-gp positive patients had a significantly lower probability of remaining in first continuous complete remission
Tendency for an increased relapse rate in P-gp positive patients
P-gp expression was independent of sex, FAB type, immunological subtype and initial WBC count
Beck et al., 1995 [55] MDR1 gene expression: 27 I ALL No difference in MDR1 mRNA levels between initial and relapsed ALL
RT-PCR 18 1st R ALL Significant increase in MDR1 expression levels in multiple relapses
7 ≥ 2nd R ALL
Tafuri et al., 1995 [56] P-gp expression: 19 I ALL Significant difference in P-gp expression levels and activity between initial and relapsed patients
FC 14 R ALL Patients in complete remission showed a significant lower P-gp expression and function compared to those
P-gp function: who failed to respond
Rho123 + Mod by FC
Ivy et al., 1996 [57] P-gp expression: 30 I ALL ALL + AML + Others:
FC 38 R ALL No difference in number of patients with P-gp expression at initial Dx or at relapse
P-gp function: 22 I AML Significant increase in P-gp function at relapse
Rho123 + Mod by FC 8 R AML
5 Others
Volm et al., 1996 [58] P-gp expression: 111 I ALL At Dx: 35% P-gp expression; At relapse: 54% P-gp expression
IC 28 R ALL At Dx, P-gp was more frequently expressed in patients who relapsed under therapy
Srinivas et al., 1997 [59] P-gp expression: 88 I ALL At Dx: 68% P-gp expression
IC
Volm et al., 1997 [60] P-gp expression: 104 I ALL At Dx: 36% P-gp expression
IC Patients with P-gp expression had a significant lower median relapse-free interval
den Boer et al., 1998 [61] P-gp expression: 112 I ALL No difference in P-gp expression levels in initial or relapsed patients
FC 22 1st R ALL No significant correlation between P-gp expression and in vitro drug resistance
In vitro drug resistance: 7 ≥ 2nd R ALL P-gp expression did not relate to age, initial WBC count or unfavorable immunophenotype
MTT assay 20 I AML P-gp expression did not differ between AML and ALL patients
6 1st R ALL
1 2nd R ALL
Kanerva et al., 1998 [62] P-gp expression: 103 I ALL At Dx: 53% P-gp expression; At relapse: 73% P-gp expression
 FC 15 R ALL No correlation between P-gp expression and early response at day 15
No relation between P-gp expression and age, sex, initial WBC count, FAB type or karyotype changes
P-gp expression was significantly higher in T-ALL compared to B-ALL patients
Gurbuxani et al., 1998 [63] MDR1 gene expression: 32 I ALL No correlation between MDR1 gene expression levels and treatment outcome
RT-PCR
den Boer et al., 1999 [64] P-gp expression: 60 I ALL After correction for cell volume:
FC 25 R ALL Intracellular DNR concentration was lower in relapsed compared with initial ALL patients
P-gp function: Inverse correlation between intracellular DNR concentration and in vitro DNR resistance
DNR acc and efflux No relation between P-gp expression and intracellular DNR concentration or in vitro DNR resistance
In vitro drug resistance:
MTT assay
Method
MDR1 gene expression:
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Table 1: Clinical importance of P-pg in childhood ALL (Continued) 
 
Author Samples Conclusions
Dhooge et al., 1999 [65] P-gp expression: 102 I ALL At Dx: 14% P-gp expression; At relapse: 34% P-gp expression
IC 35 R ALL P-gp positive patients at relapse had a 1,9-fold greater risk for adverse clinical outcome
EFS was significantly higher in patients without P-gp expression
OS curve followed the same trend but did not reach statistical significance
P-pg expression was independent of WBC count, age, sex and karyotype
P-gp expression was not induced by exposure to chemotherapy
Kakihara et al., 1999 [66] MDR1 gene expression: 40 I ALL No correlation between MDR1 gene expression and age or WBC count
RT-PCR No difference in MDR1 expression levels between high- and low-risk patients
Ogretmen et al., 2000 [67] MDR1 gene expression: 12 I ALL MDR1 mRNA was undetectable in tested samples
RT-PCR
Gurbuxani et al., 2000 [68] MDR1 gene expression: 80 I ALL At Dx: 16% MDR1 gene expression; MDR1 was not more frequently expressed at relapse
RT-PCR 9 R ALL Mean MDR1 mRNA levels were significantly higher for patients not achieving complete remission
No association between EFS and MDR1 gene expression
Wuchter et al., 2000 [69] P-gp expression: 102 I ALL At Dx: 10% P-gp function
FC No difference in P-gp expression or function between T-ALL and B-ALL
P-gp function: Neither P-gp function, nor P-gp expression correlated with response to induction chemotherapy or OS
Rho123 + Mod by FC No significant difference in P-gp expression or function between patients who relapsed and those in CCR
Kanerva et al., 2001 [70] P-gp expression: 103 I ALL No association between P-gp expression and EFS and OS
FC No correlation between P-gp expression and coexpression of myeloid antigens
Dhooge et al., 2002 [71] P-gp expression: 102 I ALL At Dx: 14% P-gp expression;  At relapse: 35% P-gp expression
IC 37 R ALL P-gp expression at diagnosis was associated with an increased risk for relapse
Association between P-gp expression and EFS
P-gp positive patients at relapse had a 2,2-fold greater risk for adverse clinical outcome
De Moerloose et al., 2003 [72] P-gp expression: 52 I ALL At Dx: 46% P-gp expression and 23% P-gp function
IC EFS and OS were significantly lower in patients with P-gp expression and function
P-gp function: Combination of P-gp expression and function is a statistically significant parameter predicting relapse
Rho123 + Mod by FC
Plasschaert et al., 2003 [73] MDR1 gene expression: 36 I ALL c Children + adults:
RT-PCR 35 I ALL a P-gp activity was higher in T-ALL than in B-ALL
P-gp function: No correlation between P-gp activity and age, hemoglobin or platelet count at Dx
Rho123 + Mod by FC Negative correlation between P-gp activity and WBC count
In T-ALL: association between P-gp activity and EFS or OS
In B-ALL: no impact of P-gp activity on EFS or OS
Casale et al., 2004 [74] P-gp expression 85 I ALL At Dx: 47% P-gp expression and 30% P-gp function
IC and FC EFS was significantly lower in the P-gp positive population
P-gp function EFS was independent of age, WBC count, immunophenotype, FAB subtype and prednisolone response
Rho123 + Mod by FC
Ramakers- P-gp expression: 469 I ALL No difference in P-gp expression between infants and older common/pre B-ALL patients
van Woerden et al., 2004 [75] FC ALL patients with MLL rearrangements had a median 1,3-fold higher P-gp expression than MLL negative cases
Stam et al., 2004 [76] MDR1 gene expression: 26 I ALL No difference in MDR1 gene expression in infants compared to older children
real time RT-PCR MDR1 expression levels did not correlate with in vitro drug resistance
In vitro drug resistance:
MTT assay
Swerts et al., 2004 [77] P-gp expression: 19 I ALL ALL + AML + Other:
FC 2 R ALL Reversable JC-1 efflux in 20% and reversable Rho123 efflux in 27% of all samples
P-gp function: 5 I AML No association between P-gp expression or activity and clinical outcome
Rho123 + Mod by FC 3 R AML
JC-1 + Mod by FC 1 Other
Valera et al., 2004 [78] MDR1 gene expression: 30 I ALL MDR1 gene expression did not correlate with age, WBC count, race, immunophenotype, FAB type, 
RT-PCR CNS infiltration, MRD on day 28, EFS and OS
Method
 
 
 
The spectrum of resistance caused by MRP1 overexpression is very similar to that of P-gp 
[86]. In vitro, enforced MRP1 expression confers resistance to anthracyclines, vinca 
alkaloids, epipodophyllotoxins, campothecins and methotrexate, but not to taxanes and 
mitoxantrone [86-89]. Various glutathione, glucuronate or sulfate conjugates such as 
cysteinyl leukotriene LTC4, an important mediator of inflammatory responses, are also 
transported by MRP1 [90,91]. In addition, Rigato et al. reported that the transport of 
unconjugated bilirubin is mediated by MRP1 [92].  
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Glutathione (GSH) plays an important role in the MRP1 transport process. However, the 
exact mechanism by which GSH participates in the MRP1-mediated efflux is unknown. Some 
compounds such as LTC4 do not require GSH to be transported by MRP1 [90]. Other 
substrates such as daunorubicin, vincristine and rhodamine are only transported in the 
presence of GSH [84,93]. Based on these findings, Salerno and coworkers proposed a new 
working model [94]. They assumed that MRP1 is composed of two interlocked wheels. The 
first wheel binds GSH and LTC4 and functions as the power unit which turns when a 
substrate is bound and energy is provided by the hydrolysis of ATP. The second wheel is 
inert and turns only when it is connected to the first wheel. In the presence of saturating 
amounts of GSH and daunorubicin, both wheels are able to turn and expel one molecule of 
GSH and one molecule of daunorubicin, respectively [95]. 
MRP1 is expressed in most tissues in the human body, especially in lung, testes, kidney, 
skeletal muscle, epithelial and hematopoietic cells [5,96]. MRP1 is also expressed in the 
endothelial cells which form the blood-brain barrier [97]. These findings suggest that MRP1 
plays an important role in the elimination and sequestration of cytotoxic drugs, leading to 
decreased concentrations at their target sites.  
MRP1 does not seem to play a major role in multidrug resistance in childhood ALL (Table 2). 
Beck and coworkers did not find a difference in MRP1 gene expression levels in samples 
taken at diagnosis or at first relapse [55]. However, the MRP1 gene expression increased 
significantly in multiple relapse samples. Den Boer et al. evaluated the MRP1 expression in 
peripheral blood or bone marrow samples from 141 children with ALL [61]. In addition, the in 
vitro cytotoxicity of daunorubicin, vincristine, etoposide, prednisolone and L-asparaginase 
was evaluated. The MRP1 expression did not differ between samples taken at diagnosis or 
at relapse and no relation between MRP1 positivity and in vitro resistance was found. The 
MRP1 expression did not correlate with a prognostically unfavorable immunophenotype, 
white blood cell count or age. These results were confirmed by others [66,67,98]. In several 
studies, no correlation between MRP1 expression at diagnosis and event-free survival was 
found [78,98]. Plasschaert et al. analyzed samples from 36 children and 35 adults with de 
novo ALL and concluded that MRP1 activity had no prognostic impact on OS and EFS [73].  
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Table 2: Clinical significance of MRP1 in childhood ALL 
(FC: flow cytometry; I ALL: Initial ALL; R ALL: Relapsed ALL; RT-PCR: reverse transcription polymerase chain 
reaction; Mod: MRP1 modulator; EFS: event-free survival; OS: overall survival; c: children; a: adults; WBC: white 
blood cell; CFDA: carboxyfluorescein diacetate) 
 
Author Samples Conclusions
Beck et al., 1995 [55] MRP1 gene expression: 27 I ALL No difference in MRP1 mRNA levels between initial and relapsed ALL patients
RT-PCR 18 1st R ALL Significant increase in MRP1 expression levels in multiple relapses
7 ≥ 2nd R ALL
den Boer et al., 1998 [61] MRP1 expression: 112 I ALL No difference in MRP1 gene expression levels between initial and relapsed ALL patients
FC 22 1st R ALL No significant correlation between MRP1 expression and in vitro drug resistance
In vitro drug resistance: 7 ≥ 2nd R ALL MRP1 expression did not relate to age, initial WBC count or unfavorable immunophenotype
MTT assay 20 I AML MRP1 expression did not differ between AML and ALL patients
6 1st R ALL
1 2nd R ALL
Kakihara et al., 1999 [66] MRP1 gene expression: 40 I ALL No correlation between MRP1 gene expression and age or WBC count
RT-PCR No difference in MRP1 gene expression between high- and low-risk patients
Ogretmen et al., 2000 [67] MRP1 gene expression: 12 I ALL MRP1 was overexpressed in most children with pre-B-ALL
RT-PCR MRP1 mRNA was undetectable in most children with T-ALL
Sauerbrey et al., 2002 [98] MRP1 gene expression: 58 I ALL No difference in MRP1 gene expression levels between initial and relapsed ALL patients 
RT-PCR 28 R ALL MRP1 overexpression was not associated with unfavorable outcome
MRP1 expression was independent of age, sex, initial blast count, FAB-type and immunological subtype
Plasschaert et al., 2003 [73] MRP1 gene expression: 36 I ALL c Children + adults:
RT-PCR 35 I ALL a No difference in MRP1 activity between T-ALL and B-ALL or adults and children
MRP1 function: High MRP1 activity did not influence EFS or OS in ALL patients
CFDA + Mod by FC No correlation between MRP activity and age, hemoglobin or platelet counts at diagnosis
Valera et al., 2004 [78] MRP1 gene expression: 30 I ALL At Dx: 16.6% MRP1 overexpression
RT-PCR MRP1 gene expression did not correlate with age, WBC count, race, immunophenotype, FAB-type,
CNS infiltration, MRD on day 28, EFS and OS
Method
 
 
 
BREAST CANCER RESISTANCE PROTEIN 
 
Chen and coworkers detected a 95 kDa ABC transporter in the human breast cancer cell line 
MCF-7/AdrVp [99]. RNA fingerprinting led to the identification of a 2.4-kb mRNA encoding a 
655 amino acid protein which was termed breast cancer resistance protein (BCRP) [100]. 
The transporter is also known as ABCG2, placental transporter or mitoxantrone resistance 
protein. BCRP is encoded by the ABCG2 gene which was mapped on chromosome 4 (4q22) 
[101]. The transporter is a half-molecule with a C-terminal transmembrane segment and a N-
terminal ATP-binding site [7]. The formation of homo- or heterodimers bridged by disulfide 
bonds is essential for its function as an active transporter [8]. In vitro, high BCRP expression 
causes resistance to anthracyclines (e.g. doxorubicin and daunorubicin), topo-isomerase I 
inhibitors (e.g. topotecan), topo-isomerase II inhibitors (e.g. bisantrene, etoposide and 
mitoxantrone), cell-cycle inhibitors (e.g. flavopiridol) and antifolates (e.g. methotrexate) 
[7,102-104]. However, a mutation in a single amino acid can change the substrate specificity 
and thereby alter the drug resistance profile. Cell lines overexpressing BCRP with an 
arginine at position 482 are able to transport mitoxantrone but not rhodamine 123 or 
doxorubicin, whereas cells with threonine or glycine at position 482 extrude rhodamine 123, 
doxorubicin and mitoxantrone [105].  
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BCRP overexpression has been described in resistant ovary, breast, colon and gastric 
cancer, fibrosarcoma cell lines, placental tissue, liver canalicular membranes, ducts and 
lobules of the breast, endothelium of veins and capillaries, epithelium of colon and small 
intestine and bile canaliculi [106]. 
Since children with ALL are treated with BCRP substrates such as methotrexate and 
doxorubicin, BCRP overexpression could be responsible for MDR. A few studies investigated 
the role of BCRP in childhood ALL (Table 3). In a retrospective study, Sauerbrey et al. 
analyzed the BCRP expression by TaqMan real-time RT-PCR in samples from 67 ALL 
patients (47 initial stage and 20 relapses) [107]. Children with T-ALL showed a lower BCRP 
expression than patients with precursor B-ALL. No relationship between BCRP expression 
and age, sex, initial blast count, prednisolone response or bone marrow response on day 15 
and 33 was found. BCRP expression levels at relapse were not significantly different from 
those at diagnosis and BCRP overexpression was not associated with unfavorable outcome. 
Stam et al. reported a lower BCRP expression in infants than in older ALL patients [76]. 
These results indicate that BCRP could play a minor role in drug resistance in precursor B-
ALL patients. However, larger studies are needed to evaluate the prognostic impact of BCRP 
expression and activity in childhood ALL. 
 
Table 3: Clinical importance of BCRP in childhood ALL 
(I ALL: Initial ALL; R ALL: Relapsed ALL; RT-PCR: reverse transcription polymerase chain reaction) 
 
Author Samples Conclusions
Sauerbrey et al., 2002 [107] BCRP gene expression 47 I ALL BCRP gene expression was lower in T-ALL than in precursor B-ALL patients
RT-PCR 20 R ALL No difference in BCRP gene expression levels between initial and relapsed ALL patients
No relationship between BCRP gene expression and age, sex, initial blast count, prednisolone reponse or
bone marrow response on day 15 and day 33
No association between BCRP overexpression and unfavorable outcome
Stam et al., 2004 [76] BCRP gene expression 26 I ALL Infants expressed 2.4-fold less BCRP mRNA than older children with ALL
RT-PCR
Method
 
 
 
LUNG RESISTANCE PROTEIN 
 
The lung resistance protein (LRP) was initially identified in an anthracycline-resistant, non-
small cell lung cancer cell line which lacked P-gp overexpression [108]. The LRP gene is 
located on chromosome 16 (16p11.2), close to the MRP1 and protein kinase C-β gene, and 
encodes a 110 kDa protein [109]. Based on the LRP amino acid sequence, no 
transmembrane fragments or ATP-binding sites, characteristic for ABC transporters, were 
identified. Therefore, LRP is not considered to be a member of the ABC transporter family. 
Screening of an expression library identified LRP as the major vault protein (MVP) [9]. Vaults 
are highly conserved ribonucleoprotein organelles that are found in all higher eukaryotes.
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They are localized in cytoplasmic vesicles and nuclear membranes and form the transporter 
core of the nuclear pore complex. Vaults are composed of the major vault protein, vault poly 
(ADP-ribose) polymerase, telomerase-associated protein 1 and small untranslated RNA 
[110]. The functional role of vaults in MDR is still unclear but it was proposed that they act by 
transporting drugs away from their subcellular targets by mediating the extrusion of 
cytostatics from the nucleus and/or the sequestration of drugs into vesicles.  
By immunocytochemistry, LRP has been found to be widely distributed in normal human 
tissues [111]. LRP overexpression has been observed in epithelia of the bronchus and 
digestive tract as well as in keratinocytes, adrenal cortex and macrophages. These results 
suggest that vaults play a role in detoxification processes.  
The enforced expression of LRP in an ovarian carcinoma cell line led to increased numbers 
of vault particles but failed to confer drug resistance to etoposide, doxorubicin and vincristine 
[9]. Siva and coworkers concluded that the upregulation of vaults may be necessary but not 
sufficient to give rise to multidrug resistance [112].  
Information about the clinical relevance of LRP in childhood ALL is limited (Table 4). In most 
studies, no difference in LRP expression between initial and relapsed ALL patients is found 
[67,98,113]. However, LRP expression was significantly higher in multiple relapse samples 
compared to diagnostic or first relapse samples [61]. Furthermore, LRP expression levels do 
not seem to differ between risk groups identified by WBC count, sex or age [61,66,98]. 
Ogretmen et al. found a high LRP expression in most children with pre-B ALL [67]. By 
contrast, LRP expression was much lower in T-ALL patients. These results are in 
accordance with those published by den Boer et al. [61]. Ramakers-van Woerden et al. found 
a high LRP expression in pro-B-ALL patients [75]. 
Volm et al. reported a significant association between LRP expression and long term survival 
in 38 children with de novo ALL [113]. This was confirmed by Sauerbrey et al. who 
demonstrated that children with a high LRP expression at diagnosis exhibited a lower 
tendency of remaining in first clinical remission [98].  
The relationship between LRP expression and in vitro resistance to daunorubicin, vincristine, 
etoposide and prednisolone was also studied [61]. The LRP expression was weakly but 
significantly related to the in vitro resistance to daunorubicin. In addition, LRP expression 
correlated inversely with the intracellular accumulated daunorubicin concentration [64]. 
These findings suggest that LRP might contribute to drug resistance in children with ALL.  
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Table 4: Clinical relevance of LRP in childhood ALL 
(FC: flow cytometry; I ALL: Initial ALL; R ALL: Relapsed ALL; IC: immunocytochemistry; RT-PCR: reverse 
transcription polymerase chain reaction; Acc: accumulation; Dx: diagnosis; WBC: white blood cells; DNR: 
daunorubicin) 
 
Author Samples Conclusions
Volm et al., 1997 [113] LRP expression: 38 I ALL At Dx: 47% LRP expression; At relapse: 68% LRP expression 
IC 25 R ALL Patients without LRP expression had a higher probability of remaining in continuous first remission
den Boer et al., 1998 [61] LRP expression: 112 I ALL No difference in LRP expression levels between initial or relapsed patients
FC 22 1st R ALL LRP expression was 1.6-fold higher in multiple relapse samples than in initial or first relapse samples
In vitro drug resistance: 7 ≥ 2nd R ALL LRP expression was 2-fold higher in AML than in ALL patients
MTT assay 20 I AML LRP expression was 1.4-fold lower in T-ALL compared with common/pre-B-ALL patients
6 1st R ALL LRP expression was weakly associated with in vitro resistance to daunorubicin
1 2nd R ALL LRP expression did not relate to age or initial WBC count 
den Boer et al., 1999 [64] LRP expression: 60 I ALL After correction for cell volume:
FC 25 R ALL Intracellular DNR concentration was lower in relapsed compared with initial ALL patients
LRP function: Inverse correlation between intracellular DNR concentration and in vitro DNR resistance
DNR Acc and efflux Accumulated DNR concentration inversely correlated with expression of LRP
In vitro drug resistance:
MTT assay
Kakihara et al., 1999 [66] LRP gene expression: 40 I ALL No correlation between LRP gene expression and age or WBC count
RT-PCR No difference in LRP expression levels between high- and low-risk patients
LRP gene expression was increased in CD10-positive ALL
Ogretmen et al., 2000 [67] LRP gene expression: 12 I ALL LRP was overexpressed in most children with pre-B-ALL
RT-PCR LRP mRNA was undetectable in most children with T-ALL
Sauerbrey et al., 2002 [98] LRP gene expression: 58 I ALL No difference in LRP gene expression between initial and relapsed ALL patients 
RT-PCR 28 R ALL Patients without LRP expression exhibited a higher tendency of remaining in continuous first remission
LRP expression was independent of age, sex, initial blast count, FAB-type and immunological subtype
Ramakers- LRP expression: 469 I ALL No difference in LRP expression between infants and older common/pre-B-ALL patients
van Woerden et al., 2004 [75] FC LRP expression was 1.4-fold higher in pro-B-ALL than in common/pre-B-ALL
Method
 
 
 
OTHER MULTIDRUG RESISTANCE PROTEINS 
 
During the past few years, several new members of the ABC transporter family have been 
identified, including eight new MRP1 homologues (MRP2 or cMOAT, MRP3, MRP4, MRP5, 
MRP6, MRP7, MRP8 or ABCC11 and MRP9 or ABCC12), the sister of P-gp (sP-gp) and the 
transporter associated with antigen processing (TAP) [114-116].  
Plasschaert et al. evaluated the MRP2 and MRP3 mRNA expression in childhood ALL [73]. 
In respectively 89% and 24% of the samples, MRP2 or MRP3 transcripts were detected. 
Steinbach and coworkers assessed the clinical relevance of MRP2-MRP5 and SMRP, a 
splice variant of MRP5, in 103 children with previously untreated ALL [117]. All five genes 
were expressed with great variability. However, only MRP3 expression was associated with a 
significantly worse prognosis. The median MRP3 levels were 10-fold higher in T-ALL 
compared to precursor B-ALL patients and 4-fold higher in boys than in girls. These findings 
suggest than MRP3 overexpression might account for the poor prognosis of male and T-ALL 
patients.  
The clinical importance of the other transport proteins in childhood ALL remains to be 
elucidated. 
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CONCLUSIONS 
 
One of the most important causes of treatment failure in childhood ALL is the emergence of 
multidrug resistance. Various mechanisms can give rise to clinical drug resistance but best 
studied is the overexpression of transmembrane transport proteins such as P-gp, MRP1, 
BCRP and LRP. In the present review, we focused on the clinical relevance and prognostic 
significance of these MDR-related efflux pumps in childhood ALL. Several authors found a 
relationship between P-gp expression and/or function and clinical outcome in pediatric ALL 
patients. Other studies, however, contradicted these findings. Data on the prognostic 
significance of other MDR proteins are scarce. LRP and BCRP might contribute to drug 
resistance in B-lineage ALL but larger studies are needed to confirm these results. MRP1 
does not seem to play a major role in MDR in childhood ALL and of all newly identified ABC 
transporters (e.g. MRP2-MRP9, sP-gp, TAP), only MRP3 expression was associated with a 
worse prognosis.  
Despite profound research, the clinical importance of MDR-related proteins in childhood ALL 
remains controversial. The comparison of data is hampered by the lack in standardized 
detection techniques, the heterogeneity in patient groups (e.g. pooled data of ALL and AML, 
initial and relapse samples, adults and children) and differences in treatment protocols. 
However, detailed information on the clinical relevance of MDR-related efflux pumps is 
needed before the potential of transporter-specific modulators can be studied. So far, phase 
3 clinical trials with first- and second-generation P-gp antagonists have yielded conflicting 
results. This may be explained by the functional redundancy between different drug 
resistance efflux pumps. Moreover, limitations in the design of early resistance reversal trials 
contribute to the disappointing results.  
It is also important to keep in mind that multidrug resistance is a multifactorial process. In 
addition to transmembrane transport proteins, other resistance mechanisms such as 
alterations in detoxification processes, apoptosis, DNA repair, cell cycle progression and 
drug uptake, might contribute to clinical drug resistance. Tools such as oligonucleotide-based 
or cDNA-based microarrays are relevant methods to screen for multifactorial mechanisms 
since they allow the determination of the expression profile of many genes in a single 
hybridization experiment [118-120]. Microarrays may open new avenues for the diagnosis of 
MDR in clinical samples. In addition, they are a helpful tool for assessing the role of 
transmembrane transport proteins in childhood ALL and will help us to obtain a clear picture 
on how to optimize treatment schedules in leukemia. 
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Acute childhood leukemias account for 25–30% of all childhood malig-
nancies. The predominant type of leukemia in childhood is the acute lym-
phoblastic leukemia (ALL) [1]. After chemotherapy was introduced, it was
clear that childhood ALL could be divided into many prognostically distinct
subtypes and the concept of risk-adapted therapy was introduced [2, 3]. In
childhood ALL, the following prognostic factors are frequently used: white
blood cell count (WBC) at diagnosis, response to treatment, age of the patient
at diagnosis, immunophenotype of the lymphoblasts, chromosomal aberra-
tions, and minimal residual disease [1, 3–5]. Despite risk-adapted therapy,
relapse occurs in 25% of the patients.
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In a previous prospective study, we demonstrated the prognostic signif-
icance of the multidrug resistance (MDR) protein P-glycoprotein (P-gp) in
childhood ALL [6]. P-gp is a 170-kD transmembrane protein, capable of ex-
truding a variety of lipophilic compounds, including amphipathic neoplastic
agents, out of the cell. Consequently, the intracellular drug concentration de-
creases and the cell becomes resistant to the drug [7]. Different structurally
and functionally unrelated chemotherapeutic agents frequently used in the
treatment of ALL, such as anthracyclines, vinca alkaloids, and epipodophyl-
lotoxins, are substrates of P-gp action.
P-gp detection in patient samples can be performed by various tech-
niques, which limits the comparison of the results of different clinical stud-
ies. Therefore, different P-gp detection assays have been evaluated in several
workshops [8, 9]. At the moment, it is recommended to validate immuno-
cytochemical test results by complementary tests, such as functional flow
cytometric assays or reverse transcriptase–polymerase chain reaction tests.
In our previous study, an immunocytochemical assay was used [6]. In
the present prospective study in childhood ALL, we combined immunocyto-
chemical test results with P-gp flow cytometric activities, to determine which
test or test combination gives the best prediction of relapse.
PATIENTS AND METHODS
Patient Characteristics
From June 1996 to January 2000, 61 newly diagnosed ALL patients were
admitted to the Department of Pediatric Hematology/Oncology of the Ghent
University Hospital. Out of these, 52 patients were included in the study and
their prognostic variables are listed in Table 1. Nine children were excluded
from the study. No material was available for P-gp determinations in 8 patients
and 1 child died because of toxicity during induction chemotherapy. The
clinical and biological characteristics and the relapse rate of these excluded
patients were not significantly different from the studied population.
The diagnosis was based on standard morphology, cytochemistry, and im-
munophenotyping of the leukemic blasts. All patients were treated accord-
ing to EORTC-CLCG (European Organization for Research and Treatment
of Cancer—Childhood Leukemia Cooperative Group) protocols (45 with
protocol 58881 and 7 with protocol 58951), including vincristine and an-
thracyclines. Six children, including the 2 patients with t(9;22), underwent
a bone marrow (BM) transplant. The mean follow-up time was 39 months
(median 40 months).
Leukemic Samples
Leukemic cells were collected from BM and/or peripheral blood. For im-
munocytochemistry, smears of BM and/or peripheral blood were air-dried for
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TABLE 1 Distribution of Prognostic Factors
Prognostic factor Number of patients (%)
Age 1–10 years 38 (73)
<1 or >10 years 14 (27)
WBC count <50 £ 109/L 39 (75)
>50 £ 109/L 13 (25)
Cytogenetic analysis Hyperdiploidy 1 (2)
Unfavorable 5 (10)
Other 44 (85)
Not determined 2 (4)
Blasts at day 8 <1 £ 109/L 47 (90)
>1 £ 109/L 5 (10)
DNA content >1.16 and <1.6 5 (10)
<1.16 and >1.6 46 (88)
Not determined 1 (2)
Gender Female 28 (54)
Male 24 (46)
Immunophenotype B-cell lineage 44 (85)
T-cell lineage or biphenotypic 8 (15)
Note. Hyperdiploidy was defined as>50 chromosomes in the blasts. Unfavorable
cytogenetic analysis included t(9;22), t(4;11), 11q23, and near-haploidy.
24 h at room temperature and stored unfixed at ¡20–C. For flow cytometry,
mononuclear cells from BM and/or peripheral blood were isolated by gradi-
ent centrifugation on Ficoll-hypaque, kept at 4–C, and analyzed within 24 h
after prelevation. All samples contained more than 80% leukemic cells, based
on morphological and immunological criteria. Dead cells were excluded with
propidium iodide staining.
Control Cell Lines
Samples of the well-characterized human myeloid leukemia cell line K562
and its P-gp-expressing resistant clone K562/VLB20 [10] were included in
each immunocytochemical and flow cytometric experiment as negative and
positive controls, respectively.
Monoclonal Antibodies
In the immunocytochemical assay, P-gp was detected by two monoclonal
antibodies (MoAbs), which recognize different extracellular epitopes of P-gp,
namely 4E3 (Dako, Carpinteria, CA USA) and MRK16 (Kamiya Biomedical,
Thousand Oaks, CA, USA). The optimal concentration for 4E3 and MRK16
was found to be 10 and 5 „g/mL, respectively.
Immunocytochemical Technique
P-gp expression on the leukemic blasts was demonstrated using the alka-
line phosphatase–anti-alkaline phosphatase (APAAP) immunocytochemical
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technique as described previously [11]. Among the different fixatives tested,
0.0125% glutaraldehyde in phosphate-buffered saline (PBS, pH 7.2) was
found to be the optimal fixative to preserve both antigen expression and
cellular morphology. The slides were fixed for 30 s at 4–C, washed, and incu-
bated with the MoAb in a humidifier at room temperature for 30 min. The
APAAP (APAAP-Dakopatts, Glostrupp, Denmark) staining procedure was per-
formed as prescribed by the manufacturer [12]. Higher assay sensitivity was
achieved by repeat incubations with the rabbit anti-mouse antibodies and
APAAP complex for an additional 5 min. Subsequently, the slides were devel-
oped with Fast-Red TR Salt (Sigma, St Louis, MO, USA) and counterstained
with gallocyanin. Isotypic matched controls and controls without primary
antibody were simultaneously examined to exclude atypical or background
staining. Slides were examined by 3 independent observers. In agreement
with the consensus recommendations on P-gp detection, no arbitrary mini-
mal cutoff points were used [8]. In each experiment, a mean of 300 blasts
were counted. In slides with poor cellularity, at least 50 blasts were counted.
A patient was defined positive for P-gp expression if a red staining pattern
along the cell membrane was observed with one of the MoAbs in at least one
blast.
Flow Cytometric Detection of P-gp Activity
According to Ludescher et al. [13], 105 cells were incubated for 1 h at
37–C with 200 ng/mL rhodamine 123 (Rho 123, Sigma), which is a P-gp
substrate, in the absence or presence of 10 „M of the P-gp inhibitor ver-
apamil (Knoll, Ludwigshafen, Germany). The intracellular Rho 123 accu-
mulation was measured on a FACSort flow cytometer (Becton Dickinson,
Erembodegem, Belgium) calibrated with QC Windows and Quantum 1000
beads (Flow Cytometry Standards, San Juan, PR, USA). At least 10,000 events
were counted and analyzed with Cell Quest software (Becton Dickinson,
Erembodegem, Belgium). Cells were washed twice with cold (4–C) HBSS
without phenol red and resuspended. After an additional incubation for 1 h
at 37–C with or without 10 „M verapamil, the remaining intracellular Rho
123 retention after the efflux period was measured. A test result was con-
sidered positive if the cells exhibited Rho 123 efflux and if the intracellular
Rho 123 fluorescence enhanced in the presence of verapamil by at least 10%,
resulting in a Rho 123 retention ratio (RR) of at least 1.10 [14, 15].
Statistical Analysis
A comparison of frequency distribution of the different prognostic vari-
ables according to the P-gp status was determined by Fisher exact tests. Cu-
mulative event-free survival (EFS) and overall survival (OS) were estimated
according the Kaplan–Meier method and the log rank test was applied to
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evaluate the difference between the P-gp-negative and -positive groups. Rela-
tive impact of baseline variables on event (D relapse or death) was expressed
as risk ratios (RR). Univariate analysis was performed according to the Cox
proportional hazard modeling. p values less than .05 were considered to be
statistically significant.
RESULTS
Remission Status, EFS, and OS
After induction treatment, complete remission (CR) was achieved in all
patients. During the study period, 10 patients relapsed and out of these, 6
children died. Three children suffered from progressive leukemia; the other
3 died because of toxicity after BM transplant. The EFS at 4 years was 79.3%
(95% confidence interval: 67.4–93.4%) and the OS 85.2% (95% confidence
interval: 74.4–97.6%).
Results of the P-gp Detection Assays
Using the immunocytochemical technique, 24/52 patients (46%) had a
positive test result. The EFS and OS were not significantly different in the
P-gp-negative group, compared to the P-gp-positive group (log rank pD :612
and .228 for EFS and OS, respectively).
P-gp activity was found in 12 patients (23%) and was not significantly
associated with a higher relapse rate (log rank pD :134) or an increased risk
of death (log rank pD :107).
Patients who scored positive in either one of the tests (30/52) did not
fare worse than the patients with 2 negative test results (log rank p D :769
and .168 for EFS and OS, respectively). However, the 6 children with P-gp
expression in the immunocytochemical assay and simultaneously a positive
functional test had a significantly worse outcome. Three of these 6 patients
relapsed, compared to 7 (15%) in the group of children scoring negative for
both tests or positive for only one test. Two positive children died, compared
to 4/46 (9%) negative children. The cumulative EFS and OS of these patients
are shown in Figure 1 (log rank pD :007 and .047, respectively).
Evaluation of Prognostic Factors
All prognostic variables were independently distributed in the P-gp-
negative and -positive patient groups (Table 2). In the patient group scor-
ing positive for the functional assay (FT), a borderline significant depen-
dence (p D :045) with gender was seen. In our study, only the combination
of P-gp expression and activity was a statistically significant parameter pre-
dicting relapse in childhood ALL (p D :021, Table 3). Moreover, the risk
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FIGURE 1 Kaplan-Meier event-free survival and overall survival of 52 children with ALL, according to
P-gp status (P-gp positive if both the immunocytochemical assay and the functional assay are positive).
of death was 4.49-fold higher in the patient group with a positive result for
both P-gp expression and activity, compared to the negative group (pD :084,
Table 3).
DISCUSSION
The link between drug resistance and relapse has often been suggested,
but not defined in clinical treatment settings. The biological markers of drug
resistance, such as P-gp, require clinical testing to evaluate them as poten-
tial therapeutic target. In the present prospective study, we report the re-
sults of immunocytochemical and functional detection of the MDR protein
P-gp in childhood ALL and their clinical relevance. Previously, we only used
immunocytochemistry for P-gp detection and we clearly demonstrated the
potential of this technique to predict relapse [6].
Despite numerous advantages of immunocytochemistry (such as discrim-
ination of malignant and normal cells and the evaluation of P-gp staining
in individual cells) [16, 17], the French workgroup on P-gp detection does
not recommend immunocytochemistry, merely because of a lack in sensitivity
and reproducibility [9]. Others promote flow cytometry as the most valuable
tool presently available for the detection of MDR in acute leukemia [18].
The functional flow cytometric assays are, in contrast to immunological tests,
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independent of the use of MoAbs, and they can directly evaluate the effect
of MDR modulators [19]. The sensitivity of the functional test using Rho 123
has been demonstrated in clinical samples [20].
Using the functional test, 23% of our patients scored positive at initial
diagnosis. This is in agreement with Tafuri et al., who observed 22.4% positive
functional test results in childhood ALL [21]. The immunocytochemical P-
gp expression rates in the present study were higher than the P-gp activity
values (46 and 23%, respectively). In our previous study [6], only 14% of
ALL patients scored positive for P-gp at initial diagnosis. We also could not
confirm the prognostic value of immunocytochemistry as single test in the
present study. The discrepancies between the two studies might be caused
by the use of different MoAbs: C219 and 4E3 in the former and MRK16 and
4E3 in the present study. MRK16 and 4E3 were chosen because the externally
binding MoAbs are more sensitive in the detection of low and variable levels
of P-gp and because C219 is not specific for the MDR1 gene product since it
also reacts with the MDR3 gene product [8, 22].
Current reports on P-gp expression, functional activity, and outcome in
childhood ALL are conflicting. Goasguen at al. used C219 and JSB1 in an
immunohistochemical assay and demonstrated a higher relapse rate and a
shorter median survival for P-gp-positive patients [23]. Sauerbrey et al. also
used C219 and immunocytochemistry and found a lower EFS in the P-gp-
positive group [24].
In other studies in childhood ALL, flow cytometric functional or im-
munological assays were performed [15, 25]. Kanerva et al. also performed a
prospective study in childhood ALL [25]. They used the MoAb JSB1, which
recognizes an internal epitope of P-gp, in an immunological flow cytometric
test and found no difference in EFS or OS between children with low or
increased P-gp expression. Other researchers prefer the functional flow cyto-
metric assay [15]. P-gp activity was studied by Wuchter et al. in 102 children
with ALL and did not correlate with immunophenotypic subgroups, response
to induction chemotherapy, relapse rate, and OS [15].
These conflicting data resulting from prospective studies based on one de-
tection technique stress the importance of combining complementary tests,
such as immunocytochemistry and functional assays. Recently, Damiani et al.
found a shorter disease-free survival in adults with ALL if P-gp overexpression
was associated with a defect in daunorubicin accumulation [26].
Among the different variables studied in our 52 ALL patients, only the
simultaneous positivity of P-gp activity and P-gp expression was significantly
associated with a higher risk for relapse. No single test results and no other
prognostic parameters in childhood ALL (age, gender, WBC count at diagno-
sis, number of blasts at day 8, immunophenotype of the blasts, DNA content,
and cytogenetic abnormalities) had a comparable increased risk for relapse
or death.
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CONCLUSION
The combined use of a functional flow cytometric assay with Rho 123 and
an immunocytochemical staining of P-gp not only allows one to determine
accurately P-gp in clinical samples, as was suggested by others [27], but addi-
tionally might contribute to the identification of patients with increased risk
for relapse.
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One of the possible causes of treatment failure in acute leukemia is the emergence of multidrug
resistance caused by P-glycoprotein (P-gp) overexpression. We compared a ﬂow cytometric assay
using JC-1 with a technique using rhodamine 123 (rho123) to evaluate the P-gp function in acute
leukemia. Samples from 50 acute leukemia patients were analyzed by both functional assays. The P-gp
expression was assessed by an immunological ﬂow cytometric test and the association between the P-
gp status and the clinical outcome was evaluated. Of all samples, 28% showed a reversible JC-1 eﬄux
and 36% scored positive for the rho123 assay. In two cases, the leukemic blasts showed a reversible
JC-1 eﬄux whereas they were negative for rho123. These patients had blast cells with a very low P-gp
activity. Six samples scored positive for the rho123 assay but were negative for the JC-1 test. Five of
these samples did not express P-glycoprotein and were considered false positive. We found a strong
correlation between the JC-1 and the rho123 test (Rs=0.59, p5 0.0001) and the JC-1 and the
immunological assay (Rs=0.29, P=0.05). There was also an association between the JC-1 status
and the clinical outcome of adult patients (w2=6.30, P=0.04). In conclusion, we recommend the
JC-1 assay to study the P-gp activity in acute leukemia because it is more speciﬁc and less labor
intensive than conventional functional ﬂow cytometric tests using rhodamine 123. In addition, the
JC-1 assay can be used to identify adult patients with an increased risk for adverse clinical outcome.
Keywords: Multidrug resistance; P-glycoprotein; JC-1; Rhodamine 123; Acute leukemia; Flow cyto-
metry
INTRODUCTION
Treatment results in acute leukemia have improved
markedly during the past 30 years. However, some
patients relapse and cannot be cured with current
chemotherapy due to the emergence of multidrug
resistance. Several mechanisms of resistance are known,
but best studied is the overexpression of a 170 kDa
transmembrane protein, P-glycoprotein (P-gp). This
ATP-dependent eﬄux pump extrudes a variety of
lipophylic, cytotoxic compounds out of the cell and
hence decreases their intracellular concentration and
toxicity [1]. Diﬀerent structurally and functionally
unrelated chemotherapeutic agents used in the treatment
of acute leukemia such as anthracyclines, vinca alkaloids
and epipodophyllotoxins, are substrates of the P-gp
pump.
In acute myeloid leukemia, the prognostic role of P-gp
has been clearly established [2 – 4]. However, the clinical
value of P-gp in childhood acute leukemia remains
unclear [5 – 10]. One of the reasons for the variability in
the published data is the variety of detection techniques.
In addition, there is a lack of sensitive and speciﬁc
detection methods. These issues have been addressed in a
number of international workshops and several recom-
mendations have been formulated [11 – 14]. Especially,
the use of a functional ﬂow cytometric assay was
promoted because it allows, in contrast to other tests,
the detection of P-gp activity [13,14].
A recently developed ﬂow cytometric assay evaluates
the P-gp function by measuring the JC-1 accumulation in
the absence or the presence of a P-gp inhibitor [15]. JC-1
is a carbocyanine liquid crystal forming probe which was
initially used to analyze the mitochondrial potential [16].
*Corresponding author. Address: Department of Pediatric Hematology and Oncology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent,
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Due to the stacking in a liquid crystal form, the
ﬂuorescence emission wavelength of this probe depends
on its concentration. When the JC-1 monomers are
excitated at 488 nm, the emission spectrum reaches its
maximum at 537 nm (green ﬂuorescence). Beyond a
critical concentration, JC-1 aggregates are formed. The
aggregates display a ﬂuorescent emission centered at
597 nm (red ﬂuorescence) in addition to the green
ﬂuorescence. Sensitive cells display both green and red
ﬂuorescence. Resistant cells, expressing functional P-gp
pumps will contain lower concentrations of JC-1. Hence
they lose the red ﬂuorescence and display a decrease in
green ﬂuorescence intensity.
In this study, we compared this new functional assay
using JC-1 with a conventional technique using rhoda-
mine 123 to evaluate the P-gp function in acute leukemia.
In addition, we studied the relation between the P-gp
function and expression in leukemic cells and evaluated
the association between the P-gp status and the clinical
outcome of the patients.
MATERIALS AND METHODS
Patients and Sample Preparation
Between May 2001 and October 2002, the P-gp function
and expression in peripheral blood or bone marrow
samples, taken at diagnosis or relapse, from 50 patients
suﬀering from acute leukemia (acute lymphoblastic
leukemia (ALL) as well as acute myeloid leukemia
(AML)), were evaluated. We analyzed samples from 30
children and 20 adults. The patient characteristics are
summarized in Table I. Approval from the Ethical
Committee was obtained.
The mononuclear cells were isolated from peripheral
blood or bone marrow using density gradient centrifuga-
tion on Ficoll-Hypaque. The cells were kept at 48C until
use and were analyzed within 24 h after peripheral blood
or bone marrow collection.
Control Cell Lines
Samples from the human chronic myeloid leukemia cell
line K562 and its P-gp expressing, resistant clone
K562/VLB were included in each ﬂow cytometric experi-
ment as a negative and a positive control, respectively
[17].
Flow Cytometry
Fluorescence was analyzed on a FACSort ﬂow cytometer
(BD Biosystems, Erembodegem, Belgium) calibrated with
the SPHEROTM Caliﬂow Kit (Spherotech, Libertyville,
USA). The FACSort ﬂow cytometer is equipped with an
argon ion laser emitting a 488 nm beam and a red diode
laser emitting a 635 nm beam which makes it possible to
analyze 6 parameters (forward scatter, side scatter and 4
ﬂuorescence parameters) at the same time. At least 10,000
events were counted and analyzed with the Cell Quest
software (BD Biosystems, Erembodegem, Belgium).
Identiﬁcation of Leukemic Blasts
Mononuclear cells (5.105) were incubated with a mono-
clonal antibody, labeled with allophycocyanin, for 30 min
at room temperature. The monoclonal antibodies CD34
(Clone 8G12), CD19 (Clone SJ25C1) or CD3 (Clone
SK7) provided by BD Biosystems (BD Biosystems,
Erembodegem, Belgium) or CD33 (Clone D3HL60.251,
Beckman Coulter, Fullerton, USA) were used to identify
the leukemic blasts. Debris, dead cells and hematogones
were excluded using the forward and side scatter. We
identiﬁed the leukemic cells combining the tumor speciﬁc
monoclonal antibody with the forward and side scatter.
Flow Cytometric Detection of P-gp Activity using
JC-1
After incubation with a tumor speciﬁc monoclonal
antibody, samples were washed twice and cells were
resuspended in 1 ml PBS (phosphate-buﬀered saline)
containing 1 g/l glucose and 0.1 mM JC-1 monomers
(Molecular Probes, Eugene, USA) with or without the
P-gp inhibitor cyclosporine A (2 mM) (Novartis AG,
Basel, Switzerland) [18]. The glucose was added to
maintain the intracellular ATP level and the solution of
the JC-1 monomers (0.1 mM) was prepared by diluting
1% (v/v) of the stock solution (1 g/l) in PBS. This
solution was then ﬁltered on a cellulose syringe ﬁlter
TABLE I Patient characteristics.
Pediatric Patients
precursor B-ALL at diagnosis 17
at relapse 2
T-ALL at diagnosis 2
Biphenotypic AL at diagnosis 1
AML at diagnosis 5
at relapse 3
Total 30
BM samples 24
PB samples 6
Female 16
Male 14
Adult Patients
precursor B-ALL at diagnosis 2
at relapse 1
Bilinear AL at diagnosis 1
AML at diagnosis 15
at relapse 1
Total 20
BM samples 14
PB samples 6
Female 8
Male 12
ALL: acute lymphoblastic leukemia; AL: acute leukemia; AML: acute myeloid
leukemia; BM: bone marrow; PB: peripheral blood
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(0.45 mm) (Sigma, St. Louis, USA) in order to remove JC-
1 aggregates. The maximum JC-1 concentration in buﬀer
without formation of aggregates is approximately
0.1 mM. After an incubation of 15 min at 378C, cells
were washed twice and samples were analyzed on the ﬂow
cytometer. The ﬂuorescence of the JC-1 monomers and
liquid crystal forms was analyzed on the FL-1 and the
FL-2 channel, respectively. Cells with functional P-gp
pumps show a shift in red and/or green ﬂuorescence
which can be reversed by cyclosporine A (Fig. 1). The
percentage of cells showing a shift in red ﬂuorescence
which could be inhibited by cyclosporine A was
determined (Fig. 1).
The threshold for positivity of the JC-1 assay was
calculated using ROC curve analysis [19,20]. The
sensitivity and the speciﬁcity of the JC-1 test were
calculated using diﬀerent cut-oﬀ values. Finally, the cut-
oﬀ value corresponding with the highest accuracy
(percentage of positive cells=18.70) was accepted as
the threshold for positivity.
Flow Cytometric Detection of P-gp Activity using
Rhodamine 123
After incubation with a tumor speciﬁc monoclonal
antibody, the cells were washed and incubated for one
hour at 378C with 200 ng/ml rhodamine 123 (Sigma, St.
Louis, USA) with or without 10 mM of the P-gp inhibitor
verapamil (Knoll AG, Ludwigshafen, Germany) [21]. The
cells were washed twice and resuspended in medium
without rho123 in the presence or absence of verapamil.
After an incubation of 1 h at 378C, the intracellular
rho123 concentration was measured with a ﬂow
cytometer. The percentage of cells showing a rhodamine
123 eﬄux which could be inhibited by verapamil was
determined.
The threshold for positivity of the rho123 assay was
calculated using ROC curve analysis [19,20]. The cut-oﬀ
value corresponding with the highest accuracy (percen-
tage of positive cells=0.49) was accepted as the thresh-
old for positivity.
Flow Cytometric Detection of P-gp Expression
Mononuclear cells (5.105) isolated from peripheral blood
or bone marrow were incubated for 30 min with the
unlabeled isotypic control antibody IgG2a (Clone: DAK-
G05, Dako Corporation, Glostrup, Denmark) or with the
unlabeled P-gp speciﬁc monoclonal antibody MRK16
(Clone: MRK16, Kamiya Biomedical Company, Thou-
sand Oaks, USA) in parallel samples. Cells were washed
twice and incubated for 20 min with ﬂuorescein isothio-
cyanate- or phycoerythrin- labeled polyclonal goat
F(ab’)2 anti-mouse IgG antibodies (Caltag Laboratories,
Burlingame, UK). Leukemic blasts were identiﬁed by
tumor speciﬁc markers and the ﬂuorescence was analyzed
on the ﬂow cytometer.
Using the Kolmogorov-Smirnov test, the ﬂuorescence
of the gated leukemic cell population incubated with
MRK16 was compared to the ﬂuorescence of the cells
incubated with the isotypic control antibody IgG2a. A D-
value of 0.15 was used as a threshold for positivity [22].
Statistical Analysis
We used the Spearman’s rank correlation coeﬃcient (Rs)
to study the correlation between diﬀerent parameters.
After classifying the results in a frequency table, a w2 test
FIGURE 1 Example of a positive (A) and a negative (B) sample. The histograms show the changes in red ﬂuorescence (FL2). Resistant cells,
expressing functional P-gp pumps will contain lower concentrations of JC-1. Below a critical concentration, no JC-1 aggregates displaying a red
ﬂuorescence are formed. Therefore, positive cells show a shift in red ﬂuorescence which can be reversed by cyclosporin A, a P-gp inhibitor. The
percentage of leukemic blasts showing a reversible shift in red ﬂuorescence was determined. The threshold for positivity was calculated using ROC
analysis and was set at 18.7%.
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was performed to study the relationship between the
diﬀerent categories. Finally, we compared proportions
using a w2 test with a Yates’ correction for continuity.
RESULTS
Analysis of the P-gp Activity using Rho123 and JC-1
In samples from 50 acute leukemia patients, the P-gp
activity was analyzed using both functional assays. The
results are summarized in Table II.
Of all tested samples, 28% (14/50) showed a reversible
JC-1 eﬄux. 36% (18/50) of all samples scored positive for
the functional assay using rho123. Twelve samples scored
positive for both tests and thirty patients showed no
functional P-gp pumps. In two pediatric cases, the
leukemic blasts showed a reversible JC-1 eﬄux but they
did not transport rho123. Six patients scored positive for
the rho123 test but were negative for the JC-1 assay.
Signiﬁcantly more AML than ALL patients had
leukemic blasts which expressed functional P-gp pumps
(for JC-1 assay: w2=5.53, P=0.019; for rho123 assay:
w2=8.27, P=0.004). Eleven out of 24 AML patients
(46%) scored positive for the functional JC-1 assay.
Fourteen AML patients (54%) were positive for the
rho123 test. In contrast, only 12% of the ALL patients
(3/26) showed a reversible JC-1 eﬄux. Four ALL patients
(15%) scored positive for the rho123 test.
The correlation between both functional tests was
strong (Rs=0.59, p5 0.0001). Based on the thresholds
for positivity, the results were classiﬁed in a frequency
table and the relationship between the JC-1 and the
rho123 assay was calculated using a w2 test. There was a
clear association between both tests (w2=17.97,
p5 0.0001). There was also a correlation between the
P-gp function evaluated by the JC-1 test and the P-gp
expression analyzed using the monoclonal antibody
MRK16 (Rs=0.29 and P=0.05). In contrast, there
was no correlation between the rho123 assay and the
immunological MRK16 test (Rs=0.12 and P=0.43).
Correlation between the Functional JC-1 Assay and
the Clinical Outcome
The patients were divided into a pediatric and an adult
group. The mean follow-up time was 40 months for the
surviving children (n=27) and 38 months for the
surviving adult leukemia patients (n=10).
Out of 30 children, three died of leukemic disease (two
AML patients and one precursor B-ALL patient) and one
child with a biphenotypic acute leukemia relapsed. None
of these four children showed a reversible JC-1 eﬄux
(Table III). Only one scored positive for the rho123 assay.
Six children scored positive for the JC-1 assay but were
still in complete remission at the time of the analysis.
There was no association between the P-gp activity and
the clinical outcome in the pediatric patients (for JC-1
assay: w2=1.15 and P=0.56; for rho123 test: w2=0.43
and P=0.81). There was also no association between the
results of the immunological assay and the clinical
outcome (w2=0.56 and P=0.76).
From a child with AML, two samples, taken at
diﬀerent time points, were analyzed using the JC-1 assay.
The ﬁrst sample was taken at relapse and the leukemic
blasts did not express functional P-gp pumps. The second
sample was collected after 3 weeks of chemotherapy and
it showed an increased percentage of leukemic blasts with
a reversible shift in red ﬂuorescence (Fig. 2). The child
died shortly thereafter.
Out of 20 adult patients, 10 (50%) died of leukemic
disease and one patient relapsed (Table III). Eight
patients (40%) showed a reversible JC-1 eﬄux. One of
them was still in complete remission at the time of the
analysis. There was an association between the JC-1
status and the clinical outcome of the adult acute
leukemia patients (w2=6.30 and P= 0.04). Ten adults
scored positive for the functional rho123 test. Of these, 3
were still in complete remission at the time of analysis.
There was no association between the results of the
rho123 or the immunological test and the clinical
outcome of the adults (for rho123: w2=2.40 and
P=0.30; for MRK16: w2=3.24 and P=0.20).
Based on the results of the adult patients, the
sensitivity, the speciﬁcity, the positive predictive value
and the negative predictive value of the functional assay
using JC-1 was calculated. They were 64, 89, 88 and 67%,
respectively.
DISCUSSION
Rhodamine 123 is most frequently used as substrate in
functional ﬂow cytometric assays evaluating P-gp func-
tion. It has a good ﬂuorescence quantum yield but a
fraction of the ﬂuorophore binds to the cell membrane
[23]. This leads to a high ﬂuorescence background and
compensation problems which hamper the identiﬁcation
of leukemic blasts. To overcome this problem, we
incubated the blasts with a tumor speciﬁc monoclonal
antibody labeled with allophycocyanin. This ﬂuoro-
chrome can only be excitated at 600 – 640 nm. Using a
ﬂow cytometer equipped with two lasers, allophycocyanin
can be excitated without causing a high ﬂuorescence
background or compensation problems related to
rhodamine 123. This makes it possible to identify small
populations of leukemic blasts or detect leukemic cells
with a low P-gp activity. Moreover, better results are
obtained with a rho123 assay based on eﬄux rather than
uptake [18]. However, eﬄux procedures are time
consuming. Finally, rho123 is also a substrate for
MRP1 although it is less eﬃciently transported by
MRP1 than by P-gp [24].
JC-1 causes no background problems because all the
detected red ﬂuorescence results from the liquid crystals
in the mitochondria of the cells [25]. In addition, this test
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does not require drug eﬄux monitoring. This makes the
assay much faster and less labor intensive compared to
the conventional functional ﬂow cytometric assay using
rho123. In contrast with the rho123 assay which takes
more than 3 h, the JC-1 test is completed in less than 1 h.
Finally, Legrand et al. found that JC-1 could not be
transported by MRP1 which increases the speciﬁcity of
the test [15].
TABLE II Results of the ﬂow cytometric evaluation of the P-gp activity using JC-1 and rho123. Samples 1 to 30: pediatric patients; Samples 31
to 50: adult patients.
NR TYPE Time Point Sample % JC-1 positive cells JC-1 % rho123 positive cells rho123 Outcome
1 AML Diagnosis BM 18,72 + 8,96 + CR
2 B-ALL Diagnosis BM 12,44 - 0,00 - CR
3 B-ALL Diagnosis BM 1,56 - 0,00 - CR
4 AML Relapse BM 18,26 - 14,29 + CR
5 B-ALL Relapse BM 13,89 - 0,00 - CR
6 B-ALL Diagnosis PB 59,78 + 3,11 + CR
7 AML Relapse PB 6,19 - 2,36 + D
8 AML Diagnosis BM 3,65 - 0,37 - CR
9 B-ALL Relapse BM 0,01 - 0,00 - D
10 B-ALL Diagnosis PB 12,33 - 0,49 + CR
11 B-ALL Diagnosis PB 3,77 - 0,00 - CR
12 AML Diagnosis BM 31,76 + 18,51 + CR
13 B-ALL Diagnosis BM 13,60 - 0,16 - CR
14 B-ALL Diagnosis BM 11,78 - 1,81 + CR
15 B-ALL Diagnosis BM 14,67 - 0,00 - CR
16 B-ALL Diagnosis PB 37,80 + 0,00 - CR
17 AML Diagnosis BM 1,91 - 0,00 - CR
18 B-ALL Diagnosis BM 12,39 - 0,00 - CR
19 T-ALL Diagnosis BM 0,44 - 0,23 - CR
20 B-ALL Diagnosis BM 4,24 - 0,30 - CR
21 Bi. ALL Diagnosis BM 8,39 - 0,00 - R
22 B-ALL Diagnosis BM 8,35 - 0,00 - CR
23 B-ALL Diagnosis BM 29,11 + 0,00 - CR
24 B-ALL Diagnosis BM 2,18 - 0,00 - CR
25 B-ALL Diagnosis PB 13,61 - 0,00 - CR
26 B-ALL Diagnosis BM 6,28 - 0,00 - CR
27 AML Diagnosis BM 53,60 + 17,09 + CR
28 B-ALL Diagnosis BM 4,01 - 0,00 - CR
29 T-ALL Diagnosis BM 0,00 - 0,00 - CR
30 AML Relapse BM 4,24 - 0,00 - D
31 AML Diagnosis BM 0,63 - 0,00 - D
32 AML Diagnosis BM 5,94 - 4,05 + CR
33 AML Diagnosis PB 18,81 + 10,98 + D
34 AML Diagnosis PB 27,63 + 3,78 + D
35 AML Diagnosis BM 24,67 + 1,30 + D
36 AML Diagnosis BM 4,59 - 0,00 - CR
37 AML Diagnosis BM 5,46 - 0,00 - D
38 AML Diagnosis BM 10,32 - 0,00 - CR
39 B-ALL Relapse BM 8,61 - 0,17 - CR
40 AML Relapse BM 57,66 + 4,00 + D
41 AML Diagnosis BM 11,03 - 0,00 - D
42 AML Diagnosis PB 85,24 + 8,77 + CR
43 B-ALL Diagnosis BM 4,63 - 0,00 - CR
44 Bilinear Diagnosis PB 13,43 - 2,04 + CR
45 B-ALL Diagnosis PB 14,13 - 0,00 - CR
46 AML Diagnosis PB 2,67 - 0,00 - D
47 AML Diagnosis BM 86,11 + 11,07 + R
48 AML Diagnosis BM 29,72 + 4,13 + D
49 AML Diagnosis BM 5,66 - 0,00 - CR
50 AML Diagnosis BM 29,42 + 27,77 + D
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; Bi.: biphenotypic, BM: bone marrow; PB: peripheral blood; D: deceased, R: relapsed, CR: complete
remission.
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In this study, we used both tests to assess the P-gp
status in leukemic blasts. Peripheral blood or bone
marrow samples from 50 acute leukemia patients were
evaluated. Fourteen samples (28%) scored positive for
the functional JC-1 test. A reversible rho123 eﬄux was
seen in 18 samples (36%). In 2 patients, no rho123
transport was detected although they were clearly positive
for the JC-1 test. These patients had blasts with a very
low P-gp activity. However, even low P-gp activity can
cause multidrug resistance. Six patients scored positive
for the rho123 test, but were negative for the JC-1 assay.
In one of these samples, the percentage of leukemic blasts
with a reversible JC-1 eﬄux was just below the threshold.
In the other samples, the percentage of leukemic blasts
showing a reversible rho123 eﬄux was very low. The
leukemic cells in these samples were negative for the
immunological MRK16 assay which means that they did
not express P-glycoprotein. Therefore, these results were
considered to be false positive. The rho123 is probably
transported by MRP1 in stead of P-gp [24].
We found a strong correlation between the functional
JC-1 assay and the rho123 test. This is in contrast with
the results of Legrand et al. [15]. They found no
correlation between the rho123 eﬄux and the percentage
of leukemic blasts showing a reversible shift in red
ﬂuorescence. This diﬀerence is probably due to the fact
that we optimized our rho123 assay by using tumor
speciﬁc monoclonal antibodies labeled with allophyco-
cyanin to identify the leukemic blasts.
AML patients exhibited a signiﬁcantly higher level of
P-gp function compared to ALL patients. Eleven out of
24 AML patients (46%) scored positive for the functional
JC-1 assay. Fourteen AML patients (58%) showed a
reversible rho123 eﬄux. Although this is less than the
FIGURE 2 Increase in the percentage of positive cells in consecutive samples taken from a child with AML. The ﬁrst sample was taken at relapse and
did not express functional P-gp pumps. The second sample was taken 3 weeks later and showed an increased percentage of leukemic blasts showing a
reversible shift in red ﬂuorescence. The child died shortly after the last analysis.
TABLE III Association between both functional ﬂow cytometric assays and the clinical outcome of the acute leukemia patients
Pediatric Patients Adult Patients
Outcome Outcome
D R CR D R CR
JC-1 + 0 0 6 6 w2= 1,15 JC-1 + 6 1 1 8 w2= 6,30
7 3 1 20 24 P=0,56 7 4 0 8 12 P=0,04
3 1 26 30 10 1 9 20
Pediatric Patients Adult Patients
Outcome Outcome
D R CR D R CR
rho123 + 1 0 7 8 w2= 0,43 rho123 + 6 1 3 10 w2= 2,40
7 2 1 19 22 P=0,81 7 4 0 6 10 P=0,30
3 1 26 30 10 1 9 20
D: deceased, R: relapsed, CR: complete remission.
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percentage of positive AML patients found by Legrand et
al. (65%) [15], it is still comparable with previously
published results [2,26,27].
We studied the association between the P-gp status and
the clinical outcome in 30 children and 20 adults suﬀering
from acute leukemia. In the pediatric group, there was no
correlation between P-gp activity and clinical outcome.
This is in accordance with the results of Kanerva et al.
and Wuchter et al. but in conﬂict with the data of De
Moerloose et al. [5,6,28]. This lack of correlation was
probably due to small patient group and the hetero-
geneity of the samples. In addition, multidrug resistance
can also be caused by the overexpression of other
transport pumps such as the members of the multidrug
resistance associated protein family (MRP 1 – 6) and the
lung cancer related protein (LRP). Further investigations
will be necessary to determine the prognostic value of
these pumps in childhood acute leukemia.
We also analyzed the P-gp function in two samples
taken at diﬀerent time points from a child with AML.
The ﬁrst sample, taken at relapse, scored negative for the
JC-1 assay. In a second sample, taken three weeks later,
20% of the leukemic cells showed a reversible JC-1 eﬄux.
This is in accordance with previously published results
showing that the treatment of leukemic patients with
anthracyclines and vinca alkaloids may further increase
the P-gp expression in previously negative patients since
these drugs are substrates of the P-gp pump [29 – 31].
Despite the small patient group and the heterogeneity
of the samples, we demonstrated a correlation between
the JC-1 status and the clinical outcome in the adult acute
leukemia patients. This is in accordance with the results
of Lamy et al., Leith et al. and Legrand et al. [2,3,26].
In conclusion, we highly recommend the JC-1 assay to
study the P-gp activity in acute leukemia because it is
more speciﬁc and less labor intensive than the conven-
tional functional ﬂow cytometric test using rhodamine
123. In addition, our results show that the functional JC-1
assay can be used to identify adult patients with an
increased risk for an adverse clinical outcome.
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4. Discussion and future perspectives 
A major cause of treatment failure in childhood ALL is pre-existent or acquired resistance to 
a variety of structurally and functionally unrelated chemotherapeutic compounds. Generally, 
MDR is associated with transmembrane protein-mediated efflux of cytotoxic compounds 
leading to a decreased intracellular drug accumulation and toxicity. Several MDR-related 
drug efflux pumps have been characterized, including P-gp, MRP1, BCRP and LRP. Current 
knowledge about the clinical relevance and prognostic significance of multidrug resistance-
related proteins in childhood ALL is reviewed in Paper 1. However, the lack in standardized 
detection techniques, the differences in treatment protocols and the heterogeneity in patient 
groups (e.g. pooled data of ALL and AML, initial and relapse samples, adults and children), 
hamper the comparison of data.  
 
Several authors reported a relationship between P-gp expression and/or function and clinical 
outcome in children with ALL.168-177 Other groups, however, contradicted these findings.178-181 
We assessed the clinical relevance of P-gp expression and activity in childhood ALL in a 
prospective study (Paper 2). The P-gp expression was analyzed using an 
immunocytochemical assay and the P-gp activity was measured by a functional flow 
cytometric test using rho123. Neither P-gp expression nor P-gp activity were associated with 
a higher relapse rate or an increased risk of death. However, the combination of P-gp 
expression and activity revealed a statistically significant parameter predicting relapse in 
childhood ALL. Furthermore, patients with a positive result for both tests had a 4.5-fold 
higher risk of death compared to the negative group. Based on our findings, we recommend 
combining complementary techniques such as immunocytochemistry and flow cytometry in 
order  to  guarantee the accurate assessment of P-gp expression and activity.  Moreover, 
pediatric ALL patients with increased risk for relapse can only be identified in case both tests 
are combined. 
 
Information on the prognostic significance of other MDR proteins is scarce. LRP and BCRP 
might contribute to drug resistance in precursor B-cell lymphoblastic leukemia but these 
findings are not confirmed yet.183-187 MRP1 does not seem to play a major role in clinical 
resistance in pediatric ALL patients176,184,186 and of all newly identified ABC transporters (e.g. 
MRP2-MRP9, sP-gp and TAP), only MRP3 expression is associated with a significantly 
worse prognosis.188  
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One of the reasons for the variability in published data is the lack in standardized, sensitive 
and specific detection techniques. Although this problem has been addressed by a number 
of international workshops, development of consensus recommendations has been difficult 
due to differences in assay sensitivity and specificity, the need to distinguish between normal 
and malignant cells, and the definition of a clinically relevant threshold.189-193 However, 
functional flow cytometric tests assessing modulator-induced changes in fluorophore 
retention and/or efflux are promoted because they allow, in contrast to immunological or 
molecular tests, the evaluation of protein activity (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: JC-1: 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolcarbocyanine iodide; 
DiOC2: 3,3’-diethyloxacarbocyanine iodide; Calcein-AM: calcein acetoxy-methyl ester;  
CFDA: carboxy fluorescein diacetate  
 
We compared a highly sensitive flow cytometric assay using the carbocyanine liquid crystal 
forming probe JC-1 with a conventional technique using rhodamine 123 (rho123) to assess 
P-gp activity in acute leukemia (Paper 3). Compared to rho123, JC-1 has several 
advantages: 1) since JC-1 does not cause background problems, up to three different tumor 
specific monoclonal antibodies can be used to identify leukemic blasts, 2) the JC-1 test does 
not require drug efflux monitoring which makes it much faster and less labor intensive than 
the conventional rho123 test, 3) JC-1 is not transported by MRP1 which increases the 
specificity of the test182, and 4) the JC-1 assay can be used to detect low P-gp activity which 
is extremely important since even a weak efflux may lead to cellular drug resistance.182 
Based on these findings, we decided to implement this novel sensitive assay in the lab.  
 
Table 3 
Functional flow cytometric assays 
 
 
MDR-related 
protein 
 
 
Substrate 
 
Inhibitor 
 
P-gp 
 
 
 
 
 
 
MRP 
 
 
 
 
BCRP 
 
 
LRP 
 
Rhodamine 123 
JC-1 
DiOC2 
Calcein AM 
Syto16 
Daunorubicin 
 
CFDA 
Calcein-AM 
Rhodamine 123 
 
 
Mitoxantrone 
Prazosin 
 
Daunorubicin 
 
Verapamil 
Cyclosporin A 
PSC833 
 
 
 
 
Buthionine Sulfoximine 
MK-571 
Probenecid 
Genistein 
 
Fumitremorgin C 
GF120918 
 
Unknown 
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In addition, a study evaluating the clinical importance of P-gp activity measured by JC-1 
accumulation in childhood ALL is underway. From May 2001 till May 2004, peripheral blood 
or bone marrow samples, taken at diagnosis or relapse, from 30 children suffering from ALL 
have been analyzed using the functional JC-1 assay. Preliminary data indicate that there is 
no association between the P-gp activity measured by JC-1 accumulation and the clinical 
outcome of these children. However, continued accrual and longer follow-up is necessary 
before a definitive conclusion can be drawn. 
 
Detailed information on the nature, function, substrate and inhibitor specificity, and clinical 
relevance of MDR-related proteins is needed before the potential of transporter-specific 
modulators can be explored. So far, phase 3 clinical trials with P-gp antagonists in adult AML 
patients have yielded conflicting results.194,195 This may be explained by the co-expression of 
other cellular drug resistance efflux pumps. The different transporters may act in concert and 
inhibition of one transporter may lead to compensation by other transport proteins. This 
functional redundancy between different MDR-related proteins represents a challenge in 
clinical studies evaluating correlations between drug sensitivity and expression of specific 
pumps. In our opinion, large and well controlled multicenter studies are needed to determine 
the prognostic significance of MDR-related transport proteins in childhood ALL. In addition, 
an international effort should be made to develop, optimize and standardize sensitive and 
specific detection techniques.  
 
In conclusion, the JC-1 assay, evaluated and optimized within the framework of this thesis, is 
an asset for studies evaluating the clinical importance of P-gp activity. In addition, the 
combination of P-gp expression and activity predicts relapse in childhood ALL. However, 
large multicenter, quality controlled, prospective clinical studies are needed to confirm our 
results and elucidate the clinical relevance of other MDR-related proteins.  
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1. Introduction 
At diagnosis, approximately 40% of the neuroblastoma patients present with high risk stage 4 
disease and bone marrow involvement.196 These children have a poor clinical outcome 
despite intensive multimodal therapy including autologous stem cell transplantation.197,198 
According to the INSS, conventional cytomorphological screening of bone marrow smears is 
still the only accepted method for the detection of disseminated neuroblastoma cells.111,118 
However, Méhes and colleagues reported that a tumor cell infiltrate below 0.1% can be 
overlooked by conventional cytomorphology.113 Consequently, more sensitive and specific 
detection techniques are urgently needed in order to guarantee correct clinical staging and 
risk assessment at diagnosis. These methods may also be applied to monitor therapeutic 
response during treatment and detect relapse before overt metastasis occur, resulting in 
earlier clinical intervention. In addition, screening of autologous stem cell preparations is 
crucial since the re-infusion of contaminated stem cell products could lead to systemic 
recurrence.199-201 
Within the framework of this thesis, three new detection techniques were developed and 
evaluated. In collaboration with the SIOPEN Bone Marrow Subcommittee, an 
immunocytochemical assay, based on the detection of GD2 disialoganglioside, was 
optimized and standardized (Paper 4). Moreover, morphological and immunological 
evaluation criteria were formulated and a work flow was designed. In paper 5, two four-color 
flow cytometric assays using different combinations of CD9, CD81, CD56, CD45 and anti-
GD2 disialoganglioside are described. Disseminated neuroblastoma cells were also detected 
by means of TH, ELAVL4 and GD2 synthetase real-time quantitative RT-PCR (QPCR) 
(Paper 6). Current knowledge about the detection techniques, used to study minimal residual 
disease, is reviewed in paper 7. 
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2.  Detection of disseminated neuroblastoma cells 
2.1. Paper 4 
 
STANDARDIZATION OF THE IMMUNOCYTOCHEMICAL DETECTION OF 
NEUROBLASTOMA CELLS IN BONE MARROW 
 
Swerts K., Ambros P.F., Brouzes C., Fernandez Navarro J.M., Gross N., Rampling D., 
Schumacher-Kuckelkorn R., Sementa A.R., Ladenstein R. and Beiske K. 
 
Journal of Histochemistry and Cytochemistry (In Press) 
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Standardization of the immunocytochemical detection of 
neuroblastoma cells in bone marrow 
 
Swerts K., Ambros P.F., Brouzes C., Fernandez Navarro J.M., Gross N., Rampling D., 
Schumacher-Kuckelkorn R., Sementa A.R., Ladenstein R. and Beiske K. 
 
Journal of Histochemistry and Cytochemistry (In Press) 
 
 
ABSTRACT 
 
Standard cytomorphological examination of bone marrow (BM) aspirates appears not 
sensitive enough to detect single neuroblastoma cells. The SIOPEN Neuroblastoma Bone 
Marrow Committee developed a sensitive and reproducible anti-GD2 immunocytochemical 
assay and introduced morphological and immunocytological criteria for the interpretation of 
results. Fixed cytospins were incubated with a commercially available anti-GD2 monoclonal 
antibody and an APAAP kit. Cells fulfilling all morphological and immunocytological criteria 
were called Criteria Positive Cells (CPC’s). Not Convincingly Interpretable Cells (NCIC’s) 
fulfilled some but not all criteria and Negative Cells (NC’s) displayed only exclusion criteria. 
The genetic profile of doubtful cells was checked by FISH. Ideally, 3x106 cells were analyzed 
to reach a 95% probability of detecting one tumor cell in 1x106 mononuclear cells. Four 
quality control (QC) rounds were organized to validate the method. A total of 111 QC 
samples were analyzed. Two main improvements were achieved: in discordant cases, the 
range between lowest and highest reported result was reduced by half, and discordant 
results were only found in samples with less than 10 CPC’s per 1x106. This paper describes 
the first internationally standardized protocol to detect and quantify rare neuroblastoma cells 
by immunocytochemistry. This method is an indispensable tool for multicenter studies 
evaluating the clinical significance of minimal residual disease in neuroblastoma. 
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INTRODUCTION 
 
Neuroblastoma (NB), a tumor originating from the sympathetic nervous tissue, is the most 
common extra-cranial solid tumor in children with a yearly incidence of 7 to 10 per million. 
The tumor consists of sympathetic neuronal elements of variable immaturity and shows a 
diverse clinical behavior. Approximately 40 % of the NB patients suffer from high risk stage 4 
disease with bone marrow (BM) involvement.1 These children have a poor clinical outcome 
despite intensive multimodal therapy.2 
The demonstration of disseminated tumor cells in BM is important for clinical staging and risk 
assessment at diagnosis and for monitoring therapeutic response during treatment. In 
addition, screening of autologous stem cell preparations is crucial since the re-infusion of 
contaminated stem cell products could lead to systemic recurrence.3-5  
According to the International Neuroblastoma Staging System (INSS), conventional cytology 
of BM smears is still the only accepted technique for the detection of disseminated NB cells.6 
However, the sensitivity of this approach is limited since a tumor cell number below 0.1 % is 
virtually not detectable by conventional cytomorphology.7,8 Therefore, the development of 
more sensitive and specific detection methods is indispensable.  
During the last decades, several assays based on immunocytology 9-11, automatic 
immunofluorescence plus FISH (AIPF) 12, reverse transcription polymerase chain reaction 
(RT-PCR) 13-16 or flow cytometry 17-20 were evaluated. However, the reliability of tumor cell 
detection and quantification by these methods remains controversial.  
A Neuroblastoma Bone Marrow Committee (NBMC) was established by the European 
Neuroblastoma Study Group to evaluate and standardize procedures for the detection of 
minimal residual disease (MRD) in NB patients. In connection with the evaluation of a new 
high risk protocol by the SIOP European Neuroblastoma (SIOPEN) group, the NBMC 
developed, optimized and standardized an immunocytochemical assay based on the 
detection of the neuroblastoma specific GD2 disialoganglioside. In addition, morphological 
and immunocytological criteria for the interpretation of results were introduced and 
standardized. Four multicenter quality control rounds were organized among nine European 
research groups to evaluate the technique and assess the inter-observer concordance. The 
latter improved markedly after the adoption of the standardized protocol.  
This paper describes a standardized immunocytochemical staining method and minimal 
morphological and immunocytological criteria for the evaluation of stained BM samples. The 
application of this protocol will lead to a more reproducible and reliable assessment of MRD 
in NB. We believe that a standardized method is needed to generate comparable results in 
multicenter studies evaluating the clinical significance of MRD 
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MATERIALS AND METHODS 
 
Sample collection 
After informed consent, bilateral BM aspirates from the iliac crest were performed following 
previously published guidelines.6,21 The second aspiration from each puncture site was used 
for immunocytology and FISH. Bilateral BM samples were not pooled and were transferred to 
the laboratory at room temperature as fast as possible.  
 
Control samples 
Slides containing cells from a NB cell line (e.g. IMR32) were included in every experiment as 
positive controls. For negative control, the primary anti-GD2 antibody was replaced with an 
antibody of the same IgG2a isotype (Dako Corporation, Glostrup, Denmark). This allowed us 
to evaluate the background staining caused by the interaction of the anti-GD2 antibody with 
Fc-receptor bearing leucocytes.  
 
Isolation, processing and storage of mononuclear cells 
Mononuclear BM cells were isolated by density gradient centrifugation using Lymphoprep 
(Nycomed, Oslo, Norway) following the instructions of the manufacturer. Aspirates from 
different sites were processed separately. After separation, the mononuclear cells were 
collected from the interphase layer and washed twice in phosphate buffered saline (PBS) 
(Gibco, Paisley, UK). 
Large diameter cytospins (17 mm) containing approximately 5x105 mononuclear cells were 
prepared. These slides should not be overcrowded and the mononuclear cells must lie well 
separated from one another. This can be achieved by centrifuging no more than 7x105 cells 
down on precoated (e.g. poly-L-lysine) glass slides in a Hettich centrifuge (Hettich 
Zentrifugen, Tuttlingen, Germany).  
The slides were air-dried overnight and stored in air-tight plastic boxes or wrapped in 
aluminum foil at –24 °C until immunocytology was performed. Before staining, the slides 
were thawed in closed boxes to avoid formation of condensation water because this could 
destroy the morphology of the cells.  
 
Standardized immunocytochemical staining protocol 
The NBMC decided to standardize the fixation, the immunocytochemical staining procedure 
and the evaluation of immunocytological results in order to improve the sensitivity, specificity 
and reproducibility of MRD detection in NB. 
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Fixation: 
The cytospins must be fixed in 4 % buffered paraformaldehyde for 10 minutes. Commercially 
available formaldehyde can also be used provided that it is free from methanol. In order to 
avoid artificial tumor cell contamination, slides must be incubated individually. After fixation, 
the cytospins are washed three times with PBS to remove remainders of the fixative.  
 
Immunocytochemical staining: 
The staining procedure comprises 10 subsequent steps. All incubations are performed in a 
humidifier at room temperature. 
 
1. Incubation of cytospins for 30 minutes with 30 µl of an unlabeled monoclonal mouse 
anti-human GD2 disialoganglioside antibody (clone 14.G2a, BD Biosystems, 
Erembodegem, Belgium) diluted 1/100 in 1 % BSA in PBS (Bovine Serum Albumin, 
Gibco, Paisley, UK).  
2. Washing twice with PBS for 5 min. 
3. Incubation for 30 minutes with 30 µl of an unlabeled rabbit anti-mouse antibody (Dako 
Corporation, Glostrup, Denmark), diluted 1/20 in 1 % BSA in PBS.  
4. Repetition of step two.  
5. Incubation with 30 µl of the APAAP complex (Dako Corporation, Glostrup, Denmark), 
diluted 1/20 in 1 % BSA in PBS.  
6. Repetition of step two. 
7. Incubation with Dako Fuchsin+ ™ Substrate Chromogene System (Dako Corporation, 
Glostrup, Denmark), prepared as indicated by the manufacturer, for no longer than 10 
minutes.  
8. Washing in running tap water for at least 5 minutes.  
9. Counterstaining with hematoxylin (Sigma, St. Louis, USA) until an appropriate blue 
nuclear stain is obtained.  
10. Mounting in aqueous mounting medium (e.g. Glycergel mounting medium, Dako 
Corporation, Glostrup, Denmark) with coverslip.  
 
Evaluation of immunocytochemically stained samples: 
The characteristics of GD2-positive disseminated NB cells and false positive hematopoietic 
cells were examined in detail. The observations lead to the following morphological and 
immunocytological guidelines for the identification of positive cells.  
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Morphological criteria:  
Cells with a round nucleus, often, but not always larger than that of small lymphocytes, 
displaying a granular chromatin structure and a scarce amount of cytoplasm are considered 
positive. Cells showing a low nuclear/cytoplasmic ratio or typical morphological features of 
hematopoietic cells are considered negative. Cells found outside or on the boarder of the 
cytospin field are excluded.  
 
Immunocytological criteria: 
Cells must display a strong, deep red staining localized to the entire cell membrane and 
cytoplasm. A weak staining and a staining restricted to a subcellular compartment or 
covering the nucleus is considered negative. In addition, cells surrounded by positively 
stained amorphous material are excluded.  
 
Based on the morphological and immunocytological criteria, cells are classified into three 
groups:  
1) CPC’s (Criteria Positive Cells): cells fulfilling all morphological and immunocytological 
inclusion criteria (Figure 1 A-D).  
2) NCIC’s (Not Convincingly Interpretable Cells): cells fulfilling some but not all inclusion 
criteria (Figure 1 E).  
3) NC (Negative Cells): cells displaying only exclusion criteria (Figure 1 F-G).  
 
Single cells as well as cells being part of a Homer Wright rosette or cell clump are evaluated, 
classified and counted. Clumps or rosettes consisting of too much cells to evaluate or count, 
are reported separately. In addition, the estimated number of evaluated mononuclear cells 
must be reported. 
When evaluating or reporting immunocytochemical results, the work flow depicted in Figure 2 
should be followed. No further review is needed when no GD2 positive cells or more than 10 
CPC’s are present. For samples with 1 to 10 CPC’s or samples containing NCIC’s, central 
review by the members of the NBMC is obligatory. When no consensus is reached, the 
genetic profile of the doubtful cells should be checked by FISH to find out whether it 
corresponds to the cytogenetic aberrations found in the primary tumor. The sequential 
immunocytological staining and molecular cytogenetic characterization can be done using an 
automated scanning and relocation system (e.g. Metafer4/RCDetect, MetaSystems, 
Altlussheim, Germany).12 GD2 positive cells showing genetic aberrations (e.g. gain of whole 
chromosomes or 17q and MYCN amplification) are called FPC’s (FISH Positive Cells) 
(Figure 3). 
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Figure 1: Immunocytochemical analysis of BM slides from NB patients according to the 
standardized protocol. A: CPC’s (Criteria Positive Cells) forming a clump. NB cells in clumps 
do not always display a round nucleus because they adjust their form to the clump. The 
entrapped erythroblast (arrow) is smaller than the NB cells and displays a different chromatin 
structure. B: The 2 CPC’s mold in a different way compared to the surrounding hematopoietic 
cells. C: Two CPC’s showing the typical nuclear size, chromatin structure and 
nuclear/cytoplasmic ratio which clearly differs from hematopoietic cells. The myeloid cells 
(arrow) are passively stained due to the shedding of the GD2 antigen by the NB cells. D: If 
the morphological and immunological criteria are fulfilled, even a single cell can be identified 
as CPC. E: The staining intensity of this cell is comparable to that of a CPC but the nuclear 
shape, size, chromatin structure and the nuclear cytoplasmic ratio do not fulfill the criteria. 
Therefore the cell is classified as NCIC (Not Convincingly Interpretable Cell). F: Neither the 
nuclear/cytoplasmic ratio nor the vesicular structure of the cytoplasm fulfils the criteria. The 
cell has the cytological features of a histiocyte. G: The cell on the left side has the same size 
and displays the same staining intensity as the CPC on the right. However, the nuclear 
shape and the nuclear/cytoplasmic ratio do not fulfill the criteria. Moreover, the cell contains 
GD2 positive material in the cytoplasm (arrow). This is a typical feature of a macrophage. H: 
Strongly positive material (right) without a visible nucleus is not reported. CPC on the left. 
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Figure 2: Work Flow (CPC’s: Criteria Positive Cells; NCIC’s: Not Convincingly Interpretable 
Cells; MNC’s: mononuclear cells; AIPF: Automatic Immunofluorescence plus FISH; FPC’s: 
FISH Positive Cells) 
 
 
 
 
Figure 3: Automatic Immunofluorescence plus FISH (AIPF) allows the sequential 
immunological staining and molecular cytogenetic characterization of disseminated NB cells. 
A: GD2 positive cells (green fluorescence). The nucleus is stained with DAPI (blue 
fluorescence). B: The genetic make up of the GD2 positive cells is visualized by FISH. Only 
one GD2 positive cell displays MYCN amplification (green fluorescence). GD2 positive cells 
displaying the same genetic aberrations as the primary tumor are called FISH Positive Cells 
(FPC’s). 
 
 
 
 
 
 
 
 
 
 
 
FPC’s (AIPF) 
Initial evaluation
Negative sample > 10 CPC’s per 
1x106 MNC’s 
1 to 10 single CPC’s 
per 1x106 MNC’s 
Only NCIC’s 
present 
No further review Central review 
A B
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RESULTS 
 
Sensitivity 
The sensitivity of the immunocytochemical assay is not limited by the technique itself. On the 
contrary, the number of analyzed cells defines the sensitivity. When enough cells are 
analyzed, a high sensitivity can be reached. The Poisson Distribution f(X) = µX.e-µ/X! can be 
used to calculate the statistics of tumor cell detection.11 The parameter µ = n.p (where n is 
the total number of cells analyzed and p is the true frequency of tumor cells) represents the 
total number of tumor cells present. The variable X denotes the number of tumor cells 
actually detected. When X = 0, f(X) is the possibility of missing a tumor cell. When only one 
tumor cell is present in the midst of 999999 normal cells, the probability of missing the tumor 
cell after counting 3x106 cells is less than 5%. This means at least 3x106 cells should be 
analyzed to reach a 95% chance of detecting one tumor cell in 1x106 normal mononuclear 
cells. Therefore, six cytospins, each containing 5x105 cells, should be analyzed to secure the 
analysis of 3x106 mononuclear cells. 
 
Quality Control 
From 2001 to 2003, 4 multicenter quality control (QC) rounds were organized among the 
nine members of the NBMC to develop and validate the staining protocol, the morphological 
and immunocytological criteria and the work flow. A total of 111 QC samples were analyzed. 
Every research group sent preferably three slides from at least two different BM samples to 
every other member. The participants fixed and stained the cytospins independently of each 
other. They evaluated the samples unaware of any clinical information. Individual screening 
results were disclosed and the level of inter-observer concordance was assessed during 
subsequent quality control meetings. In addition, samples with discordant results were 
reviewed by all participants resulting in an optimized staining protocol and refined 
morphological and immunocytological criteria. The results of quality control round 1 and 4 are 
shown in Table 1. Only samples analyzed by at least four participants were included in the 
study. Participants 1 to 8 used the immunocytochemical staining assay to evaluate the 
quality control samples. Participant 9 detected residual NB cells using automatic 
immunofluorescence plus FISH. 
Quality control round 1 was organized before the immunocytochemical staining protocol was 
standardized and the morphological and immunocytological criteria were formulated. A total 
of 33 QC samples were analyzed. Two samples were excluded because they were analyzed 
by only three participants. Considerable differences were found both in the number of 
positively scored samples and in the number of GD2 positive cells per individual sample. Six 
samples were scored positive by all participating centers. In five samples, no positive cells 
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were found. Discordant results were found in 20 samples (65%). In these samples, the 
average difference between the highest and the lowest reported number of GD2 positive 
cells was 19.  
Quality control round 4 was organized after the standardization of the staining method, the 
formulation of the criteria and the design of the work flow. Thirteen samples were fixed, 
stained and evaluated by each participant in a blinded way and, in accordance with the work 
flow, samples containing less than 10 CPC’s or samples with NCIC’s were reviewed during a 
quality control meeting. Since we noticed a remarkable improvement in the sensitivity and 
specificity of the method and in the reproducibility of the results after analyzing 13 samples, 
QC round 4 was terminated at that point. After central review, the results were concordant in 
10 samples. Only in 3 samples (23 %) discordant results were found. In these samples, the 
average difference between the highest and the lowest reported number of CPC’s was 9. 
Discordant results were only found in samples with less than 10 CPC’s per 1x106. 
The standardization of the assay led to a significant decrease in the number of discordant 
results (χ2 = 4.91, p = 0.027, dF = 1). The range between the highest and the lowest reported 
number of positive cells decreased from 19 to 9.  
The immunocytochemical results (participants 1 to 8) were also compared to those obtained 
with AIPF (participant 9). In quality control round 1, 15 samples scored positive for the 
immunocytochemical assay whereas no neuroblastoma cells were detected by AIPF. The 
discrepancies in four of these samples were probably due to sample variability since only 
one or two IC positive cells were found. All other samples (11) were most likely false positive. 
In QC round 4 only one discordant result was found (8%). Participant 7 reported 8 CPC’s 
whereas no FPC’s were detected by participant 9. These results prove that the 
standardization of the staining and evaluation procedures reduced the number of false 
positive results dramatically 
 
Minimal Residual Disease 
84 
Table 1: Results of quality control rounds 1 and 4. Participants 1 to 8 used an 
immunocytological staining assay to evaluate the quality control samples. Participant 9 
detected residual neuroblastoma cells using an automatic immunofluorescence plus FISH 
device (AIPF). The number of GD2 positive cells (quality control round 1) or the number of 
CPC’s (quality control round 4) is reported. (NE: not evaluable; ND: not done; C: 1 or 2 
positive clusters; >100: more than 100 positive cells or more than 2 clusters) 
 
Cytospin Label Lab 1 Lab 2 Lab 3 Lab 4 Lab  5 Lab 6 Lab 7 Lab 8 Lab 9
QC1 A1 NE 0 0 1 NE NE 0 ND 0
QC1 A2 NE 0 0 0 ND NE 0 ND 0
QC1 A3 NE 0 0 0 ND NE 0 ND 0
QC1 A4 0 0 0 0 ND 1 0 ND 0
QC1 B1 0 6 9 5 > 100 53 42 ND 10
QC1 B2 0 0 0 0 ND 3 15 ND 0
QC1 B3 0 0 0 4 ND 3 1 ND 0
QC1 C1 > 100 > 100 NE > 100 > 100 > 100 > 100 ND > 100
QC1 C2 50 > 100 NE > 100 > 100 > 100 > 100 ND > 100
QC1 C3 NE 0 0 2 1 0 4 ND 0
QC1 G1 > 100 > 100 > 100 > 100 NE > 100 > 100 ND > 100
QC1 G2 C 1 2 0 NE 0 15 ND 0
QC1 G3 NE 0 0 0 NE 0 18 ND 0
QC1 G4 0 1 0 0 NE 0 21 ND 0
QC1 I1 > 100 > 100 NE NE > 100 NE > 100 ND ND
QC1 I2 1 1 0 NE 0 NE ND ND ND
QC1 I3 0 0 0 0 0 0 1 ND 0
QC1 I4 11 C 5 2 4 3 32 ND 7
QC1 I5 0 0 0 0 ND 0 0 ND 0
QC1 I6 40 > 100 > 100 > 100 ND > 100 > 100 ND > 100
QC1 I7 0 2 ND 0 ND 0 0 ND 0
QC1 I8 0 0 ND 2 ND 0 8 ND 0
QC1 N1 0 > 100 C C ND 23 92 ND 80
QC1 N2 0 0 0 NE ND 0 4 ND 2
QC1 N3 1 1 2 0 ND 7 14 ND 7
QC1 S1 0 ND 0 2 1 NE 16 ND 0
QC1 S2 0 ND 0 0 0 NE 18 ND 0
QC1 S3 0 ND 0 0 0 0 0 ND ND
QC1 S4 0 ND 0 0 0 0 0 ND ND
QC1 S5 0 1 3 0 ND 1 22 ND 0
QC1 S6 C 3 2 0 ND 0 27 ND 0
Cytospin Label Lab 1 Lab 2 Lab 3 Lab 4 Lab  5 Lab 6 Lab 7 Lab 8 Lab 9
QC4 A1 0 0 NE NE 0 0 0 0 0
QC4 A2 0 0 0 0 0 0 8 0 0
QC4 B1 0 0 0 0 0 0 0 0 0
QC4 B2 0 0 0 0 0 0 0 0 0
QC4 C1 > 100 > 100 > 100 > 100 > 100 > 100 > 100 ND > 100
QC4 C2 0 C ND ND 0 0 1 ND 4
QC4 F1 0 3 0 0 0 1 2 0 10
QC4 F2 0 0 0 0 0 0 0 0 0
QC4 G1 48 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100
QC4 N1 0 0 0 0 0 0 0 0 0
QC4 N2 0 0 0 0 0 0 0 0 0
QC4 S1 0 0 0 0 0 0 0 0 0
QC4 S2 0 0 0 0 0 0 0 0 0
Results Quality Control Round 1
Results Quality Control Round 4
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DISCUSSION 
 
The detection of occult NB cells in BM has important therapeutic and prognostic implications 
since BM disease is associated with an unfavorable outcome for most children.22,23 On the 
other hand, children with stage 4S disease have a good prognosis although they may 
present with BM metastases. Cytomorphological screening of BM smears is still the only 
accepted method for the detection of disseminated NB cells. However, Méhes et al. reported 
that a tumor cell infiltrate below 0.1% can be overlooked by conventional cytomorphology 
because the unspecific morphological appearance of NB cells limits the sensitivity of this 
method.7 During recent years, numerous alternative approaches using immunological and 
molecular biological techniques were developed to improve the detection of residual NB cells 
in BM.9-20 However, the sensitivity and specificity of these assays vary markedly and hamper 
studies evaluating the clinical significance of MRD. Therefore, the standardization of 
detection techniques is urgently needed.  
In connection with a phase III study organized by the SIOP European Neuroblastoma 
(SIOPEN) group, the NBMC developed, optimized and standardized an immunocytochemical 
assay based on the detection of the NB specific GD2 disialoganglioside. This antigen is 
highly and consistently expressed in neuroectodermal tumors and is not found in normal BM 
or peripheral blood cells.11,24,25 Since all NB are believed to express GD2, the possibility of a 
false negative result can practically be excluded. However, the uneven distribution of NB 
cells in the body may hamper the detection of disseminated tumor cells. To avoid false 
negative results caused by sampling error, a sufficient number of cells must be analyzed. 
The Poisson Distribution f(X) = µX.e-µ/X! can be used to calculate the statistics of tumor cell 
detection.11 At least 3.106 cells must be analyzed to reach a 95% probability of detecting one 
tumor cell in 1x106 normal mononuclear cells. 
Immunocytochemical results can also be obscured by false positive events.26-28 These can 
be caused by the active or passive take up of the tumor cell derived GD2 ganglioside by 
hematopoietic cells. Furthermore, a very small subset of mature plasma cells producing 
antibodies against alkaline phophatase can be false positive since they react directly with the 
enzyme.27 Finally, the illegitimate expression of the targeted antigen, the cross-reactivity of 
the applied monoclonal antibody and interactions between antibodies and Fc-bearing 
leukocytes can give rise to false positive results. 
As long as the members of the NBMC stained their slides using different 
immunocytochemical staining methods and analyzed their results according to individual 
morphological criteria, considerable discrepancies were observed. The evaluation of stained 
samples by the whole group using a multiheaded microscope, clearly demonstrated the 
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urgent need for developing a standardized immunocytochemical staining protocol and 
introducing morphological and immunocytological criteria. Consequently, the NBMC agreed 
upon one staining method and formulated morphological and immunocytological criteria for 
the interpretation of the results. Only cells with a round nucleus, often, but not always larger 
than that of small lymphocytes, a granular chromatin and a limited amount of cytoplasm are 
considered positive. In addition, a strong, deep red staining localized to the entire cell 
membrane and cytoplasm must be present. To our knowledge, this is the first time that a 
standardized protocol including morphological and immunological criteria for the detection of 
NB cells in BM has been designed.  
However, when applying these criteria the NBMC discovered that a small proportion of 
immunocytochemically stained cells could not unequivocally be classified as positive (i.e. NB 
cells) because they did not fulfill all postulated morphological and immunocytological criteria. 
Therefore, it was decided to categorize all immunocytochemically stained cells into three 
groups: Criteria Positive Cells (CPC’s) fulfilling all postulated criteria, Not Convincingly 
Interpretable cells (NCIC’s) displaying some but not all inclusion criteria and Negative Cells 
(NC’s) which, in spite of their staining, were identified as non-malignant hematopoietic cells. 
Borgen et al. published a similar approach for the analysis of circulating carcinoma cells by 
applying the anti-cytokeratin antibodies AE1/AE3 and an alkaline phosphatase-based 
detection method on cytospins prepared from mononuclear BM cells.29 They also 
categorized immunologically stained cells into three groups which they called tumor cells, 
probable tumor cells (?), and hematopoietic cells. In order to discriminate between these 
groups they presented a catalogue of pictures illustrating a large number of morphological 
and immunological variants of these categories. However, regarding the detection of NB cells 
using an anti-GD2 antibody, the members of the NBMC do not believe that it is feasible to 
cover all possible variants of immunocytochemically stained BM cells by means of 
illustrations. Therefore, they decided to introduce a workflow including two additional 
analytical steps (Figure 2). Firstly, samples with 1 to 10 CPC’s or samples containing NCIC’s 
are simultaneously reviewed by the members of the NBMC. Secondly, if no consensus is 
reached, the genetic profile of the doubtful cells is checked by automatic 
immunofluorescence plus FISH to disclose the identity of these cells. If the genetic 
aberrations in the doubtful cells correspond to those found in the primary tumor, the cells are 
called FISH positive cells (FPC’s). Finally, the morphological and immunocytological features 
of these FPC’s are carefully studied in order to refine the standardized evaluation criteria. 
The standardized staining protocol, the morphological and immunocytological criteria and the 
work flow were evaluated during four multicenter quality control rounds, organized among the 
nine members of the NBMC. A total of 111 QC samples were analyzed. The concordance 
between the different observers, with regard to the staining and the evaluation of the 
Minimal Residual Disease 
87 
immunocytochemical results was assessed. After standardization, a significant decrease in 
the number of discordant results was reported. In addition, the range between the highest 
and the lowest reported result was reduced by half and discordant results were only found in 
samples with less than 10 CPC’s per 1x106 mononuclear cells. 
Immunocytology has been used in the clinical practice of hematology and oncology for many 
years and has many advantages compared with flow cytometry or RT-PCR. In contrast to the 
latter, immunocytology allows the reliable quantification of tumor cells. This is important when 
the number of disseminated tumor cells appears to be prognostically important and not 
purely the presence or the absence of disease. The immunocytological technique is cost-
effective and simple and since no expensive equipment is needed, immunocytological 
stainings can be performed in virtually every routine laboratory around the world. 
This paper describes the first international standardization of an immunocytochemical 
staining and evaluation method developed to detect and quantify small numbers of 
neuroblastoma cells in BM. The results of our quality control rounds show that the 
standardization of the staining method, the formulation of morphological and 
immunocytological criteria and the design of the work flow resulted in a higher reproducibility, 
sensitivity and specificity. Methodological standardization is indispensable and must be 
agreed upon before multicenter studies, designed to assess the clinical importance of 
minimal residual disease, can be initiated. 
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Detection of Residual Neuroblastoma Cells in Bone
Marrow: Comparison of Flow Cytometry
With Immunocytochemistry
Katrien Swerts,1* Barbara De Moerloose,1 Catharina Dhooge,1 Be´ne´dicte Brichard,2
Yves Benoit,1 Genevie`ve Laureys,1 and Jan Philippe´3
1Department of Pediatric Hematology and Oncology, Ghent University Hospital, Ghent, Belgium
2Department of Pediatric Hematology and Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
3Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium
Background: Because the cytomorphologic examination of bone marrow (BM) aspirates appears not
sensitive enough to detect residual neuroblastoma cells, two four-color ﬂow cytometric assays using
different combinations of CD9, CD81, CD56, CD45, and anti-GD2 were evaluated.
Methods: The sensitivity of the ﬂow cytometric assays was assessed by spiking experiments in normal
peripheral blood samples. Twenty-eight BM samples, 12 biopsies, and 3 peripheral blood stem cell (PBSC)
preparations from 22 patients with neuroblastoma were analyzed. The results were compared with those of
an anti-GD2 immunocytochemical reference assay.
Results: Flow cytometric and immunocytochemical analyses showed residual neuroblastoma cells in four
BM samples. One PBSC preparation and 20 BM samples were negative for both assays. Four BM and two
PBSC samples scored positive for the immunocytochemical assay but were negative for the ﬂow cytometric
tests. This was due to the limited number of cells that were ﬂow cytometrically analyzed. A strong correlation
between the ﬂow cytometric and immunocytochemical tests was found (2  6.4, P  0.011).
Conclusions: When an equal amount of cells is analyzed, the sensitivity of the ﬂow cytometric assays is
to be about 10 times lower than that of the immunocytochemical test. However, the ﬂow cytometric assays
can be used to screen for residual cells in clinical samples with a sensitivity of one neuroblastoma cell in
104 to 105 normal mononuclear cells. Flow cytometry is simple, quick, and cost effective compared with
immunocytochemistry. In addition, the ﬂow cytometric assays can be used to screen for residual neuro-
blastoma cells in case of a GD2-negative primary tumor. Therefore we recommend ﬂow cytometry for the
detection of residual neuroblastoma cells. © 2004 Wiley-Liss, Inc.
Key terms: neuroblastoma; minimal residual disease; ﬂow cytometry; immunocytochemistry
Neuroblastoma (NB), a tumor originating from the sym-
pathic nervous tissue, is the most common extracranial
solid tumor in children. It shows a wide range of biologic,
genetic, and morphologic characteristics and exhibits a
diverse clinical behavior. Some children present with a
localized tumor associated with a good prognosis,
whereas others have a highly metastatic, aggressive tumor
with an unfavorable outcome (1).
Approximately 40% of patients with NB have high-
risk stage 4 disease with bone marrow (BM) involve-
ment. These children have a poor clinical outcome,
with a 5-year survival rate of approximately 30% (2).
The presence of NB cells in the BM during therapy can
predict relapse or clinical outcome (3–6). The detec-
tion of BM involvement is thus critical for accurate
staging and risk assessment.
Myeloablative chemotherapy in combination with au-
tologous BM or peripheral blood stem cell (PBSC) trans-
plantation is commonly used to treat children with stage 4
disease (7). Residual NB cells can contaminate the stem
cell product (8). This can cause the recurrence of the
disease due to the reinfusion of neuroblastoma cells (9).
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Therefore, stem cell preparations must be screened for
the presence of residual neuroblastoma cells (10).
The cytomorphologic examination of BM aspirates is
not sensitive enough to detect residual NB cells (11). More
sensitive assays, based on the use of immunocytochemis-
try, reverse transcription–polymerase chain reaction (RT-
PCR) or ﬂow cytometry, were developed to screen for NB
cells (12–19).
Komada et al. evaluated a triple-color ﬂow cytometric
assay using CD9 in combination with CD56 and CD45
(12). This test was optimized by Nagai et al. (14) who
combined CD81, CD56, and CD45. Warzynski et al. tested
several combinations (18). They used CD45, CD56, a
monoclonal antibody against neuron-speciﬁc enolase
(NSE) and anti-GD2. GD2 disialoganglioside is highly ex-
pressed in almost all NBs and the GD2 density in NB cells
is high (5 to 10  106 molecules/cell) (20–23). Warzynski
et al. evaluated different double- and triple-color assays
and analyzed anti-GD2, CD81, CD45, and CD56 expres-
sions of the NB cell line SK-N-DZ by using a four-color ﬂow
cytometric assay that they currently use to evaluate their
clinical samples (18).
In this study, we developed a new four-color ﬂow cy-
tometric assay combining CD9, CD81, CD56, and CD45.
In addition, we evaluated CD81, CD56, and CD45 in
combination with an anti-GD2 monoclonal antibody.
CD9 reacts with a 24-kDa type III transmembrane pro-
tein that is expressed on platelets, pre-B cells, activated
and differentiating B cells, activated T cells, eosinophils,
basophils, monocytes, endothelial and epithelial cells,
brain, peripheral nerves, and muscular cells. Various in
vitro studies have shown consistent expression of the
CD9 antigen on NB cells (24,25).
The expression of CD81 in neuroblastoma cell lines has
also been described (26). CD81 identiﬁes a 26-kDa type III
transmembrane protein (TAPA-1) that is involved in cell
growth and signal transduction. It is broadly expressed on
cells of hematopoietic origin. In addition, it is present on
endothelial and epithelial cells.
CD56 reacts with the 175-/220-kDa glycosylated antigen
isoforms present on a subpopulation of peripheral blood,
large, granular lymphocytes that demonstrate natural killer
activity. It is also present on a subset of CD4 and CD8 T
cells in peripheral blood, neural-derived cells and tumors,
large granular lymphocyte and myeloid leukemias, small cell
lung carcinomas, and myelomas. The expression of neural
cell adhesion molecule in human neuroblastoma cells lines
has been reported by Lipinski et al. (27).
GD2 disialoganglioside is expressed by neuroectoder-
mally derived tumors such as melanoma, neuroblastoma,
small cell carcinoma, and glioma. GD2 expression is not
found in normal BM or peripheral blood samples (28).
CD45 reacts with the isoforms of the leukocyte common
antigen present on all human white blood cells, including
lymphocytes, monocytes, granulocytes, eosinophils, and thy-
mocytes. It is not expressed in NB cell lines (29).
We analyzed 12 tumor samples from patients with NB
and used the four-color ﬂow cytometric assays to screen
for residual NB cells in 28 BM samples and three PBSC
preparations. The sensitivity of the ﬂow cytometric assays
was evaluated with spiking experiments. We assessed the
speciﬁcity of our four-color ﬂow cytometric tests by ana-
lyzing samples from a ganglioneuroma, a Wilms tumor, a
lung sequester, a rhabdomyosarcoma, and a desmoplastic
infantile ganglioglioma (DIG). Wilms tumors and rhab-
domyosarcomas, like NBs, Ewing sarcomas, non-Hodgkin
lymphomas, retinoblastomas, medulloblastomas, some
small cell carcinomas, and primitive neuroectodermal tu-
mors, belong to the family of “small blue round cell”
neoplasms. Because the members of this family can often
be morphologically confused with NB, the two four-color
ﬂow cytometric assays could be used to differentiate be-
tween NB and the other neoplasms.
The results of the ﬂow cytometric assays were com-
pared with those of an anti-GD2 immunocytochemical
test, which was considered the reference method.
MATERIALS AND METHODS
Patients and Sample Preparation
Between May 2001 and August 2003, 12 biopsies, 28 BM
samples, and 3 PBSC preparations from 22 patients with NB,
taken at diagnosis or during treatment, were examined. In
addition, samples of a ganglioneuroma, a Wilms tumor, a
lung sequester, a rhabdomyosarcoma, and a DIG were ana-
lyzed. Patient characteristics are summarized in Table 1.
Bilateral BM samples were considered as two samples be-
cause they were analyzed separately.
Clinical staging was done according to the International
Neuroblastoma Staging System (1). The ethical committee
approved the study, and informed consent was obtained
from patients and/or their parents.
From fresh tumor samples, single-cell suspensions were
prepared by using collagenase (1,000 U/ml in RPMI me-
dium) for 1 h at 37°C. Subsequently, cells were washed
and resuspended, and cell clumps were removed by ﬁl-
tering through a 70-m nylon membrane.
Immediately after collection, mononuclear cells from
BM samples and PBSC preparations were isolated by den-
sity gradient centrifugation on Ficoll-Hypaque.
All cells were kept at 4°C and analyzed within 24 h after
collection.
Control Samples
The NB cell line CLB-GA (kindly provided by F. Speleman,
Medical Genetics, Ghent University Hospital, Ghent,
Belgium) was included in the experiments as a positive
control. BM samples from 10 adults without malignant dis-
ease were used as negative controls and were analyzed with
the ﬂow cytometric and immunocytochemical tests.
Monoclonal Antibodies
NB cells were detected by a four-color ﬂow cytometric
assay using ﬁve different monoclonal antibodies (CD9,
CD81, CD56, anti-GD2, and CD45). We evaluated CD9
(clone P1/33/2) labeled with ﬂuorescein isothiocyanate
(FITC), CD81 (clone JS-81) labeled with phycoerythrin
(PE), CD45 (clone 2D1) labeled with peridinin chloro-
10 SWERTS ET AL.
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phyll protein (PerCP), CD56 (clone N901) labeled with
allophycocyanin (APC), and an unlabeled monoclonal an-
tibody that interacts with GD2 disialoganglioside (clone
14G2a).
CD9 was purchased from Dako Corporation
(Glostrup, Denmark); CD81, CD45, and anti-GD2 were
obtained from BD Biosystems (Erembodegem, Bel-
gium); and CD56 was purchased from Beckman Coulter
(Fullerton, CA, USA).
Flow Cytometric Assay
Mononuclear cells (5  105 cells) isolated from BM
samples, PBSC preparations, or fresh tumor samples were
resuspended in 100 l RPMI medium and incubated for
30 min with an unlabeled isotypic control antibody immu-
noglobulin G2a as a control for the GD2 assay (5 l; Dako
Corporation). In parallel, cells were incubated with 5 l
CD9-FITC, 5 l CD81-PE, 5 l CD45-PerCP, and 3 l
Table 1
Patient Characteristicsa
Patient Diagnosis Stage
Age
(months) Sex Sample Time pointb
A NB 4 87 M Biopsy Diagnosis
B NB 3 13 F Biopsy Diagnosis
BM left Diagnosis
BM right Diagnosis
C NB 1 27 M Biopsy Diagnosis
D NB 4 93 M Biopsy Diagnosis
E NB 4 22 M Biopsy Diagnosis
Biopsy 16
BM 28
F NB 4S 9 F Biopsy Diagnosis
G NB 3 160 F Biopsy Diagnosis
BM left Diagnosis
H NB 4 267 M Biopsy Relapse
I NB 2 36 F Biopsy Diagnosis
J NB 1 29 M Biopsy Diagnosis
K NB 1 32 F Biopsy Diagnosis
L NB 4 49 F BM Diagnosis
M NB 4S 31 F BM left Diagnosis
BM right Diagnosis
N NB 4 74 M BM left Diagnosis
BM 7
BM right 13
PBSC 1 13
PBSC 2 13
O NB 3 34 M BM Diagnosis
P NB 3 21 F BM Diagnosis
Q NB 4 53 M BM Diagnosis
R NB 3 44 F BM left Relapse
BM right Relapse
S NB 4S 43 F BM 59
T NB 4 62 M BM 13
PBSC 13
BM left 23
BM right 23
BM right 40
U NB 4 71 F BM Diagnosis
BM 11
V NB 4 106 F BM left Diagnosis
BM right Diagnosis
BM left 7
BM right 7
BM left 13
BM right 13
W DIG NA 25 F Biopsy 11
X GN NA 179 F Biopsy Diagnosis
Y Wilms NA 55 F Biopsy Diagnosis
Z LS NA 17 M Biopsy Diagnosis
AA RM NA 103 M BM Diagnosis
aNB, neuroblastoma; DIG, desmoplastic infantile ganglioglioma; GN, ganglioneuroma;
Wilms, Wilms tumor; LS, lung sequester; RM, rhabdomyosarcoma; M, male; F, female; BM,
bone marrow; NA, not applicable. PBSC, peripheral blood stem cell.
bWeeks after diagnosis.
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CD56-APC. In addition, 5  105 cells were incubated with
2 l of the unlabeled anti-GD2 antibody, which was di-
luted 1:50 in phosphate buffered saline (PBS). The vol-
umes of the different antibodies were titrated against the
CLB-GA cell line.
The cells were washed twice with PBS. The samples
incubated with the isotypic control antibody or the anti-
GD2 antibody were incubated for another 30 min with a
goat F(ab)2 anti-mouse immunoglobulin G antibody la-
beled with FITC (1 l; Caltag Laboratories, Burlingame,
UK). After another wash with PBS, we incubated the cells,
which had been incubated with the anti-GD2 antibody,
with 5 l CD81-PE, 5 l CD45-PerCP, and 3 l CD56-APC.
The cells were washed twice and resuspended in PBS. The
ﬂuorescence was analyzed on a FACSort ﬂow cytometer
(BD Biosystems). At least 10,000 events were counted and
analyzed with Cell Quest software (BD Biosystems). NB
cells were positive for GD2, CD9, CD81, and CD56 but
negative for CD45. Therefore, percentages of CD9/
CD81/CD45/CD56 and GD2/CD81/CD45/CD56
cells were calculated by using the following gating strat-
egy. On a forward scatter/side scatter dot plot, the mono-
nuclear cells were identiﬁed by region R1. In all other dot
plots, only the cells lying in R1 were represented. Region
R2 deﬁned the CD56/CD45 cells. The anti-GD2/
CD81 or CD9/CD81 cells were identiﬁed by region
R3. Samples were considered positive when at least 10 to
20 cells clustering together in R1, R2, and R3 were de-
tected (30).
Spiking Experiments
The sensitivity of the four-color ﬂow cytometric and the
immunocytochemical assays was evaluated by using spik-
ing experiments. Cells from NB cell line CLB-GA were
added to peripheral blood mononuclear cells that had
been isolated from healthy volunteers. The concentrations
of the NB cells in this dilution experiment were 1%, 0.1%,
0.01%, 0.001%, and 0.0001%. The cells were suspended in
RPMI medium.
The dilutions from 1% to 0.001% were evaluated ﬂow
cytometrically. With the different dilutions, 3 104, 5 104,
3  105, and 2  106 events were acquired.
The three highest dilutions (0.01% to 0.0001%) were
immunocytochemically analyzed, and 5  105, 1  106,
and 3  106 cells were evaluated. Because convincing
results were obtained, the experiments were performed
only once.
Immunocytochemistry
After air drying and ﬁxation with 4% paraformaldehyde,
large-diameter (17 mm) cytospins (Hettich Zentrifugen,
Tuttlingen, Germany) containing 5  105 mononuclear
cells were incubated with 30 l of an unlabeled monoclo-
nal antibody against GD2 disialoganglioside (clone 14G2a,
diluted 1:100 in PBS) in a humidiﬁer at room temperature
for 30 min. Controls, in which the primary antibody was
replaced by PBS buffer, were included to evaluate the
background staining. During a second and a third incuba-
tion step, cells were incubated for 30 min with 30 l of a
polyclonal goat anti-mouse antibody (diluted 1:20 in PBS;
Dako Corporation) and 30 l of a polyclonal rabbit anti-
goat antibody (diluted 1:20 in PBS; Dako Corporation),
respectively. Both antibodies were labeled with alkaline
phosphatase (31). The bound alkaline phosphatase com-
plexes were stained with the new fuchsin chromogen
(Sigma, St. Louis, MO, USA) (32). The slides were coun-
terstained with hematoxylin (Sigma) and examined under
a light microscope by two independent observers. Prefer-
ably six slides, each containing 5  105 cells, were ana-
lyzed. Cells with a round nucleus, a granular chromatin
structure, a sparse amount of cytoplasm, and a strong
staining around the entire cell were considered positive.
Cells with an aberrant morphology or a pink staining
restricted to a subcellular compartment were considered
negative. The number of positive single cells and positive
cells being part of a Homer-Wright rosette or cell clump
were counted. The number of evaluated mononuclear
cells was also reported. When the two local observers
disagreed or fewer then 10 positive cells were found,
pictures of the doubtful cells were sent to an external
expert. The results were discussed until agreement was
reached.
Statistics
After classifying the results in a frequency table, a 2 test
was performed to study the relation between the different
categories. In addition, a  test was used to measure the
agreement between the different assays.
RESULTS
Phenotype of NB Cells
Cells from the NB cell line CLB-GA were phenotyped
with the four-color ﬂow cytometric assay. The CLB-GA
cells showed a strong expressions for GD2, CD9, CD81,
and CD56 and were negative for CD45 (Fig. 1).
The same markers were analyzed in NB cells from 12
tumor samples. All samples were positive for CD9, CD81,
and CD56 and negative for CD45. In one sample, the NB
cells lacked GD2 expression. This result was conﬁrmed by
immunocytochemistry.
Ten BM samples from healthy donors were included as
negative controls. None of these samples scored positive
on the immunocytochemical or ﬂow cytometric tests.
Speciﬁcity of the Four-Color Flow Cytometric Assay
We assessed the speciﬁcity of the four-color ﬂow cyto-
metric tests by analyzing tumor samples from a DIG, a
ganglioneuroma, a Wilms tumor, a lung sequester, and a
rhabdomyosarcoma.
The cells from the DIG were CD9/CD81/CD56/
CD45 and GD2/CD81/CD56/CD45. Consequently,
it was impossible to distinguish between a NB and a DIG
by using our four-color ﬂow cytometry assay. The immu-
nocytochemical test was negative because the DIG cells
did not meet the morphologic criteria.
Based on our limited results, it was possible to differ-
entiate between NB and the other tumors by using the
four-color ﬂow cytometric assay. Tumor cells from the
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FIG. 1. Phenotype of the neuroblastoma cell line CLB-GA. The CLB-GA cells show strong GD2, CD9, CD81, and CD56 expressions and are negative
for CD45 (immunoglobulin G2a [IGG2a], isotypic control; 14G2a, anti-GD2 monoclonal antibody).
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ganglioneuroma and the lung sequester showed weak
CD56 and GD2 expressions. The Wilms tumor was nega-
tive for CD56 and GD2 and showed only weak CD9 and
CD81 expressions. Rhabdomyosarcoma cells were nega-
tive for GD2. None of these tumors scored positive for the
immunocytochemical assay.
Sensitivity Experiments
The sensitivity of the ﬂow cytometric assays was eval-
uated with spiking experiments. CLB-GA cells were di-
luted into normal mononuclear cells that had been iso-
lated from peripheral blood taken from healthy
volunteers. Four different dilutions (1%, 0.1%, 0.01%, and
0.001%) were analyzed. As few as one NB cell in 104 to 105
normal mononuclear cells could be detected with the
four-color ﬂow cytometric assays. Regression analysis was
performed:
CD9/CD81/CD45/CD56: log (Y)  0.41  1.09 log (X)
standard error of the slope  0.10, corresponding
P  0.0082, residual standard deviation  0.22
GD2/CD81/CD45/CD56: log (Y)  0.44  1.23 log (X)
standard error of the slope  0.13, corresponding
P  0.010, residual standard deviation  0.28
Both tests performed equally well during the spiking ex-
periment.
It is important to analyze a sufﬁcient number of cells
when the tumor load in a sample is low (	0.01%) because
samples can be considered positive only when at least 10
to 20 cells with the correct immunophenotype, clustering
together in the different dot plots, are detected. In our
study, at least 2  104 cells were ﬂow cytometrically
analyzed. This means that a sensitivity of 0.1% to 0.2% was
reached.
The sensitivity of the immunocytochemical test was
also evaluated with spiking experiments. Three different
dilutions (0.01%, 0.001%, and 0.0001%) were analyzed.
When 3  106 cells were evaluated, one NB cell in 106
normal mononuclear cells could be detected.
Detection of NB Cells in BM and PBSC Preparations
Twenty-eight BM samples and three PBSC preparations
were analyzed with the ﬂow cytometric assay. The results
are summarized in Table 2. Flow cytometry scored posi-
tive in four BM samples, and 24 samples were negative.
Table 2
Results of BM and PBSC Preparations
Patients Samples Stage Time pointa
Flow
Cytometry
Cells
evaluated
Immuno-
cytochemistry
Cells
evaluated
L BM 1 4 Diagnosis  2,00E  04  1,00E  06
B BM 2 3 Diagnosis  2,00E  04  5,00E  05
BM 3 3 Diagnosis  2,00E  04  7,00E  05
E BM 4 4 28  2,00E  04  1,70E  06
M BM 5 4S Diagnosis  2,00E  04  1,00E  06
BM 6 4S Diagnosis  2,00E  04  1,00E  06
N BM 7 4 Diagnosis  2,00E  04  3,00E  06
BM 8 4 7  2,00E  04  2,50E  06
BM 9 4 13  3,38E  05  1,50E  06
O BM 10 3 Diagnosis  2,00E  04  3,00E  06
P BM 11 3 Diagnosis  2,00E  04  3,00E  05
Q BM 12 4 Diagnosis  2,00E  04  1,50E  06
G BM 13 3 Diagnosis  2,00E  04  5,00E  05
R BM 14 3 Relapse  2,00E  04  1,50E  06
BM 15 3 Relapse  2,00E  04  1,50E  06
S BM 16 4S 59  2,00E  04  4,00E  05
T BM 17 4 13  2,00E  04  1,00E  06
BM 18 4 23  2,00E  04  7,00E  05
BM 19 4 23  2,00E  04  1,20E  06
BM 20 4 40  2,00E  04  9,00E  05
U BM 21 4 Diagnosis  2,00E  04  7,00E  05
BM 22 4 11  2,00E  04  4,00E  05
V BM 23 4 Diagnosis  2,00E  04  1,40E  05
BM 24 4 Diagnosis  2,00E  04  1,00E  05
BM 25 4 7  2,00E  04  3,00E  06
BM 26 4 7  2,00E  04  3,00E  06
BM 27 4 13  2,00E  04  2,00E  05
BM 28 4 13  2,00E  04  9,50E  05
N PBSC 1 4 13  1,00E  05  3,00E  06
PBSC 2 4 13  4,00E  05  2,50E  06
T PBSC 3 4 13  2,00E  04  1,00E  06
aWeeks after diagnosis, BM, bone marrow; PBSC, peripheral blood stem cell.
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These results were compared with the results of an im-
munocytochemical assay. We found concordant results in
24 of 28 BM samples (86%). The four samples were pos-
itive for the ﬂow cytometric assay and for the immunocy-
tochemical test. Twenty BM samples were negative for
both assays. During therapy, discordant results were
found in four BM samples and two PBSC preparations.
Although these samples scored positive for the immuno-
cytochemical test, fewer than 10 cells clustering together
in the different dot plots were found after four-color ﬂow
cytometric analysis. In these samples, the number of re-
sidual NB cells was very small (Table 3). In addition, there
was a signiﬁcant difference in the number of mononuclear
cells analyzed by both techniques. Using ﬂow cytometry,
an average of 3.3  104 cells was analyzed. In contrast, an
average of 1.2  106 cells was evaluated using immuno-
cytochemistry.
Figure 2 shows an example of a BM sample that scored
positive for the ﬂow cytometric and immunocytochemical
assays. Figure 3 shows an example of discordant results.
Three positive cells were detected after immunocyto-
chemical analysis of 3  106 mononuclear cells. Because
only 5  105 cells were ﬂow cytometrically analyzed,
theoretically only 0.5 tumor cells could have been de-
tected by the ﬂow cytometric assays. Both samples were
only recently analyzed and are not included in the statis-
tically processed data.
There was no change in the intensity of the antigen
expression or the immunophenotype of the tumor cells
when, on more than one occasion, NB cells were de-
tected.
Based on the results of the BM and PBSC samples, an
association between the ﬂow cytometric and immunocy-
tochemical test was found (2  6.4, P  0.011, df  1).
In addition, the  statistic showed a moderate level of
agreement between tests (  0.48).
DISCUSSION
Many children with NB present with disseminated dis-
ease, including BM involvement. The detection of contam-
inating NB cells in the BM plays an important role in
clinical staging and risk assessment. Moreover, the detec-
tion of disseminating tumor cells in the autologous stem
cell preparations may signify the need for ex vivo manip-
ulations such as tumor cell purging and/or CD34 cell
selection to avoid the reinfusion of malignant cells (33).
Different techniques for the detection of residual NB cells
such as immunocytochemistry, RT-PCR, and ﬂow cyto-
metry are described in the literature (12–19).
Flow cytometry has been used in the clinical practice of
hematology and oncology for many years and has many
advantages compared with immunocytochemistry or RT-
PCR. The ﬂow cytometric assay provides information on
the antigen expression from a single tumor cell in a mul-
ticolor assay and allows the analysis of large cell numbers.
In addition, ﬂow cytometry, like automated ﬂuorescence
microscopy, allows a more objective quantiﬁcation of the
number of NB cells compared with conventional immu-
nocytochemistry or quantitative RT-PCR (17,34).
In this study, we developed a new four-color ﬂow cy-
tometric assay using CD9, CD81, CD45, and CD56 to
detect NB cells in BM. A second four-color assay based on
the use of anti-GD2, CD81, CD45, and CD56 was evalu-
ated (18). Twelve NB tumor samples were analyzed. One
tumor lacked GD2 expression. This result was conﬁrmed
by the immunocytochemical assay. The sample was taken
from a 13-year-old girl with a palpable mass in the abdo-
men. The NSE serum concentration and the urinary dopa-
mine concentration were elevated. Magnetic resonance
imaging showed a large tumor extending from the right
kidney to the pelvis and into the lumbar foramina. No
metastases were found. Immunohistologically, the tumor
cells showed strong CD56 and NSE expressions. They
were moderately positive for chromogranin and synapto-
physin. There were no obvious signs of cytodifferentia-
tion. After genetic analysis, no MYCN ampliﬁcation or 1p
deletion was found, but 70% of the tumor cells had an
extra copy of chromosome 17 and 18% showed 17q gain.
The diagnosis of a stroma-poor, poorly differentiated,
stage 3 NB was made for this very unusual GD2-negative
case. Because nearly all NBs express high levels of GD2
(21–23), immunotherapy using anti-GD2 antibodies is con-
sidered a promising treatment strategy (35). However,
when the primary tumor lacks GD2 expression, treatment
with anti-GD2 immunotherapy is useless. Therefore, we
recommend the evaluation of GD2 expression in tumor
samples from all NB patients at diagnosis.
It can be difﬁcult to differentiate between NB and other
members of the small blue round cell tumor family. Our
results suggest that the four-color ﬂow cytometric assays
are helpful in making a differential diagnosis. Only cells
Table 3
Discordant Flow Cytometric and Immunocytochemical Results
Patients Samples Stage
Time
pointa
Flow
cytometry
Cells
evaluated
Immuno-
cytochemistry
Cells
evaluated
No. of
positive cells
T BM 17 4 13  2,00E  04  1,00E06 5
BM 20 4 40  2,00E  04  9,00E05 4
V BM 27 4 13  2,00E  04  2,20E05 2
BM 28 4 13  2,00E  04  9,50E05 3
N PBSC 1 4 13  1,00E  05  3,00E06 2
T PBSC 3 4 13  2,00E  04  1,00E06 5
aWeeks after diagnosis, BM, bone marrow; PBSC, peripheral blood stem cell.
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FIG. 2. Example of a bone marrow positive for the ﬂow cytometric and
immunocytochemical assays. A: Flow cytometric results. On a forward
scatter (FSC)/side scatter (SSC) dot plot, the mononuclear cells were
identiﬁed by region R1. In all other dot plots, only the cells lying in R1 were
represented. R2 deﬁned the CD56/CD45 cells. The CD9/CD81 cells
were identiﬁed by R3. Because more than 10 to 20 cells clustering
together in R1, R2, and R3 were detected, the sample was considered
positive. A total of 5  105 cells/tube was analyzed (immunoglobulin G2a,
isotypic control; 14G2a, anti-GD2 monoclonal antibody). B: Immunocyto-
chemical results. The sample was considered positive because clusters of
positive cells fulﬁlling the criteria were detected. A total of 3  106 was
immunocytochemically analyzed.
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FIG. 3. Example of a bone marrow in which the residual neuroblastoma cells were found only after immunocytochemical analysis. A: Flow cytometric
results. No tumor cells were detected. A total of 5  105 cells/tube were analyzed. B: Immunocytochemical results. One single cell and a cluster of three
tumor cells fulﬁlling the criteria were found.
17FLOW CYTOMETRIC DETECTION OF RESIDUAL NEUROBLASTOMA CELLS
Minimal Residual Disease 
101 
from the DIG tumor, containing mature gangliocytes,
were CD9/CD81/CD45/CD56 and GD2/CD81/
CD45/CD56. Because the CD56 expression on the DIG
cells was as high as the CD56 expression on NB cells, it
was impossible to differentiate between them. The GD2
expression on the ganglioneuroma cells was very weak.
Others have reported the absence of GD2 in more differ-
entiated ganglioneuroblastomas and ganglioneuromas
(18,20).
In six samples, discordant ﬂow cytometric and immu-
nocytochemical results were obtained. In these samples,
taken during therapy, only a few residual NB cells were
found after immunocytochemical analysis. The discrep-
ancy was probably due to sample variability and the dif-
ference in the number of analyzed cells. Because the
conventional immunocytochemical assay was considered
the gold standard for minimal residual disease detection in
patients with an undifferentiated NB, priority was given to
this test and 3  106 cells were immunocytochemically
evaluated. The remaining cells were analyzed with the
two four-color ﬂow cytometric assays. Because BM sam-
ples taken during therapy are often aplastic, in some cases
only 2  104 cells could be ﬂow cytometrically analyzed.
This means a sensitivity of 0.1% was reached. Seeger et al.
reported that a sensitivity of 0.1% (100 NB cells/105 BM
cells) after three to four cycles of therapy most likely
represents the clinically useful threshold for patients (4).
Children who demonstrated less sensitivity survived,
whereas those with greater sensitivity died. Therefore, the
collection of 1  104 cells/tube was considered adequate.
Two combinations of different monoclonal antibodies
are currently used to screen for residual NB cells. This
means that at least 2  1.106 cells must be analyzed to
reach a sensitivity of 0.001%. This amount of cells is
sometimes not available. In the near future, we plan to
develop a ﬁve-color ﬂow cytometric assay so that we can
decrease the amount of required cells by one-third.
The discrepancy between the immunocytochemical
and ﬂow cytometric results can also be explained by a
difference in sensitivity. Our immunocytochemical test
has a targeted sensitivity of 0.0001%. This is approxi-
mately 10 to 100 times more sensitive than that reported
in previous publications (4,28,36,37). The sensitivity of
the assay is not limited by the technique but by the
number of analyzed cells. When enough cells are ana-
lyzed, a high sensitivity can be reached. The Poisson
distribution, f(X)  X  e/X!, can be used to calculate
the statistics of tumor detection (28). At least 3 106 cells
must be analyzed to have a 95% chance to detect one
tumor cell in a million normal mononuclear cells. In pre-
vious reports, fewer than 3  106 cells were analyzed,
which decreased the sensitivity of the assays. In contrast,
the ﬂow cytometric assay has a sensitivity of 0.01% to
0.001% based on spiking experiments. This corresponds
with previously published reports (12,14,18). In our
study, a sensitivity of 0.1% to 0.2% was reached because at
least 2  104 cells were ﬂow cytometrically analyzed.
In conclusion, the sensitivity of the ﬂow cytometric
assays is lower than that of the immunocytochemical
assay in spiking experiments. However, the ﬂow cyto-
metric assays can be used to screen for residual cells in
clinical samples with a sensitivity of one NB cell in 104
to 105 normal mononuclear cells. They are less labor
intensive and time consuming than the immunocyto-
chemical test. The results are available only a few hours
after collection, and the technique is simple and cost
effective. Further, in contrast to our immunocytochem-
ical assay, the four-color ﬂow cytometric tests can be
used to screen for residual NB cells in case of a GD2-
negative primary tumor. Therefore, we recommend
ﬂow cytometry for the detection of residual NB cells
in BM.
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ABSTRACT 
Purpose: 
Reliable detection of neuroblastoma (NB) cells in bone marrow (BM) is critical since BM 
involvement influences staging, risk assessment and evaluation of therapeutic response in 
NB patients. Standard cytomorphological examination of BM aspirates appears not sensitive 
enough to detect single tumor cells. Therefore, more sensitive and specific detection 
methods are needed.  
Experimental design: 
Disseminated NB cells were detected by means of tyrosine hydroxylase (TH), GD2 
synthetase (GALGT) and ‘Embryonic Lethal, Abnormal Vision, Drosophila-like 4’ (ELAVL4) 
real-time quantitative RT-PCR (QPCR). The sensitivity of the molecular assays was 
assessed using spiking experiments. Ninety-seven tumor, BM, peripheral blood (PB) or 
peripheral blood stem cell (PBSC) samples from 30 patients were analyzed. The QPCR 
results were compared to those of a standardized immunocytochemical (IC) assay. 
Results:  
The molecular markers were highly expressed in all evaluated tumor samples. In addition, 
32%, 11% and 38% of all BM, PB and PBSC samples scored positive for TH, GALGT or 
ELAVL4, respectively. The sensitivity of the TH and ELAVL4 assay was 1:106. By contrast, 
one NB cell in 104 mononuclear cells could be detected using GALGT QPCR.  
The potential prognostic value of TH, GALGT and ELAVL4 QPCR was assessed by 
analyzing subsequent samples from 3 stage 4 patients. Preliminary results indicate that 
persistence of high ELAVL4 expression has prognostic value. 
Conclusions: 
ELAVL4 QPCR can be used to detect residual NB cells in clinical samples. However, it is 
advisable to combine several molecular markers (ELAVL4-TH) and screening techniques 
(IC) to assure the reliable assessment of MRD in NB.  
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INTRODUCTION 
 
Neuroblastoma (NB), the most common extracranial malignant solid tumor in children, 
originates from the sympathetic nervous tissue in the neural crest. Its clinical behavior ranges 
from a localized tumor with a good prognosis to disseminated disease with unfavorable 
outcome. Many clinical and biological factors have been shown to affect the prognosis of NB 
patients (1).  
The evaluation of BM metastasis is crucial for correct clinical staging and risk assessment at 
diagnosis. The detection of residual NB cells in BM is also important for monitoring 
therapeutic response during treatment. In addition, screening of autologous stem cell 
preparations is crucial since the re-infusion of contaminated stem cell products could lead to 
systemic recurrence (2-4).  
According to the International Neuroblastoma Staging System, conventional cytology of BM 
smears is still the only accepted technique for the detection of residual NB cells (5). 
However, the sensitivity of this method is limited since a tumor cell number below 0.1 % 
cannot be detected by conventional cytomorphology (6, 7). Therefore, the development of 
more sensitive and specific detection methods is indispensable.  
During the last decades, sensitive assays based on immunocytology (8-10), automatic 
immunofluorescence plus FISH (11) and flow cytometry (12-16) were evaluated. In addition, 
several molecular tests based on reverse transcriptase-polymerase chain reaction (RT-PCR) 
have been developed. The usefulness of various tumor specific gene-transcripts such as 
tyrosine hydroxylase (17-19), GAGE (20, 21), MAGE 1 to 4 (22), neuroendocrine protein 
PGP 9.5 (23, 24), GD2 synthetase (25, 26), dopamine decarboxylase (27) and chromogranin 
A (28) was assessed. 
Most neuroblastomas (90-95%) are characterized by a high catecholamine production. The 
first and rate-limiting step in the biosynthesis of catecholamines is catalyzed by tyrosine 
hydroxylase (TH). Therefore, this enzyme is often used as a molecular marker for the 
detection of disseminated NB cells in peripheral blood (PB), BM and peripheral blood stem 
cell (PBSC) preparations.  
GD2 synthetase (GALGT) (β1,4-N-acetylgalactosaminyltransferase) catalyzes the transfer of 
1,4-N-acetylgalactosamine to GD3 ganglioside and plays a key role in GD2 
disialoganglioside biosynthesis (29). Since GALGT is strongly expressed in neural crest-
derived tumors such as melanoma and neuroblastoma (30), the enzyme is frequently used 
as a molecular marker for minimal residual disease (MRD) detection in NB. 
ELAVL4 (Embryonic Lethal, Abnormal Vision, Drosophila-like 4) or HuD (Hu antigen D) is 
also a potential molecular marker which can be used to detect rare NB cells. The gene 
belongs to the elav gene family of Drosophila melanogaster and has been reported to be 
Minimal Residual Disease 
107 
highly specific for neuroectodermally derived tumors (31). So far, the use of ELAVL4 mRNA 
for MRD detection in NB has not been reported.  
In this study, real-time quantitative RT-PCR (QPCR) tests for TH, GALGT and ELAVL4 
mRNA were developed and evaluated. The sensitivity of the assays was assessed using 
both spiking experiments and clinical samples. Thirty PB or BM samples from patients 
without malignant disease were included as negative controls. The TH, GALGT and ELAVL4 
gene expression was analyzed in 18 tumor, 70 BM, 5 PB and 4 PBSC samples, collected at 
diagnosis or during treatment. Finally, the molecular results were compared to those of a 
standardized anti-GD2 immunocytochemical reference assay.  
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MATERIALS AND METHODS 
 
Patients and sample preparation 
Between April 2001 and October 2004, 18 tumor, 70 BM, 5 PB and 4 PBSC samples from 
one ganglioneuroblastoma (GNB), one ganglioneuroma (GN) and 28 neuroblastoma 
patients, taken at diagnosis or during treatment, were examined. Bilateral BM samples were 
considered as two different samples because they were analyzed separately. Patient 
characteristics are summarized in Table 1. The MYCN and 1p status was evaluated using 
FISH following the guidelines of the European Neuroblastoma Quality Assessment (ENQUA) 
group (32).  
The NB patients were diagnosed and staged according to the International Neuroblastoma 
Staging System (1). Treatment depended on the patient’s age, tumor stage and biological 
risk factors. The Ethical Committee approved the study and informed consent was obtained 
from the patients and/or parents. 
From fresh tumor samples, single cell suspensions were prepared using collagenase     
(1000 U/ml in RPMI for 1h at 37 °C). Subsequently, cells were washed and cell clumps were 
removed using a 70 µm nylon membrane filter. 
BM, PB and PBSC samples were collected into EDTA containing tubes. Immediately after 
collection, mononuclear cells were isolated using density gradient centrifugation on Fycoll-
Hypaque. 
All cells were resuspended in 75% ethanol and stored at -80 °C until analysis. 
 
Control Samples 
The NB cell line CLB-GA was included in the experiments as positive control. BM and PB 
samples from 30 adults without malignant disease were used as negative controls. BM 
samples from healthy pediatric patients were not included in the study because we expected 
it to be too difficult to obtain informed consent from their parents.  
 
Sensitivity 
Spiking experiments were performed to evaluate the sensitivity of the TH, GALGT and 
ELAVL4 QPCR assays. RNA from the NB cell line IMR32 was added to 1 µg of RNA isolated 
from normal PB mononuclear cells. Five 10-fold dilutions containing 10,000 to 10 pg of 
IMR32 RNA were analyzed.  
The sensitivity of the molecular assays was also assessed using patient samples. QPCR 
results were compared to those of an immunocytochemical reference assay (sensitivity 
1:106) which was considered to be the gold standard. All samples were handled as described 
below.  
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Table 1: Patient characteristics (Dx: Diagnosis; M: Male; F: Female; MYCN +: MYCN 
amplification; 1p del: Deletion of 1p; NE: not evaluated; NB: neuroblastoma; GNB: 
ganglioneuroblastoma; GN: ganglioneuroma) 
 
Nr Diagnosis Stage Age at Dx (months) Sex MYCN + 1p del Catecholamine production at Dx
1 NB 1 2 M NO NO Elevated
2 NB 2a 0 F NO IMBALANCE Elevated
3 NB 3 8 F NO NO Elevated
4 NB 3 27 M NO NO Elevated
5 NB 3 14 M NO NO Elevated
6 NB 3 9 F NO NO NE
7 NB 3 157 F NO IMBALANCE Elevated
8 NB 3 8 F NO NO Elevated
9 NB 3 6 F NO NO Elevated
10 NB 3 8 F NO YES Elevated
11 NB 3 23 F NO IMBALANCE Elevated
12 NB 4 82 M NO IMBALANCE Elevated
13 NB 4 25 F YES NO Not Elevated
14 NB 4 10 F YES NO Elevated
15 NB 4 72 M NO NO Elevated
16 NB 4 16 F YES YES Elevated
17 NB 4 53 M NO NO Elevated
18 NB 4 3 M NO NO Elevated
19 NB 4 70 M NO YES Elevated
20 NB 4 26 M NO NO Elevated
21 NB 4 26 M YES NO Not Elevated
22 NB 4 21 F NO NO Elevated
23 NB 4 70 F NO NO Elevated
24 NB 4 31 M NO NO Elevated
25 NB 4 35 F YES YES Elevated
26 NB 4 6 F NO NO Elevated
27 NB 4 92 F YES YES Elevated
28 NB 4S 4 F NO NO Not Elevated
29 GNB 2 33 F NO NO Elevated
30 GN 3 44 F NO NO Elevated  
 
 
RNA isolation and Reverse Transcription 
Total RNA was extracted from 5x106 to 1x107 cells using TRIzol Reagent (Invitrogen, 
Carlsbad, CA, USA) following the instructions of the manufacturer. Briefly, TRIzol Reagent 
maintains the integrity of the RNA while disrupting cells and dissolving cell components. The 
addition of chloroform followed by centrifugation separates the solution into an aqueous and 
an organic phase. The RNA remains exclusively in the aqueous phase and is recovered by 
precipitation with isopropyl alcohol. Finally, the RNA is resuspended in RNase-free water. 
The concentration and purity of the recovered RNA were measured by OD at 260 and 280 
nm. The integrity of the isolated RNA was verified by quantitative real-time RT-PCR for 
human beta-2-microglobulin and ubiquitin C. 
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Total RNA (1 µg in 5 µl) was denatured at 95 °C for 5 min (OmniGene thermal cycler, 
Thermo Electron, Waltham, MA, USA) and subsequently placed on ice. An equal volume of 
the RT reaction mixture (5 µl) was added. The final concentrations of the reagents in the 
reaction (10 µl) were 1x TaqMan Buffer A (Applied Biosystems, Foster City, CA, USA), 1 mM 
of each deoxynucleotide triphosphate (Amersham Biosciences, Piscataway, NJ, USA), 8 mM 
MgCl2 (Sigma-Aldrich, St. Louis, MO, USA), 0.3 µg of Random Hexamer Primers 
(Invitrogen), 8 units of RNA Guard (Amersham Biosciences) and 10 units of Moloney Murine 
Leukemia Virus reverse transcriptase (Amersham Biosciences). The RNA was reverse 
transcribed at 37 °C for 1 h followed by the inactivation of the enzyme at 95 °C for 5 min. 
  
Real-time quantitative RT-PCR 
Detection chemistry: 
TH, GALGT and ELAVL4 transcripts were quantified using the ABI PRISM 7700 Sequence 
Detection System (Applied Biosystems). A fluorogenic probe, labeled with a reporter (FAM) 
at the 5’ end and a quencher (TAMRA) at the 3’ end, was used. All primers and probes were 
designed using the Primer Express software (Applied Biosystems) and are listed in Table 2. 
To avoid the amplification of genomic DNA, primers were located in successive exons. The 
primers and probe for TH were designed to hybridize to exons not influenced by alternative 
splicing.  
The quencher suppresses the fluorescent emission of the reporter whenever the probe is 
intact. During the extension phase of the PCR, the annealed probe is cleaved by the 5’ 
exonuclease activity of the Taq polymerase resulting in the release of the reporter. This is 
coupled to an increase in the fluorescent emission. Since this event occurs during every PCR 
cycle, the fluorescence increases proportional to the amount of synthesized PCR products. 
After a number of PCR cycles, the fluorescence will reach a threshold. The position of the 
threshold is chosen based on the variability of the baseline data. The point at which the 
fluorescence crosses the threshold is defined as Ct value. 
 
Quantification: 
In order to construct relative standard curves for the quantification of TH, GALGT and 
ELAVL4 transcripts, serial dilutions of cDNA from the NB cell line CLB-GA were used. For 
each assay, 10-fold serial dilutions, starting from relative copy number 100,000 
(corresponding to 100 ng of CLB-GA RNA) to relative copy number 10 (corresponding to 10 
pg of CLB-GA RNA), were analyzed in duplicate. A standard curve was established by 
plotting the Ct value versus the logarithm of the relative copy number (Figure 1A). 
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Table 2: Sequences and locations of the primers and probes 
 
Gene Location
TH Forward primer 5' ATT GCT GAG ATC GCC TTC CA 3' Exon 6
NM_00360 Reverse primer 5' AAT CTC CTC GGC GGT GTA CTC 3' Exon 7
Probe 5' (FAM) ACA GGC ACG GCG ACC CGA TTC (TAMRA) 3' Exon 6-7
GALGT Forward primer 5' AGC CGA AGC TAC CAG ACC AA 3' Exon 6
NM_001478 Reverse primer 5' GGA TAG TGA AAG CAG CCT CAT GT 3' Exon 7
Probe 5' (FAM) ACA GCA GAC ACA GTC CGG TTC TCC ACC (TAMRA) 3' Exon 6-7
ELAVL4 Forward primer 5' AAT GGA CTC AGA CTC CAG ACC AA 3' Exon 5
NM_021952 Reverse primer 5' CAT AGA GGT TAG CAT CCC TGA TTG A 3' Exon 6
Probe 5' (FAM) CCA TAA AGG TCT CAT ATG CCC GTC CGA (TAMRA) 3' Exon 5-6
B2M Forward primer 5' GAG TAT GCC TGC CGT GTG 3' Exon 2
NM_004048 Reverse primer 5' AAT CCA AAT GCG GCA TCT 3' Exon 4
Probe 5' (FAM) CCT CCA TGA TGC TGC TTA CAT GTC TC (TAMRA) 3' Exon 3-4
UBC Forward primer 5' TGT GAT CGT CAC TTG ACA ATG CA 3' Exon 1-2
NM_021009 Reverse primer 5' CGA TGG TGT CAC TGG GCT C 3' Exon 2
Probe 5' (FAM) AAG ACT CTG ACT GGT AAG ACC ATC ACC CTC GA (TAMRA) 3' Exon 2
Primer and probe
 
 
Figure 1: Quantification of ELAVL4 mRNA using real-time quantitative RT-PCR. A: Standard 
curve used for ELALV4 quantification (R2 = 0.999; slope = -3,461). Ten-fold serial dilutions 
from NB cell line CLB-GA were evaluated (relative transcript number from 100,000 to 10). 
Each sample was analyzed in duplicate. The Ct values and relative transcript numbers were 
plotted on a logarithmic scale. (Ct: threshold cycle: cycle at which the fluorescence crosses 
the threshold) B: Amplification plot. (∆Rn: normalized fluorescence signal minus baseline 
fluorescence; RTN: relative transcript number)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RTN: 100,000 RTN: 10
A
B
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Normalization: 
Accurate normalization of gene expression levels is an absolute prerequisite to obtain 
reliable results. Because the expression of a single housekeeping gene can vary 
considerably, several references genes should be combined to calculate a normalization 
factor (33). In this study, TH, GALGT and ELAVL4 transcript numbers were normalized to 
two reference genes (beta-2-microglobulin (B2M) (34) and ubiquitin C (UBC)) by dividing the 
relative transcript number of the target genes by the geometric mean of the transcript number 
of the two reference genes.  
PCR conditions: 
All PCR reactions were performed on an ABI Prism 7700 Sequence Detection System 
(Applied Biosystems). A 3-by-3-primer matrix (combination of 300, 600 and 900 nM of each 
forward and reverse primer) was analyzed to determine the optimal primer concentrations. In 
addition, three different MgCl2 concentrations (3, 5 and 7 mM) were evaluated. The 
concentrations resulting in the lowest threshold cycle and the highest fluorescent signal were 
chosen. PCR samples were prepared as follows. Five µl of cDNA was added to the reaction 
mixture and every sample was analyzed in duplicate. The amplification mixture for TH (25 µl) 
contained 1x TaqMan Buffer A (Applied Biosystems), 5 mM MgCl2 (Applied Biosystems), 1.2 
mM of each deoxynucleotide triphosphate (Amersham Biosciences), 150 nM of the probe, 
600 nM of the forward and the reverse primer and 0.6 units of AmpliTaq Gold (Applied 
Biosystems). The amplification mixture for GALGT and ELAVL4 (25 µl) contained 1x TaqMan 
Buffer A, 7 mM MgCl2, 1.2 mM of each deoxynucleotide triphopsphate,150 nM of the probe, 
600 nM of both primer and 0.6 units of AmpliTaq Gold.  
Due to their high expression, B2M and UBC were more efficiently amplified in 50 µl than in 
25 µl. A reaction mixture (50 µl) containing 1x TaqMan Buffer A, 5 mM MgCl2, 1.2 mM of 
each deoxynucleotide triphopsphate,150 nM of the probe, 600 nM of both primer and 1.25 
units of AmpliTaq Gold was used. 
The conditions for the PCR were 10 minutes at 95 °C, 50 cycles at 95 °C for 30 seconds and 
60 °C for 1 minute. 
 
Immunocytochemistry 
Cytospins were immunocytochemically stained as described previously (16). Briefly, large 
diameter (17 mm) cytospins containing 5.105 mononuclear cells were incubated with an 
unlabeled monoclonal antibody against GD2 disialoganglioside. GD2 is expressed by 
neuroectodermally derived tumors such as melanoma, neuroblastoma and small cell 
carcinoma but is not found in normal PB or BM cells. Controls where the primary antibody 
was replaced by buffer were included to evaluate the background staining. During a second 
and a third incubation step, cells were incubated with a polyclonal goat anti-mouse antibody 
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and a polyclonal rabbit anti-goat antibody, respectively. Both were labeled with alkaline 
phosphatase. The bound alkaline phosphatase complexes were stained using the new 
fuchsin chromogen. The cells were counterstained with hematoxylin and examined under a 
light microscope by two independent observers. Preferably six slides, each containing 5.105 
cells, were analyzed. Cells with a round nucleus, a granular chromatin structure, a scarce 
amount of cytoplasm and a strong staining around the entire cell were considered positive. 
Cells with an aberrant morphology or a pink staining restricted to a subcellular compartment 
were called negative. The number of positive single cells and positive cells being part of a 
Homer Wright rosette or cell clump were counted. The number of evaluated mononuclear 
cells was also reported. When the two local observers disagreed or less then 10 positive 
cells were found, pictures of the doubtful cell(s) were sent to an external expert. The results 
were discussed until agreement was reached. We were able to detect one NB cell in 106 
mononuclear cells using this immunocytochemical staining method (16). 
 
Statistics 
After the classification of the results in a frequency table, a χ² test with Yates’ correction for 
continuity was performed to study the relationship between the different categories. The 
Fisher's exact test was computed when a cell in the 2x2 table had an expected frequency 
less than 5. In addition, a Kappa test was used to measure the agreement between the 
different assays.  
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RESULTS 
 
Expression of molecular markers in negative control samples 
The TH, GALGT and ELAVL4 expression was evaluated in 15 PB and 15 BM samples from 
patients without malignant disease. The results are summarized in Table 3.  
Since TH, GALGT and ELAVL4 transcripts were detected in normal PB and BM samples, a 
threshold for positivity, based on the mean normalized transcript number and the standard 
deviation (SD), was defined. All clinical samples with a normalized relative transcript number 
higher than (mean + 4 SD) were considered positive.  
 
Table 3: Normalized expression of TH, GALGT and ELAVL4 in 30 PB or BM samples taken 
from patients without malignant disease. All samples with a normalized relative transcript 
number higher than (mean + 4 SD) were considered positive. (PB: peripheral blood; BM: 
bone marrow; SD: standard deviation) 
 
Nr. Sampe Type TH GALGT ELAVL4
1 PB 0,00E+00 2,43E-05 2,52E-06
2 PB 0,00E+00 2,80E-05 7,74E-06
3 PB 0,00E+00 1,94E-05 1,45E-05
4 PB 2,24E-06 8,30E-06 1,81E-05
5 PB 0,00E+00 9,47E-06 2,78E-06
6 PB 0,00E+00 2,90E-05 9,42E-06
7 PB 0,00E+00 1,86E-05 1,51E-05
8 PB 0,00E+00 3,97E-05 1,56E-05
9 PB 0,00E+00 1,16E-05 1,26E-05
10 PB 0,00E+00 2,78E-05 9,41E-06
11 PB 0,00E+00 4,43E-05 5,36E-06
12 PB 0,00E+00 1,99E-05 7,92E-06
13 PB 0,00E+00 3,31E-05 4,93E-06
14 PB 0,00E+00 2,45E-05 8,37E-06
15 PB 0,00E+00 3,59E-05 2,59E-05
16 BM 1,80E-06 5,87E-05 1,77E-07
17 BM 0,00E+00 0,00E+00 0,00E+00
18 BM 0,00E+00 8,29E-05 6,38E-06
19 BM 0,00E+00 6,66E-04 3,15E-05
20 BM 0,00E+00 4,93E-04 1,66E-06
21 BM 0,00E+00 1,80E-03 0,00E+00
22 BM 0,00E+00 2,93E-05 0,00E+00
23 BM 0,00E+00 5,52E-06 1,55E-06
24 BM 0,00E+00 1,31E-04 0,00E+00
25 BM 0,00E+00 2,55E-04 1,73E-06
26 BM 0,00E+00 4,66E-05 0,00E+00
27 BM 0,00E+00 6,24E-05 2,17E-06
28 BM 0,00E+00 2,75E-04 1,37E-06
29 BM 0,00E+00 3,37E-05 0,00E+00
30 BM 0,00E+00 5,09E-05 7,41E-07
Mean 1,35E-07 1,45E-04 6,92E-06
SD 5,15E-07 3,46E-04 8,08E-06
Mean + 4 SD 2,20E-06 1,53E-03 3,92E-05  
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Sensitivity of the QPCR assays 
The sensitivity of the TH, GALGT and ELAVL4 real-time quantitative RT-PCR assays was 
assessed by means of spiking experiments and clinical samples. The results are 
summarized in Table 4. 
Different amounts of IMR32 RNA were added to 1 µg of RNA isolated from normal PB 
mononuclear cells. Five 10-fold dilutions (10,000 to 10 pg of IMR32 RNA) were evaluated.  
It was possible to detect 10 pg of IMR32 RNA in 1µg of normal RNA by means of TH and 
ELAVL4 QPCR. The sensitivity of the GALGT assay was lower. Only 100 pg of IMR32 RNA 
was reliably detected. 
Both QPCR and immunocytochemistry were used to screen for residual neuroblastoma cells 
in patient samples. TH and ELAVL4 transcripts were detected in clinical samples containing 
only one neuroblastoma cell per 106 mononuclear cells. The sensitivity of the GALGT QPCR 
assay was lower. No GALGT transcripts were found in clinical samples containing less than 
100 NB cells per 106 mononuclear cells 
 
Table 4: Sensitivity of the TH, GALGT and ELAVL4 QPCR assays. The sensitivity was 
evaluated using spiking experiments and clinical samples. (MNC: mononuclear cells, NB: 
neuroblastoma) 
 
Spiking Experiments Clinical Samples
(pg IMR32 RNA / µg normal MNC RNA) (# NB cells per million normal MNC's)
TH 10 1
GALGT 100 100
ELAVL4 10 1
Detection Limit
 
 
 
TH, GALGT and ELAVL4 expression in clinical samples 
The TH, GALGT and ELAVL4 expression was evaluated in 18 tumor, 70 BM, 5 PB and 4 
PBSC samples from a GNB, a GN and 28 NB patients.  
The three markers were highly expressed in all primary tumors (1 stage 1, 1 stage 2, 6 stage 
3, 7 stage 4, 1 stage 4S and 1 GNB). Even two tumor samples from NB patients without 
elevated catecholamine levels scored positive for TH.  
In addition, 32% (25/79), 11% (9/79) and 38% (30/79) of all BM, PB and PBSC samples 
scored positive for TH, GALGT or ELAVL4, respectively. Based on these results, a clear 
association between the different QPCR assays was found (TH and GALGT: Fisher’s exact 
test: p < 0.0001, κ = 0.44; TH and ELAVL4: χ2 = 20.15 and p < 0.0001, κ = 0.53; GALGT and 
ELAVL4: Fisher’s exact test: p < 0.0001, κ = 0.35).  
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Comparison of real-time quantitative RT-PCR with immunocytochemistry 
The QPCR results of 68 BM, PB and PBSC samples were compared to those of an anti-GD2 
immunocytochemical assay (IC). The latter was considered to be the gold standard.  
When comparing TH or ELAVL4 QPCR with immunocytochemistry, only a few discordant 
results were found. There was a good association between the QPCR and 
immunocytochemical tests (TH and IC: χ2 = 33.74 and p < 0.0001, κ = 0.74; ELAVL4 and IC: 
χ2 = 37.27 and p < 0.0001, κ = 0.77) (Table 5). 
More discordant results were found when GALGT QPCR and immunocytochemistry were 
compared. Fourteen samples were QPCR-/IC+, none were QPCR+/IC-. This reflects the 
difference in sensitivity between both assays. The association between the GALGT QPCR 
assay and the IC test was moderate (Fisher’s exact test: p < 0.0001, κ = 0.46). 
Fourteen diagnostic BM samples from 9 stage 4 patients were analyzed. The results are 
summarized in Table 6. Seven samples scored positive for all three markers. The NB cells 
were also detected by IC and conventional cytomorphology (CM). In one BM sample, only 
TH and ELAVL4 were highly expressed. Another sample scored only positive for TH QPCR. 
In these samples no disseminated NB cells were found by CM or IC. Five BM samples were 
negative for QPCR, IC and CM.  
The TH, GALGT and ELAVL4 expression was also evaluated in 12 diagnostic BM samples 
from 7 stage 3 patients. None of them scored positive for all three markers. However, in 4 
samples ELAVL4 was highly expressed. One sample scored positive for TH QPCR. All 
samples were negative for IC and CM. 
 
Table 5: Comparison of molecular and immunocytochemical results. (IC: immuno-
cytochemistry) 
+ -
TH + 19 4 23 χ2 = 33,74 p < 0,0001
- 4 41 45 κ = 0,74 Good association
23 45 68
+ -
GALGT + 9 0 9 Fisher's exact test p < 0,0001
- 14 45 59 κ = 0,46 Moderate association
23 45 68
+ -
ELAVL4 + 20 4 24 χ2 = 37.27 p < 0,0001
- 3 41 44 κ = 0,77 Good association
23 45 68
IC
IC
IC
 
Minimal Residual Disease 
117 
Potential prognostic value of detection of disseminated NB cells using real-time 
quantitative RT-PCR 
To investigate whether the detection of TH, GALGT and ELAVL4 transcripts could be used to 
study MRD in NB, 30 subsequent BM, PB or PBSC samples from 3 stage 4 patients were 
studied. The samples were taken at diagnosis, during treatment, at relapse or during follow-
up. The QPCR results were compared to immunocytochemical and cytomorphological data 
(Table 6).  
In 14 out of 30 samples (47%) concordant results were found. Four samples scored positive 
in each assay. In 10 samples, no residual NB cells were found.  
Patient 27 with subsequent positive results by IC, TH and ELAVL4 QPCR relapsed 14 
months after diagnosis and died shortly thereafter.  
In several PB and BM samples from patient 26 residual NB cells were found by IC, TH and 
ELAVL4 QPCR. This patient is still in complete remission at the conclusion of this study. 
However, follow-up time is short (3 months).  
Patient 19 tested repeatedly negative at different sampling times and is still alive and disease 
free at the end of his treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Detection of TH, GALGT and ELAVL4 transcripts in BM, PB and PBSC samples 
from stage 3 and stage 4 patients. The samples were taken at diagnosis, during treatment, at 
relapse or during follow up. (Dx: diagnosis; CM: cytomorphology; IC: immunocytochemistry; 
BM: bone marrow; PB: peripheral blood; PBSC: peripheral blood stem cell preparation; NA: 
not analyzed; NE: not evaluable) 
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Patient Sample Stage Timepoint Months after Dx CM IC PCR TH PCR ELAVL4 PCR GD2S
3 BM left 3 Diagnosis 0 - - - - -
BM right 3 Diagnosis 0 - - - - -
4 BM left 3 Diagnosis 0 - - - - -
BM right 3 Diagnosis 0 - - - - -
5 BM 3 Diagnosis 0 - - - - -
6 BM 3 Diagnosis 0 - - - - -
7 BM left 3 Diagnosis 0 - NE + - -
BM right 3 Diagnosis 0 - NE - + -
8 BM left 3 Relapse 33 - - - - -
BM right 3 Relapse 33 - - - - -
BM 3 On Treatment 39 - - - - -
PBSC 3 On Treatment 39 NA - - - -
BM 3 End Therapy 48 - NE - - -
9 BM left 3 Diagnosis 0 - NA - + -
BM right 3 Diagnosis 0 - NA - + -
BM 3 On Treatment 14 - - - - -
11 BM left 3 Diagnosis 0 - NE - - -
BM right 3 Diagnosis 0 - NE - + -
12 BM left 4 On treatment 8 - NA - - -
BM right 4 On treatment 8 - NA - - -
14 BM right 4 Diagnosis 0 + + + + +
15 BM left 4 Diagnosis 0 + + + + +
BM right 4 Diagnosis 0 + + + + +
PB 4 Diagnosis 0 - + + + -
16 BM left 4 Diagnosis 0 - + + + -
BM right 4 Diagnosis 0 - + + + -
18 BM 4 Follow-up 6 - - - - -
BM 4 Follow-up 11 - - - - -
19 BM 4 On treatment 2 - - + - -
BM left 4 On treatment 3 - NE + + -
BM right 4 On treatment 3 - + + + -
PBSC 4 On treatment 3 NA - - - -
BM 4 On treatment 4 - - - - -
BM left 4 On treatment 5 - - - - -
BM right 4 On treatment 5 - + - - -
PB 4 On treatment 5 - - - - -
PBSC 4 On treatment 5 NA - - - -
PBSC 4 On treatment 5 NA - - - -
BM left 4 On treatment 6 - - - - -
BM right 4 On treatment 6 - - - - -
BM left 4 On treatment 8 - - - - -
BM 4 End Therapy 16 - - - - -
20 BM left 4 On treatment 8 - - - - -
BM right 4 On treatment 8 - - - - -
BM left 4 End Therapy 15 - - - - -
BM right 4 End Therapy 15 - - - - -
21 BM 4 Diagnosis 0 - - - - -
22 BM left 4 Diagnosis 0 - - - - -
BM right 4 Diagnosis 0 - - - - -
23 BM left 4 Diagnosis 0 - - - - -
BM right 4 Diagnosis 0 - - + - -
24 BM left 4 On treatment 2 - + - + -
BM 4 On treatment 3 - + - - -
BM left 4 On treatment 5 - - - - -
BM right 4 On treatment 5 - - + - -
BM 4 On treatment 8 - - - - -
BM right 4 On treatment 9 + + + + +
25 BM 4 Diagnosis 0 + + + + +
BM left 4 On treatment 3 - - - - -
BM right 4 On treatment 3 - - + - -
26 BM 4 Diagnosis 0 + + + + +
BM 4 On treatment 2 - + + + -
BM 4 On treatment 3 - + + + -
BM 4 End Therapy 7 - - - + -
PB 4 Follow-up 8 NA - - + -
BM 4 Follow-up 10 - + + - -
27 BM left 4 Diagnosis 0 + + + + +
BM right 4 Diagnosis 0 + + + + +
BM left 4 On treatment 1 - + + + -
BM right 4 On treatment 1 - + + + -
BM 4 On treatment 3 - + + + -
BM 4 On treatment 5 - NA - + -
BM left 4 On treatment 7 - - - + -
BM right 4 On treatment 7 - - - + -
PB 4 On treatment 13 - + - + -
PB 4 On treatment 14 + + + + +  
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DISCUSSION 
 
The detection of residual NB cells in BM has important therapeutic and prognostic 
implications since BM disease is usually associated with unfavorable outcome (35, 36). 
Moreover, the detection of disseminated tumor cells in autologous stem cell preparations 
may signify the need for ex vivo manipulations such as tumor cell purging and/or CD34+ cell 
selection (37).  
The cytomorphological screening of BM smears is still the only accepted technique for the 
detection of disseminated NB cells. However, the sensitivity of this method is limited. 
Therefore, alternative approaches, based on immunology or molecular biology, have been 
developed to improve the detection of rare NB cells. 
In this study, disseminated NB cells were detected by means of TH, GALGT and ELAVL4 
real-time quantitative RT-PCR. This technique offers several advantages compared to other 
methods. In contrast to conventional RT-PCR, no labor-intensive post-PCR processing such 
as gel electrophoresis and hazardous radioactive hybridization is needed to detect and 
quantify PCR products. In addition, carry-over contamination is minimized since both 
amplification and detection are performed within a closed system. Most importantly, real-time 
quantitative RT-PCR allows the detection of a very small number of transcripts and offers a 
wide dynamic range of quantification. As a consequence, this technique is particularly suited 
for monitoring changes in the tumor cell burden throughout the disease course.  
We assessed the TH, GALGT and ELAVL4 expression in 18 primary NB tumors. Each tumor 
sample scored positive for TH, GALGT and ELAVL4. These findings suggest a possible 
applicability for TH, GALGT and ELAVL4 QPCR in the study of MRD in NB.  
In tumor samples from 2 NB patients (stage 3 and 4S) with normal urinary catecholamine 
levels, a strong TH expression was found. This is in accordance with previously published 
results (38). The expression of the molecular markers was also evaluated in 79 BM, PB or 
PBSC samples. Respectively 32%, 11% and 38% of these samples scored positive for TH, 
GALGT or ELAVL4. 
BM samples from 3 patients with a stage 3 neuroblastoma without MYCN amplification, 
scored positive for TH or ELAVL4 at diagnosis. In one of these patients a distal pathological 
lymph node was detected after diagnosis suggesting that this patient was stage 4 in stead of 
stage 3. Fourteen months after diagnosis, an additional BM sample from this patient was 
analyzed but no residual NB cells were found. All three patients are still alive and in complete 
remission at the conclusion of this study.  
Using spiking experiments, we demonstrated that 10 pg of IMR32 RNA in 1µg of normal PB 
mononuclear cell RNA could be detected by TH or ELAVL4 QPCR. The sensitivity of the 
GALGT assay was about ten times lower.  
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The sensitivity of the molecular assays was also assessed using patient samples. QPCR 
results were compared to those of a standardized immunocytochemical assay which was 
considered to be the gold standard. We were able to detect TH and ELAVL4 transcripts in 
clinical samples containing only one NB cell per 106 mononuclear cells. This is in accordance 
with previously published data (38). The sensitivity of GALGT QPCR was lower since no 
GALGT transcripts were found in clinical samples containing up to 100 NB cells per 106 
mononuclear cells. These results are in contrast with those published by Cheung and 
coworkers (39, 40). They evaluated the efficacy of adjuvant immunotherapy in NB patients 
using GALGT real-time quantitative RT-PCR and were able to detect one NB cell in 106 
normal mononuclear cells.  
When TH or ELAVL4 QPCR was compared to immunocytochemistry, only a few discordant 
results were found. The discrepancies were probably due to sample variability (related to 
Poisson’s law) since only a few TH or ELAVL4 transcripts were detected in the QPCR+/IC- 
samples. In addition, less than 10 NB cells per 106 mononuclear cells were found in QPCR-
/IC+ samples. 
More discordant results were found when GALGT QPCR and immunocytochemistry were 
compared. Fourteen samples scored positive for the IC assays. However, no GALGT 
transcripts were detected. This reflects the difference in sensitivity between both assays (IC 
1.10-6 and GALGT 1.10-4).  
The potential prognostic value of the detection of TH, GALGT and ELAVL4 transcripts was 
assessed analyzing 30 subsequent BM, PB and PBSC samples from 3 stage 4 NB patients.  
A 7.5 year old girl suffering from a stage 4 neuroblastoma with MYCN amplification and 1p 
deletion, tested repeatedly positive for IC, TH and ELAVL4 QPCR. In fact, ELAVL4 was 
highly expressed in every PB or BM sample taken during therapy. This child relapsed 14 
months after diagnosis and died of malignant disease shortly thereafter. These preliminary 
data suggest that the persistence of a high ELAVL4 expression has prognostic value. 
Additional studies with larger patient groups are required to confirm these findings. 
A 6 months old girl presented with a stage 4 neuroblastoma without MYCN amplification or 
1p deletion. Several samples, collected at different time points during treatment, scored 
positive for TH and/or ELAVL4. This patient is still in complete remission at the conclusion of 
the study. However, follow-up time is limited (3 months).  
A 6 year old boy diagnosed with a stage 4 neuroblastoma with 1p deletion and no MYCN 
amplification, tested repeatedly negative at different time points during therapy. This boy is 
still alive and in complete remission.  
These data indicate that ELAVL4 and TH QPCR can be used to study bone marrow 
involvement in clinical samples collected during therapy or follow up. By contrast, 
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conventional cytomorphology and GALGT QPCR are not sensitive enough to study MRD and 
can only be used at diagnosis or relapse. 
In conclusion, real-time quantitative RT-PCR for ELAVL4 mRNA can be used to study 
minimal residual disease in a sensitive and reliable way. However, we believe it is essential 
to combine multiple molecular markers (e.g. ELAVL4 and TH) with immunocytochemistry in 
order to avoid false positive or negative results.  
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ABSTRACT 
 
While cyto- and histological screening of bone marrow samples are still accepted as the gold 
standard for initial staging of neuroblastoma patients, these applications are insufficient 
during or after therapy because it is not always possible to detect tumour cell infiltration 
below the level of 1% by morphology alone. For monitoring of minimal residual disease, 
techniques offering a considerably higher sensitivity have been developed. Immunocytology, 
RT-PCR and flow cytometry are most frequently used, but differ with regard to targets (single 
cells, RNA transcripts), measured parameters (tumour cell number, antigen expression, 
cytomorphology, cytogenetic aberrations, level/number of RNA transcripts), specificity (uni-
/multi-parameter analysis) and sensitivity (number of investigated cells). The pros and cons 
of these methods are reviewed. Precise quantification of residual tumour cells in bone 
marrow and blood may show a future impact on risk grouping and therapeutic strategies for 
patients with disseminated disease, but the potential clinical application of these techniques 
has to be preceded by thorough standardisation and validation in multi-centre studies. 
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INTRODUCTION 
  
Since bone marrow infiltration is frequently seen in neuroblastoma patients suffering from 
widespread disease, the detection of tumour cells at this site is a prerequisite for correct 
staging and monitoring of response to therapy [1,2]. For more than 20 years, morphological 
screening of bone marrow aspirates [3] and trephine biopsies [4] has been the gold standard, 
based on the identification of clumps or rosettes of tumour cells [5] or accompanying stromal 
changes [6]. Although the majority of comparative studies conceded a higher sensitivity to 
trephine biopsies, in particular when post-chemotherapy specimens were concerned, the 
representativity of biopsies was found to be inferior [7], with a high proportion of inadequate 
samples especially in infants [8]. Considering a detection level of 1% tumour cells for 
cytological and/or histological screening of bone marrow samples [9], it seems conceivable 
that morphological techniques alone were not regarded as reliable and sensitive enough to 
monitor minimal residual disease (MRD). For this purpose, an increasing number of new 
methods have been developed through the last two decades, based on the expression of 
biological, (i.e. immunological, cytogenetic and molecular genetic) markers by circulating 
tumour cells. Most of these techniques have shown a considerable higher sensitivity than 
morphology, and they have been applied to detect tumour cells not only in bone marrow, but 
also in peripheral blood. Provided that adequate controls are included, the identification of 
tumour cells by biological markers may also be expected to introduce a greater level of 
objectivity than morphological assays alone, and thus create the basis for a reliable 
quantification of single tumour cells. At the present, immunocytology with or without 
cytogenetic investigations, molecular genetic analyses (RT-PCR), and flow cytometry are the 
most frequently applied methods and will be briefly reviewed.  
 
 
IDENTIFICATION OF CIRCULATING NEUROBLASTOMA CELLS BY 
IMMUNOCYTOLOGY 
 
Immunocytological methods exploit the properties of monoclonal antibodies to bind to cell 
lineage- or differentiation-associated antigens expressed at high levels by tumour cells. 
Bound antibodies can be visualized by light or fluorescence microscopic detection methods 
and enable the morphological evaluation and quantification at the single cell level which is an 
essential prerequisite when the prognostic significance of very few residual tumour cells is 
addressed. However, due to the restricted specificity of some markers and to certain other 
technical aspects, e.g. shedding of the target antigen from tumour cells on to normal cells, 
not all immunocytological positive cells can be taken as representing tumour cells. Therefore, 
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combinatorial techniques have been developed which aim to verify the neoplastic nature of 
immunostained cells either by co-expression of hematopoietic or non-hematopoietic markers 
or by the presence of cytogenetic abnormalities.  
 
Antigens 
Subsequent to the introduction of the hybridoma technique in 1978, monoclonal antibodies 
were raised against fetal brain and neuroblastoma cell lines [10,11,12,13], and were shown 
to recognize more or less well characterized antigens on neuroblastoma cells. In addition, 
mono- and polyclonal antibodies against established neuronal markers, e.g. neurone specific 
enolase [14], synaptophysin [15] and chromogranin A [16] were reported to bind to primary 
and metastatic tumour cells. However, regarding their reliability to detect MRD in bone 
marrow, many of these markers showed one or several restrictions, i.e. heterogeneous 
labelling of tumour cells in individual patients and cross-reactivity with normal hematopoietic 
cells [17] or differential expression on primary versus metastatic and on undifferentiated 
versus differentiated tumour cells [18]. To control cross-reactivity with hematopoietic cells, 
co-staining with anti-HLA-DR- [19], anti-CD10- [17] or anti-CD45- [20] antibodies were 
proposed. To overcome the heterogeneous inter- and intra-tumoural expression of individual 
markers, some researchers applied simultaneous staining with cocktails of antibodies of 
various specificities [21,22].   
Among all markers summarized so far, two have gained special attention because of their 
relatively high sensitivity and/or specificity in MRD detection. Monoclonal antibody UJ13A 
was reported to be more sensitive and specific than other reagents produced by this group 
[23] and successfully applied also by others [20,24]. It recognizes the neural cell adhesion 
molecule CD56 (N-CAM) [25,26] which is expressed at very high levels by practically all 
neuroblastomas. In contrast to its high sensitivity, its specificity is restricted, because CD56 
is also expressed by osteoblasts and – at considerable lower levels – by natural killer cells, 
subsets of plasma cells and macrophages [20, 27]. The other marker, disialoganglioside 
GD2, is a cell surface glycosphingolipid detected in the vast majority of neuroblastomas 
[13,28,29]. Undifferentiated neuroblasts are strongly positive, while differentiating tumour 
cells gradually loose the antigen [30]. GD2
 
is also expressed by melanomas, gliomas and 
focally in rhabdomyosarcomas and osteosarcomas [30]. GD2-specific antibodies were 
reported not to bind to normal hematopoietic cells [29] which render these reagents highly 
suitable for detection of MRD in the bone marrow. However, this antigen is not only down 
regulated during neuroblastic differentiation, but also continuously shed from the surface of 
neuroblasts [31]. Soluble antigen in the patients plasma can be ingested by bone marrow 
macrophages or unspecificly attach to the surface of hematopoietic cells and thus contribute 
to false positive results (Figure 1: D, E and F). 
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Antibodies against neuroblastoma-associated antigens have also been applied on sections 
of core biopsies in order to detect tumour cells by means of immunohistology. Some of these 
studies showed an increased sensitivity as compared to histomorphology alone [32, 33], but 
immunohistology never gained ground as a generally accepted technique for MRD detection. 
There may be at least three reasons why immunocytological analysis of aspirates prevailed: 
(1) the most specifically expressed molecule, GD2, is easily detected on unfixed, ethanol- or 
formaldehyde-fixed, but not on paraffin-embedded tumour cells. (2) As outlined in the 
introduction, biopsies are, in spite of being more sensitive, often less representative than 
aspirates, and the technical inadequacy of infant biopsies is well documented [8]. (3) The 
precise enumeration of a few positive cells and the obligatory assessment of 
nuclear/cytoplasmic details and subcellular localization of the immunolabel are easier 
achieved in cytological preparations of single cells than tissue sections. This brief review 
focuses therefore exclusively on cytological techniques.  
 
 
Figure1: A-F: Immunocytochemical detection of circulating neuroblastoma cells. Cytospin 
preparations of mononuclear bone marrow cells were stained with anti-GD2 antibody 
14.G2a, alkaline phosphatase anti-alkaline phosphatase (APAAP) and Fuchsin + substrate. 
All images were taken with x60 objective and show identical final magnification. A, B: Criteria 
positive cells (CPC’s), i.e. tumour cells, frequently show a larger nucleus than lymphocytes, 
granular chromatin structure, scarce cytoplasm and strong GD2
 
membrane staining. C: This 
positive cell is considered as NCIC (not convincingly interpretable cell) because it is smaller 
than typical CPC’s and shows a weaker GD2
 
staining leaving out parts of the cell membrane 
(arrow). The true nature of this cell can only be disclosed by additional immunological or 
cytogenetic analyses. D: Two strongly GD2-positive CPC’s shed large amounts of antigen in 
between and on the surface of surrounding normal hematopoietic cells (arrows) simulating 
membrane staining of non-tumour cells. E, F: Shed GD2 antigen is taken up by 
macrophages and monocytes. Note striking cytoplasmic, but not membrane staining (arrows) 
of these cells which distinguishes them from CPC’s. G-H: Immunocytologic/cytogenetic 
analysis. This sample was stained with fluorescein-labelled anti-GD2 antibody (G) and 
subsequently hybridised with a fluorescein-labelled MYCN probe and a Rhodamin-labelled 
reference probe for chromosome 2 (H). Evaluation of each analytical step was performed by 
means of automated immunofluorescence plus FISH (AIPF). In spite of an only moderate 
and discontinuous GD2
 
membrane expression (G), the cell in the centre is proven to be a 
tumour cell by MYCN amplification (H).  
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Immunological detection methods 
Both fluorescence- and light microscopy-based detection methods have been used [24, 34]. 
Each of them has its pros and cons. Light microscopic techniques usually involve 
enzyme/substrate reactions; alkaline phosphatase (AP) has been preferred to horseradish 
peroxidase due to the high amount of peroxidase in normal myelocytes. A light microscopic 
analysis enables the investigator to recognise established cytomorphological criteria for in-
/exclusion of positively stained cells. Moreover, enzymatic staining results are stable over 
time and the immunocytological features of positively stained cells can be reviewed 
simultaneously by several investigators using a multi-headed microscope which is an 
essential element in the process of methodological standardisation between different 
laboratories. However, enzyme-based techniques are unsuited for the synchronous detection 
of a second antigen in the same subcellular localisation, i.e. a hematopoietic membrane 
antigen in addition to membrane GD2, because the molecular complexes of enzyme, 
substrate and chromogen cover an unpredictable number of neighboured epitopes like a 
shield. A combination with fluorochrome-labelled antibodies can neither be recommended 
due to the strong autofluorescence of most chromogens involved in AP/substrate reactions. 
Some individuals present in their bone marrow with very few normal plasma cells producing 
anti-AP antibodies [35] which could bind the enzyme/substrate complex in an unwanted 
manner. However, it is usually unproblematic to discriminate plasma cells from 
neuroblastoma cells on light microscopic grounds, and the presence of such false positive 
cells is detected in appropriate negative controls.  
Fluorescence-based detection methods display features which by and large are inverse to 
those summarised for enzyme-based techniques. Fluorochromes are small molecules which 
do not require chemical reactions for visualisation. They are therefore ideal for the 
simultaneous demonstration of antigens, genes and chromosomes at the single cell level 
(see below). However, not all light microscopically defined cytomorphological features of 
neuroblastoma and hematopoietic cells can be recognised in a fluorescent microscope after 
nuclear staining with DNA-binding dyes e.g. DAPI. Moreover, the staining results cannot be 
reviewed in a multi-headed microscope and fade over time. They have to be documented by 
digital images which do not always contain all optical information about cell size and specific 
label as gained by direct fluorescence microscopy. Cheung and coworkers [36] reported four 
different staining patterns (background cytoplasmic, weak membrane, clear patchy 
membrane, and intense staining of the cell membrane), but no attempts have been published 
so far to standardise the criteria for evaluation and interpretation of fluorescent staining 
results for the purpose of MRD detection among different laboratories.   
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Immunocytology and cytogenetics 
Ambros and Méhes took advantage of the properties of fluorescence-based systems to 
analyse simultaneously the expression of GD2 and of cytogenetic abnormalities in circulating 
neuroblastoma cells. They designed software for automated screening of immunofluorescent 
and fluorescent in situ hybridisation (FISH) signals in single cells [37]. The purpose of this 
approach was to prove the neoplastic origin of GD2–positive bone marrow cells by the 
simultaneous presence of e.g. hypersomy of chromosome 1 or 2, 17q gain, or MYCN 
amplification (fig. 1G and H). They showed that the very few (<10 per 106) GD2–positive cells 
in bone marrow aspirates from stage 1, 2A and B, and stage 3 patients did not carry the 
cytogenetic aberrations known from the corresponding primary tumour, while those of all 
stage 4/4S patients did, and concluded therefore that the vast majority of GD2–positive cells 
in low stage patients do not represent neuroblastoma cells [38].   
 
Clinical significance 
Hallmarks of immunocytological assays for MRD detection are their high sensitivity and the 
enabling of a precise quantification of circulating tumour cells. Since even one single GD2-
positive cell among 106 or even more mononuclear cells can be demonstrated to be a 
neoplastic cell either by certain cytomorphological features, coexpression/lack of other 
antigens or cytogenetic aberrations, the sensitivity of this method depends on the number of 
investigated bone marrow cells and is therefore practically unlimited.  
Some studies aimed to correlate the number of immunocytologically identified tumour cells to 
the patients’ outcome. Moss and co-workers [21] found a statistically significant impact on 
progression-free survival for stage 2 and 3 patients older than one year if their aspirates 
contained more than six tumour cells per 105 bone marrow cells, while the corresponding cut-
off for stage 4 patients below one year was 20 tumour cells per 105. Seeger et al [22] 
performed the so far largest study on 466 patients with metastatic disease. Focusing on 
three-year event-free survival, they concluded that a cut-off of 100 tumour cells per 105 bone 
marrow cells had a statistically significant predictive value when found in aspirates analysed 
before therapy, after 12 weeks, at bone marrow harvest and at the end of induction, but not 
after four weeks of treatment. Only at the time point of bone marrow collection, a lower 
number of tumour cells (20 per 105) could herald an adverse prognosis. The lack of 
prognostic significance of small numbers of circulating tumour cells was ascribed to possible 
sampling variability due to differences in numbers of investigated bone marrow cells. In 
contrast to the data published by Moss et al, the number of bone marrow infiltrating tumour 
cells had no influence on the outcome of stage 3 patients.  
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With regard to peripheral blood, Seeger et al confirmed previous reports indicating 
considerable lower numbers of circulating tumour cells as compared to bone marrow [39, 
40]. The presence of more than one tumour cell per 106 peripheral blood cells foreboded 
reduced event-free survival only when found at diagnosis, but not at the time of marrow 
collection.  
In a recent study, Modritz et al [41] applied the combined immunocytologic/cytogenetic 
detection method in order to address the prognostic significance of bone marrow clearance 
in stage 4 patients at a detection level of one in 106 mononuclear bone marrow cells. With 
regard to five-year survival, a statistically significant difference was found between patients 
obtaining bone marrow clearance within four cycles of chemotherapy and those who did not, 
even at the age of more than one year. However, the predictive value of rapid bone marrow 
clearance was only true for children with MYCN amplification and/or 1p deletion.  
 
Standardization of immunocytological detection 
The immunocytological studies reviewed above appear to disagree on a number of points, 
e.g. the presence and prognostic significance of tumour cells in the bone marrow of low 
stage patients, and the level of tumour cell infiltration which is able to predict the outcome of 
stage 4 patients before and during therapy. It seems highly probable that the differences in 
the results obtained by various laboratories are related to differences in their 
immunocytological methods, spanning from the number of investigated cells to details of the 
staining procedure and individual criteria for evaluation of staining results. In this respect, the 
Bone Marrow Subcommittee of the SIOP European Neuroblastoma Group has made a 
cooperative effort, based on contributions from laboratories in Austria, Belgium, France, 
Germany, Italy, Norway, Spain, Switzerland and UK, in order to standardise an 
immunocytological method for detection of MRD [42]. Since the sensitivity of 
immunocytological investigations varies with the number of investigated cells, the standard 
sample size was set to 3x106, thereby allowing a sensitivity of near one in 106. Further 
standardisation steps comprised the same fixative (formaldehyde), a single monoclonal anti-
GD2 antibody from the same commercial source, and the same detection method based on 
a commercially available alkaline phosphatase anti-alkaline phosphatase (APAAP) system. 
Since GD2 can be taken up or passively stick to normal bone marrow cells from 
neuroblastoma patients (fig. 1D, E and F), cytomorphological inclusion and exclusion criteria 
were developed. Positively stained cells were grouped into criteria-positive cells (CPC’s) (fig. 
1 A, B and D) or not convincingly interpretable cells (NCIC’s) (fig. 1 C), a term applying to 
GD2-positive cells which neither fit unequivocally to CPC’s nor to any known hematopoietic 
category. The validity and reproducibility of this method was tested by quality control rounds 
where the participating laboratories analysed slides from the same aspirate and compared 
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their results. After introduction of the new standard method, the number of discordant results 
reported by individual laboratories decreased significantly (p = 0,013). Another important 
experience gained from this work concerns the evaluation of samples with less than 10 GD2-
positive cells per 106. Among so few stained cells, it can sometimes be difficult to identify 
cells which unequivocally display all inclusion criteria for CPC’s or form characteristic clumps. 
Therefore, these samples and those, which only contain NCIC’s, are subjected to an 
international central review performed by all collaborating laboratories at a multi-headed 
microscope. If no consensus is reached at this level, slides from such samples are analysed 
by the combined immunocytological/cytogenetic method which aims to clarify the neoplastic 
nature of positively stained cells by the presence or absence of cytogenetic aberrations. The 
subsequent steps of this standard procedure are summarised in the workflow scheme 
depicted in Figure 2. It is currently applied to investigate bone marrow aspirates and 
peripheral stem cell collections from patients enrolled in the European High Risk Study and it 
is expected to facilitate an unambiguous identification and quantification of tumour cells as a 
prerequisite for the assessment of prognosis and response to therapy in these patients.   
 
 
Figure 2: Work flow for immunocytologic/cytogenetic MRD analysis within the European 
High Risk Study. Initial sample analysis is performed in the national laboratories applying the 
standardised immunocytochemical method as described in the text. Depending on the 
number of CPC and/or NCIC detected per 106 mononuclear cells (MNC), the stained slides 
are centrally reviewed and a decision is made whether cytogenetic analysis by AIPF 
(automated immunofluorescence plus FISH) must be performed.  
 
 
 
 
FPC’s (AIPF) 
Initial evaluation
Negative sample > 10 CPC’s per 
1x106 MNC’s 
1 to 10 single CPC’s 
per 1x106 MNC’s 
Only NCIC’s 
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No further review Central review 
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MOLECULAR DETECTION OF NEUROBLASTOMA 
 
Methods currently used in routine clinical practice for assessing disease status in 
neuroblastoma typically depend on radiographic studies and assessment of bone marrow for 
infiltrating neuroblastoma cells by Romanovsky stained smears and/or haematoxylin and 
eosin stained trephines. These methods are informative when extensive disease is present.  
However, for 10% of children with stage 4 disease at diagnosis, and most of them during 
follow up, these detection techniques may be suboptimal. Alternative methods with increased 
sensitivity to measure occult tumour cells are important for the early detection of metastases 
and relapse, and may also result in improved accuracy in staging and treatment strategies 
for some children with disease that is currently defined as low risk (stages 1-3). Such 
methods may identify the optimal timing for marrow or peripheral blood stem cell collection, 
and be useful tools to evaluate the efficacy of adjuvant therapies.  
Numerous investigators have used reverse transcriptase polymerase chain reaction (RT-
PCR) for tissue and tumour specific targets to detect minimal disease burden (reviewed in 
[43]). This is most specific when the target mRNA for RT-PCR is tumour specific e.g. the 
EWS-ETS gene rearrangement transcripts in tumours of the Ewing’s sarcoma family. 
However for most solid tumours, including neuroblastoma, such a tumour specific target has 
not yet been defined, leading to the exploitation of tissue specific targets. This approach 
requires the identification of target mRNA expressed in tumour cells but not in the 
compartments to be studied, namely bone marrow and peripheral blood. Using this 
methodology, clinically significant disease has been detected in peripheral blood [44, 45, 46, 
47, 48] and bone marrow [22, 44, 46, 49, 50, 51, 52, 53] samples from children with 
neuroblastoma at diagnosis, on therapy, during follow up and at relapse. From such studies 
the persistent expression of target mRNA in bone marrow or peripheral blood from children 
with stage 4 disease despite intensive chemotherapy, is predictive of relapse [47, 53] and 
suggests the early use of novel therapeutic strategies may be appropriate in these children. 
Such an approach may also provide an early indicator of response and treatment efficacy, for 
example in patients receiving adjuvant immunotherapy [54].  
Neuroblastoma cells express catecholamines, consequently the first enzyme in the 
catecholamine synthesis pathway tyrosine hydroxylase (TH) has successfully been exploited 
for the detection of clinically significant neuroblastoma cells by RT-PCR [55]. Other targets 
for RT-PCR, such as GD2 synthase, the key enzyme for the synthesis of GD2 (a ubiquitous 
and abundant antigen on neuroblastoma [51]), have shown promise as molecular markers. 
Although RT-PCR for TH mRNA detects clinically significant disease with increased 
sensitivity and specificity compared to more conventional methods, it is clear that tumour 
cells are not detected in bone marrow or peripheral blood of all children with high-risk 
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disease. This has been interpreted by some as a “false” negative result, although the 
absence of tumour cells in these samples may reflect the biology of tumour cell shedding, 
dilution of tumour cells within the compartment and technical features such as the volume 
and frequency of samples analysed. In some tumours this might also reflect differences in 
target mRNA expression, suggesting that the detection of tumour cells by RT-PCR may be 
enhanced by using multiple molecular markers to overcome any tumour heterogeneity [56]. It 
is therefore important to identify and evaluate the sensitivity and specificity of new markers, 
as well as to validate their clinical utility.   
The development of semi-quantitative methods, comparing levels of target mRNA to those of 
a house-keeping gene such as β2-microglobulin, has allowed potentially useful evaluation of 
changes in tumour cell burden within peripheral blood of children throughout the disease 
course (Figure 3A) [47]. Recent studies have also used quantitative real-time RT-PCR to 
determine target gene transcript level in clinical samples from children with neuroblastoma 
(Figure 3B) [51, 57, 58, 59]. Such quantitation may allow more precise risk assessments in 
disease monitoring. Real-time quantitative PCR is an attractive technology, with a wide linear 
dynamic range, superior sensitivity, high throughput capacity, and elimination of post-PCR 
handling steps. The selection of an optimal reference gene against which the test samples 
can be normalised is essential [60]; the use of target specific calibrators that allow the 
accurate quantification of transcript number within a sample is desirable [57]. Nevertheless, 
the high sensitivity of the real-time PCR assay can lead to the detection of illegitimate target 
gene transcripts and an increased number of false positives with some targets. Thus, clinical 
validation of these markers detected by real-time RT-PCR is vital.   
Although the capacity to detect neuroblastoma micrometastases does not by itself inevitably 
translate into improved outcome for children with this disease, the ability to detect occult 
tumour cells in the bone marrow and peripheral blood may allow evaluation of new strategies 
targeting this disease (Figure 3C) [48, 55]. The detection of clinically relevant 
micrometastases may also result in a redefinition of what constitutes remission and relapse, 
possibly leading to improved risk-stratification of children for a better curative therapy. 
However, the clinical utility of molecular detection still remains unclear, reflecting the 
relatively small number of children studied and the inconsistency in methodology and 
reporting. Thus, there is a need for large, multi-centre, quality controlled clinical outcome 
efficacy studies to maximize the clinical benefit of RT-PCR detection of disease for children 
with neuroblastoma.  
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Figure 3: A: Detection of TH mRNA by RT-PCR in sequential blood samples (1-10) from a 
child with stage 4 neuroblastoma. (RT+ve = reverse transcriptase present, RT-ve = reverse 
transcriptase absent (negative control), TH = tyrosine hydroxylase mRNA. β2m = β2 
microglobulin mRNA (house-keeping gene), W=water negative control. C1 = RNA from 
neuroblastoma cell line, C2 = 10 neuroblastoma cells spiked into 2ml of whole blood (positive 
controls), M=molecular weight markers.) B: Amplification plot generated by real-time RT-PCR 
for GD2 synthase mRNA, and quantification (against standards) of GD2 synthase mRNA in 
bone marrow samples from children with stage 4 neuroblastoma. C. Potential clinical utility of 
RT-PCR detection of neuroblastoma cells.   
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DETECTION OF RESIDUAL NEUROBLASTOMA CELLS USING CYTOMETRY 
 
The first triple-colour flow cytometric assay for the detection of disseminated neuroblastoma 
cells in peripheral blood or bone marrow was developed by Komada and coworkers [61]. The 
assay was based on the detection of CD9, CD56 and CD45.   
CD9, a 24 kDa Type IV transmembrane protein belonging to the family of tetraspanins, is 
expressed on platelets, pre-B cells, activated and differentiating B cells, activated T cells, 
eosinophils, basophils, monocytes, endothelial and epithelial cells, brain, peripheral nerves 
and muscular cells. Various in vitro studies confirmed the consistent expression of CD9 on 
neuroblastoma cells [62]. The CD56 antibody reacts with 175/220 kDa glycosylated antigen 
isoforms present on natural killer cells. It is also present on a subset of CD4+ and CD8+ T 
cells in peripheral blood, neural derived cells and tumours, large granular lymphocyte and 
myeloid leukaemias, small cell lung carcinomas and myelomas. The neural cell adhesion 
molecule (NCAM) is also expressed on neuroblastoma cells [63]. The leukocyte common 
antigen CD45, present on all human leukocytes but absent on neuroblastoma cells, was 
included as a negative marker. Sorted CD9+/CD56+/CD45- cells were considered to be true 
neuroblastoma cells since all of them showed a neuroblast-like morphology. Using this triple-
colour flow cytometric assay, Komada was able to detect one neuroblastoma cell in 104 to 
105 mononuclear cells.  
Komada’s flow cytometric assay was modified by Nagai et al. [64]. He replaced CD9 with 
CD81 because he suspected that the interaction between CD9 and platelets could lead to 
platelet aggregation. CD81, a 26 kDa member of a multimeric cell surface signal transduction 
complex, is expressed on hematopoietic, endothelial and epithelial cells. The expression of 
CD81 on neuroblastoma cells has also been described [65]. Based on comparative studies, 
the combination of CD81/CD56/CD45 was found to be more sensitive and specific than 
CD9/CD56/CD45 for the detection of disseminated neuroblastoma cells. Nagai was able to 
detect CD81+/CD56+/CD45- cells at a concentration of 0.005%.   
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Warzynski and coworkers evaluated several combinations [66]. Initially, a cocktail of CD45, 
CD56 and cytoplasmic neuron specific enolase (NSE) was used to detect rare 
neuroblastoma cells. This procedure was later refined and modified to a less laborious anti-
GD2/CD56/CD45 test eliminating the cell permeabilization step for cytoplasmic NSE 
analysis. GD2 disialoganglioside is highly expressed by neuroectodermally derived tumours 
such as melanoma, neuroblastoma, small cell carcinoma and glioma. GD2 expression is not 
found in normal bone marrow or peripheral blood samples [36]. Finally, CD81 was added to 
the previous combination. Using patient samples instead of artificially spiked material, 
Warzynski was able to detect neuroblastoma cells in bone marrow at a level of 0.002%.  
Tsang et al. compared the triple-colour CD81/CD56/CD45 flow cytometric assay to tyrosine 
hydroxylase reverse transcriptase-polymerase chain reaction (RT-PCR) and found a 
significant correlation between both techniques [67]. Given the advantage of flow cytometry 
in analysing large cell numbers, Tsang recommended to combine flow cytometry with 
qualitative RT-PCR for TH to assess tumour regression and to monitor minimal residual 
disease in neuroblastoma patients.   
A combination of two four-colour flow cytometric assays (CD9/CD81/CD56/CD45 and anti-
GD2/CD81/CD56/CD45) was used to detect residual neuroblastoma cells in a study 
published by Swerts et al. [68]. Based on spiking experiments, a sensitivity of 1.10-5 was 
reached. When flow cytometric results were compared to immunocytochemical data, a strong 
correlation between both assays was found.   
Flow cytometry has been used in the clinical practice of haematology and oncology for many 
years and has some advantages compared to immunocytochemistry or RT-PCR. Flow 
cytometry provides information on multiple cellular parameters such as cell size, granularity 
and marker expression in a multicolour assay. In addition, it allows the identification of dying 
cells and cellular debris which makes it possible to exclude irreversibly damaged cells which 
are unable to expand. Large numbers of cells can be rapidly screened and the technique is 
relatively simple and cost-effective. One specific advantage of flow cytometry over PCR 
based assays is that it allows direct quantification of MRD rather than extrapolating it from 
amounts of PCR products. This makes quantification easier and more accurate.   
Flow cytometric assays have also limitations. In contrast to immunocytochemistry or RT-
PCR, it is virtually impossible to detect one neuroblastoma cell in 106 or more mononuclear 
cells (0.0001%). However, such an extreme sensitivity may not be relevant. Seeger and 
coworkers reported that the failure to reduce neuroblastoma cells in bone marrow to fewer 
than 100 tumor cells per 105 bone marrow (0.1%) cells within 12 weeks after start of 
treatment has a prognostic value, indicating that the sensitivity of most flow cytometric 
assays is sufficient to study MRD in neuroblastoma patients [22].   
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CONLUSIONS 
 
Immunocytology, RT-PCR and flow cytometry are the most frequently applied techniques for 
detecting MRD in neuroblastoma patients. The sensitivity of cell counting methods 
(immunocytology and flow cytometry) is in the range of 1 tumour cell per 105 to 106 
mononuclear cells or even higher and thus clearly beyond the sensitivity of cyto-
/histomorphological screening. Immunocytology is the oldest of these techniques, and 
enables both a critical cytomorphological evaluation and precise quantification of positively 
stained cells. The simultaneous detection of additional immunological and cytogenetic 
markers is an important tool (1) to exclude false positive cells and (2) to analyse circulating 
tumour cells for other biological and possibly prognostic significant properties. The sensitivity 
of this method is practically unlimited. Also flow cytometry measures the expression of 
antigens on single cells and can easily be used to detect several markers at the same time in 
order to increase the specificity and/or biological information provided by the analysis. 
Compared to immunocytology, flow cytometry is able to screen a much larger number of 
cells in a shorter time, but its sensitivity is limited (1 in 105). RT-PCR is a highly sensitive 
technique which can demonstrate the presence of low levels of tumour-specific RNA 
transcripts in blood and bone marrow. Semi-quantitative RT-PCR and quantitative real-time 
RT-PCR have been designed to analyse the relative level and even the exact number of 
tumour-specific transcripts, respectively. Up to now, the differences between the parameters 
measured by each technique make it difficult to directly compare the sensitivity of 
cytologic/flow cytometric analyses to the one of molecular genetic assays, mainly because of 
two reasons: (1) Due to a possible heterogeneous gene expression between and within 
various tumours, the amount of transcripts identified by RT-PCR does not necessarily 
correspond to the number of tumour cells in the sample. (2) Results of molecular genetic 
analyses are often reported in relation to the volume of investigated blood/bone marrow, but 
not to the total cell number in the sample which may vary tremendously depending on the 
phase of treatment. As outlined previously, the number of investigated cells is an essential 
parameter for calculating the sensitivity of cytologic and flow cytometric investigations.   
Despite all the technical progress which has been made to detect small numbers of 
circulating tumour cells, the clinical significance of these observations remains unclear. 
Published reports disagree on the numbers of bone marrow infiltrating tumour cells which 
appear to have prognostic significance. Large multi-centre studies are needed to address 
these issues and may be expected to identify cut-off levels of tumour cell infiltration/RNA 
transcripts which could be useful to define risk groups and to tailor therapeutic strategies for 
patients suffering from MRD. However, such co-operative efforts can only reach reliable 
conclusions if the involved laboratories apply techniques of identical sensitivity and 
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specificity. It is therefore crucial that all participants agree upon a standardisation of their 
method before starting on this work. The SIOP Europe Neuroblastoma Bone Marrow 
Subcommittee has recently proposed a standardisation of the immunocytological method 
designed for the analysis of bone marrow and peripheral stem cell harvests of children within 
the European High Risk Study, and similar efforts are in progress to standardise molecular 
genetic investigations.   
 
Minimal Residual Disease 
143 
REFERENCES  
 
1. G. Brodeur, R.C. Seeger, A. Barrett, F. Berthold, R.P. Castleberry, G. D’Angio, B. De 
Bernadi, A.E. Evans, M. Favrot, A.I. Freeman, G. Haase, O. Hartmann, F.A. Hayes, L 
Helson, J. Kemshead, F. Lampert, J. Ninane, H. Ohkawa, T. Philip, C.R. Pinkerton, J. 
Pritchard, T, Sawada, S. Siegel, E. Ide Smith, Y. Tsuchida, P.A. Voute, International 
criteria for diagnosis, staging, and response to treatment in patients with 
Neuroblastoma, J. Clin. Oncol. 6 (1988) 1874-1881.  
2. G.M. Brodeur, J. Pritchard, F. Berthold,  N.L. Carlsen, V. Castel, R.P. Castelberry, B. 
De Bernardi, A.E. Evans, M. Favrot, F. Hedborg, M. Kaneko, J. Kemshead, F. Lampert, 
R.E.J. Lee, A.T. Look, A.D.J. Pearson, T. Philip, B. Roald, T. Sawada, R.C. Seeger, Y. 
Tsuchida, P.A. Voute, Revisions of the international criteria for neuroblastoma 
diagnosis, staging, and response to treatment, J. Clin. Oncol. 11 (1993) 1466-1477.  
3. D.R. Head, P.S. Kennedy, R.E. Goyette, Metastatic neuroblastoma in bone marrow 
aspirate smears, Am. J. Clin. Pathol. 72 (1979) 1008-1011.  
4. B. Bostrom, M.E. Nesbit Jr, R.D. Brunning, The value of bone marrow trephine biopsy 
in the diagnosis of metastatic neuroblastoma, Am. J. Pediatr. Hematol. Oncol. 7 (1985) 
303-5.  
5. A.E. Mills, A.R. Bird, Bone marrow changes in neuroblastoma, Pediatr. Pathol. 5 (1986) 
225-234.  
6. M.M. Reid, P.J. Hamilton, Histology of neuroblastoma involving bone marrow: the 
problem of detecting residual tumour cells after initiation of chemotherapy, Br. J. 
Haematol. 69 (1988) 487-490.  
7. M. Brisigotti, D. Medicina, L. Bercich, M.F. Bonetti, G. Fabbretti, C. Gambini, M.S. Lo 
Piccolo, C. Milanaccio, C. Rosanda, A. Garaventa, B. De Bernadi, F. Callea, The 
morphological assessment of bone marrow infiltration in neuroblastoma, Pediatr. Med. 
Chir. 20 (1998) 169-174.  
8. M.M. Reid, B. Roald for the European Neuroblastoma Study Group, Bone marrow 
trephine biopsy in infants. European Neuroblastoma Study Group, Arch. Dis. Child. 77 
(1997) 60-61.  
9. N.K. Cheung, G. Heller, B.H. Kushner, C. Liu, I.Y. Cheung, Detection of metastatic 
neuroblastoma in bone marrow: when is routine marrow histology insensitive?, J. Clin. 
Oncol. 15 (1997) 2807-2817.  
10. R.H. Kennett, F. Gilbert, Hybrid myelomas producing antibodies against a human 
neuroblastoma antigen present on fetal brain, Science 203 (1979) 1120-1121.  
 
 
Minimal Residual Disease 
144 
11. C.P. Reynolds, R.G. Smith, (1982) A sensitive immunoassay for human neuroblastoma 
cells, in: M.S. Mitchell and H.F. Oettgen (Eds) Hybridomas in cancer diagnosis and 
treatment, Raven Press, New York, 1982 pp. 235-240.  
12. J.T. Kemshead, A. Goldman, J. Fritschy, J.S. Malpas, J. Pritchard, Use of panels of 
monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic 
disorders, Lancet 1 (1983) 12-15.  
13. G. Schulz, D.A: Cheresh, N.M. Varki, A.Yu, L.K. Staffileno, R.A. Reisfeld, Detection of 
ganglioside GD2 in tumor tissues and sera of neuroblastoma patients, Cancer Res. 44 
(1984) 5914-5920.  
14. A.P. Dhillon, J. Rode, A. Leathem, Neurone specific enolase: an aid to the diagnosis of 
melanoma and neuroblastoma, Histopathology 6 (1982) 81-92. 
15. V.E. Gould, B. Wiedenmann, I. Lee, K. Schwechheimer, B. Dockhorn-Dworniczak, J.A. 
Radosevich, R. Moll, W. Franke, Synaptophysin expression in neuroendocrine 
neoplasms as determined by immunocytochemistry, Am. J. Pathol. 126 (1987) 243-57.  
16. L.J. Helman, A.F: Gazdar, J.G. Park, P.S. Cohen, J.D. Cotelingam, M.A. Israel, 
Chromogranin A expression in normal and malignant human tissues, J. Clin. Invest. 82 
(1988) 686-690.  
17. T. Sugimoto, T.Sawada, T. Matsumura, J.T. Kemshead, Y. Horii, T. Saida, S. 
Imashuku, Y. Takeuchi, Diagnosis of neuroblastoma metastasis in bone marrow with a 
panel of monoclonal antibodies, Med. Pediatr. Oncol. 16 (1988) 190-196.  
18. M. Nowicki, B. Mis kowiak, Comparison of the cell immunophenotype of metastatic and 
primary foci in stage IV-S neuroblastoma, Folia Histochem. Cytobiol. 40 (2002) 297-
303. 
19. A.E. Evans, G.C. Griffin, M. Tartaglione, R.H. Kennett, A method of detecting 
neuroblastoma in human bone marrow by means of two monoclonal antibodies PI 
153/3 and KE2, Hybridoma 4 (1985) 289-96.  
20. V. Combaret, M.C. Favrot, B. Kremens, I. Philip, C. Bailly, B. Fontaniere, O. 
Gentilhomme, F. Chauvin, J.M. Zucker, J.L. Bernard, T. Philip, Immunological detection 
of neuroblastoma cells in bone marrow harvested for autologous transplantation, Br. J. 
Cancer 59 (1989) 844-847.  
21. T.J. Moss, C.P. Reynolds, H.N. Sather, S.G. Romansky, G.D. Hammond, R.C. Seeger, 
Prognostic value of immunocytologic detection of bone marrow metastases in 
neuroblastoma, N. Engl. J. Med. 324 (1991) 219-226.  
22. R.C. Seeger, C. Patrick Reynolds, R. Gallego, D.O. Stram, R.B. Gerbing, K.K. Matthay, 
Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in 
stage IV neuroblastoma: a Children's Cancer Group Study, J. Clin. Oncol. 18 (2000) 
4067-4076.  
Minimal Residual Disease 
145 
23. D.W. Rogers, J.G. Treleaven, J.T. Kemshead, J. Pritchard, Monoclonal antibodies for 
detecting bone marrow invasion by neuroblastoma, J. Clin. Pathol. 42 (1989) 422-426.  
24. M.C. Favrot, D. Frappaz, O. Maritaz, I. Philip, B. Fontaniere, O. Gentilhomme, C. Bailly, 
J.M. Zucke, J.C. Gentet, J. Kemshead J, T. Philip, Histological, cytological and 
immunological analyses are complementary for the detection of neuroblastoma cells in 
bone marrow, Br. J. Cancer 54 (1986) 637-641.  
25. A. Goldman, G. Vivian, I. Gordon, J. Pritchard, J. Kemshead J, Immunolocalization of 
neuroblastoma using radiolabeled monoclonal antibody UJ13A, J. Pediatr. 105 (1984) 
252-256.  
26. K. Patel, S.E. Moore, G. Dickson, R.J. Rossell, P.C. Beverley, J.T. Kemshead, F.S. 
Walsh, Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal 
antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma, Int. J. 
Cancer 44 (1989) 573-578.  
27. J. Nagai, H. Kigasawa, K. Tomioka, N. Koga, H. Nishihira, T. Nagao, 
Immunocytochemical detection of bone marrow-invasive neuroblastoma cells, Eur. J. 
Haematol. 53 (1994) 74-77.  
28. S.J. Shochat, A.B. Abt, C.L. Schengrund, VCN-releasable sialic acid and gangliosides 
in human neuroblastomas, J. Pediatr. Surg. 12 (1977) 413-418.  
29. N.K. Cheung, U.M. Saarinen, J.E. Neely, B. Landmeier, D. Donovan, P.F. Coccia, 
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells, Cancer 
Res 45 (1985) 2642-2649.  
30. H. Sariola, H. Terävä, J. Rapola, U.M. Saarinen, Cell-surface ganglioside GD2 in the 
immunohistochemical detection and differential diagnosis of neuroblastoma, Am. J. 
Clin. Pathol 96 (1991) 248-252.  
31. S. Ladisch, Z.L. Wu, S. Feig, L.Ulsh, E. Schwartz, G. Floutsis, F. Wiley, C. Lenarsky, R. 
Seeger, Shedding of GD2 ganglioside by human neuroblastoma, Int. J. Cancer. 39 
(1987) 73-76.  
32. B.R. Oppedal, I. Storm-Mathisen, J.T. Kemshead, P. Brandtzaeg, Bone marrow 
examination in neuroblastoma patients: a morphologic, immunocytochemical, and 
immunohistochemical study, Hum. Pathol. 20 (1989) 800-805.  
33. G.S. Crary, T.P. Singleton, J.P. Neglia, P.E. Swanson, J.G. Strickler, Detection of 
metastatic neuroblastoma in bone marrow biopsy specimens with an antibody to 
neuron-specific enolase, Mod. Pathol. 5 (1992) 308-311.  
34. D. Beck, O. Maritaz, N. Gross, M. Favrot, N. Vultier, C. Bailly, I. Villa, O. Gentilhomme, 
T. Philip, Immunocytochemical detection of neuroblastoma cells infiltrating clinical bone 
marrow samples, Eur. J. Pediatr. 147 (1988) 609-612.  
 
Minimal Residual Disease 
146 
35. E. Borgen, K. Beiske, S. Trachsel, J.M. Nesland, G. Kvalheim, T.K. Herstad, E. 
Schlichting, H. Qvist, B. Naume, Immunocytochemical detection of isolated epithelial 
cells in bone marrow: non-specific staining and contribution by plasma cells directly 
reactive to alkaline phosphatase, J. Pathol. 185 (1998) 427-434.  
36. N.K. Cheung, D.D. Von Hoff, S.E. Strandjord, P.F. Coccia, Detection of neuroblastoma 
cells in bone marrow using GD2 specific monoclonal antibodies, J. Clin. Oncol. 4 
(1986) 363-369.  
37. G. Mehes, A. Luegmayr, C.M. Hattinger, T. Lorch, I.M. Ambros, H. Gadner, P.F. 
Ambros, Automatic detection and genetic profiling of disseminated neuroblastoma cells, 
Med. Pediatr. Oncol. 36 (2001) 205-209.  
38. G. Mehes, A. Luegmayr, I.M. Ambros, R. Ladenstein, P.F. Ambros, Combined 
automatic immunological and molecular cytogenetic analysis allows exact identification 
and quantification of tumor cells in the bone marrow, Clin. Cancer Res. 7 (2001) 1969-
1975.  
39. T.J. Moss, D.G. Sanders, Detection of neuroblastoma cells in blood, J. Clin. Oncol. 8 
(1990) 736-740.  
40. L.B. Faulkner, V. Tintori, A. Tamburini, A. Paoli, A. Garaventa, E. Viscardi, F. Tucci, 
A.A. Lippi, B. De Bernardi, G. Bernini, High-sensitivity immunocytologic analysis of 
neuroblastoma cells in paired blood and marrow samples, J. Hematother. 7 (1998) 361-
366.  
41. D. Modritz, R. Ladenstein, I. Ambros, A. Luegmayr, H. Gadner, P.F. Ambros, Tumour 
cell clearance in the bone marrow of stage 4 neuroblastoma – Can it predict outcome?, 
Advances in Neuroblastoma Research, 11
th
 Conference, June 16-19, 2004, Genova.  
42. K. Swerts, P.F. Ambros, C. Brouzes, J.M. Fernandez Navarro, N. Gross, D. Rampling, 
R. Schumacher-Kuckelkorn, A.R. Sementa, R. Ladenstein, K. Beiske, Development 
and standardization of an immunocytochemical assay to detect residual neuroblastoma 
cells, J Histochem Cytochem (2005) in press. 
43. S.A. Burchill, P.J. Selby, Molecular detection of low-level disease in patients with 
cancer, J. Pathol. 190 (2000) 6-14.  
44. T. Kuroda, M. Saeki, M. Nakano, S. Mizutani, Clinical application of minimal residual 
neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction, J. 
Pediatr. Surg. 32 (1997) 69-72.  
45. S.A. Burchill, F.M. Bradbury, P. Selby, I.J. Lewis, Early clinical evaluation of 
neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-
PCR) for tyrosine hydroxylase mRNA, Eur. J. Cancer 31 (1995) 553-556.  
46. K. Shono, T. Tajiri, Y. Fujii, S. Suita, Clinical implications of minimal disease in the bone 
marrow and peripheral blood in Neuroblastoma, J. Pediatr. Surg. 35 (2000) 1415-1420.  
Minimal Residual Disease 
147 
47. S.A. Burchill, I.J. Lewis, K.R. Abrams, R. Riley, J. Imeson, A.D. Pearson, R. Pinkerton, 
P. Selby, Circulating neuroblastoma cells detected by reverse transcriptase polymerase 
chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic 
indicator in stage 4 neuroblastoma in children over 1 year, J. Clin. Oncol. 19 (2001) 
1795-1801.  
48. I.Y. Cheung, A. Sahota, N.K. Cheung, Measuring circulating neuroblastoma cells by 
quantitative reverse transcriptase-polymerase chain reaction analysis, Cancer 101 
(2004) 2303-2308.  
49. Y. Miyajima, K. Horibe, M. Fukuda, K. Matsumoto, S. Numata, H. Mori, K. Kato, 
Sequential detection of tumor cells in the peripheral blood and bone marrow of patients 
with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for 
tyrosine hydroxylase mRNA, Cancer 77 (1996) 1214-1219.  
50. I.Y. Cheung, S.N. Chi, N.K. Cheung, Prognostic significance of GAGE detection in 
bone marrows on survival of patients with metastatic Neuroblastoma, Med. Pediatr. 
Oncol. 35 (2000) 632-634.  
51. I.Y. Cheung, N.K. Cheung, Quantitation of marrow disease in neuroblastoma by real-
time reverse transcription-PCR, Clin. Can. Res. 7 (2001) 1698-1705.  
52. K. Horibe, M. Fukuda, Y. Miyajima, K. Matsumoto, M. Kondo, J. Inaba, Y. Miyashita, 
Outcome prediction by molecular detection of minimal residual disease in bone marrow 
for advanced neuroblastoma, Med. Pediatr. Oncol. 36 (2001) 203-204.  
53. M. Fukuda, Y. Miyajima, Y. Miyashita, K. Horibe, Disease outcome may be predicted by 
molecular detection of minimal residual disease in bone marrow in advanced 
neuroblastoma: a pilot study, J. Pediatr. Hematol. Oncol. 23 (2001) 10-13.  
54. I.Y. Cheung, M.S. Lo Piccolo, B.H. Kushner, N.K. Cheung, Early molecular response of 
marrow disease to biologic therapy is highly prognostic in neuroblastoma, J. Clin. 
Oncol. 21 (2003) 3853-3858.  
55. S.A. Burchill, Micrometastases in neuroblastoma: are they clinically important?, J. Clin. 
Path. 57 (2004) 14-20.  
56. I.Y. Cheung, D. Barber, N.K. Cheung, Detection of microscopic neuroblastoma in 
marrow by histology, immunocytology, and reverse transcription-PCR of multiple 
molecular markers, Clin. Cancer Res. 4 (1998) 2801-2805.  
57. C. Träger, P. Kogner, M. Lindskog, F. Ponthan, A. Kullman, B. Kågedal, Quantitative 
Analysis of Tyrosine Hydroxylase mRNA for Sensitive Detection of Neuroblastoma 
Cells in Blood and Bone Marrow, Clin. Chem. 49 (2003) 104-112.  
 
 
 
Minimal Residual Disease 
148 
58. A. Pession, V. Libri, R. Sartini, R. Conforti, E. Magrini, L. Bernardi, R. Fronza, E. 
Olivotto, A. Prete, R. Tonelli, G. Paolucci, Real-time RT-PCR of tyrosine hydroxylase to 
detect bone marrow involvement in advanced neuroblastoma, Oncol. Rep. 10 (2003) 
357-362.  
59. L.H. Lambooy, C.E. Gidding, L.P. van den Heuvel, C.A. Hulsbergen-van de Kaa, M. 
Ligtenberg, J.P. Bokkerink, R.A. De Abreu, Real-time analysis of tyrosine hydroxylase 
gene expression: a sensitive and semiquantitative marker for minimal residual disease 
detection of neuroblastoma, Clin. Can. Res. 9 (2003) 812-819.  
60. E. Beillard,  N. Pallisgaard, V.H. van der Velde, W. Bi, R. Dee, E. van der Schoot, E. 
Delabesse, E. Macintyre, E. Gottardi, G. Saglio, F. Watzinger, T. Lion, J.J. van Dongen, 
P. Hokland, J. Gabert, Evaluation of candidate control genes for diagnosis and residual 
disease detection in leukemic patients using 'real-time' quantitative reverse-
transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program, 
Leukemia 17 (2003) 2474-2486.  
61. Y. Komada, X.L. Zhang, Y.W. Zhou, H. Inaba, T. Deguchi, E. Azuma, M. Sakurai, Flow 
cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with 
neuroblastoma, Cancer 82 (1998) 591-599.  
62. Y. Komada, E. Azuma, H. Kamiya, M. Sakurai, Phenotypic profile of human 
neuroblastoma cell lines: association with morphological characteristics, Br. J. 
Haematol. 54 (1986) 711-715.  
63. M. Lipinski, M.R. Hirsch, H. Deagostini-Bazin, O. Yamada, T. Tursz, C. Goridis, 
Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and 
neuroblastoma cell lines, Int. J. Cancer 40 (1987) 81-86.  
64. J. Nagai, Y. Ishida, N. Koga, Y. Tanaka, K. Ohnuma, Y. Toyoda, A. Katoh, Y. 
Hayabuchi, H. Kigasawa, A new sensitive and specific combination of 
CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells 
in peripheral blood using flow cytometry, J. Pediatr. Hematol. Oncol. 22 (2000) 20-26. 
65. R. Oren, S. Takahashi, C. Doss, R. Levy, S. Levy, TAPA-1, the target of an 
antiproliferative antibody, defines a new family of transmembrane proteins, Mol. Cell 
Biol. 10 (1990) 4007-4015.  
66. M.J. Warzynski, D.M. Graham, R.A. Axtell, J.V. Higgins, Y.A. Hammers, Flow 
cytometric immunophenotyping test for staging/monitoring neuroblastoma patients, 
Cytometry 50 (2002) 298-304.  
67. K.S. Tsang, C.K. Li, W.C. Tsoi, Y. Leung, M.M.K. Shing, K.W. Chik, V. Lee, M.H.L. Ng, 
P.M.P. Yuen, Detection of micrometastasis of neuroblastoma to bone marrow and 
tumor dissemination to hematopoietic autografts using flow cytometry and reverse 
transcriptase-polymerase chain reaction, Cancer 97 (2003) 2887-2897 
Minimal Residual Disease 
149 
68. K. Swerts, B. De Moerloose, C. Dhooge, B. Brichard, Y. Benoit, G. Laureys, J. Philippé, 
Detection of residual neuroblastoma cells in bone marrow: comparison of flow 
cytometry with immunocytochemistry, Cytometry 61 (2004) 9-19.  
 
  
 
 
 
 
Minimal Residual Disease 
151 
3. Clinical importance of neuroblastoma micrometastases 
3.1. Staging and risk assessment at diagnosis 
Evaluation of bone marrow aspirates and biopsies is essential for clinical staging and risk 
assessment at diagnosis. The presence of neuroblastoma cells in diagnostic bone marrow 
samples identifies those children with an unfavorable prognosis by association with disease 
stage.197,198 Standard cytology reveals bone marrow metastases in 80% to 90% of stage 4 
patients.114,197,198 By contrast, 95% to 100% of these children are positive when analyzed by 
immunocytochemistry or RT-PCR suggesting that the prevalence of bone marrow 
involvement is underestimated by conventional cytomorphology.196,202,203 The detection of 
occult neuroblastoma cells in diagnostic bone marrow samples from children with stage 4 
disease is unlikely to have an effect on outcome since these patients are already classified 
as high risk and treated accordingly. By contrast, it might be clinically relevant to use 
sensitive techniques to screen for bone marrow involvement in children with apparently 
localized disease.196,204 Whether or not these patients would benefit from upstaging and more 
aggressive treatment remains to be evaluated.  
Several research groups evaluated the clinical importance of circulating neuroblastoma cells 
in peripheral blood at diagnosis. Seeger and colleagues found a significant association 
between circulating neuroblastoma cells and unfavorable outcome in stage 4 patients over 1 
year of age.205 These results were confirmed by Burchill and coworkers.206 In addition, 
detection of circulating tumor cells in peripheral blood of stage 3 patients appears to correlate 
with poor prognosis.204,207 
 
3.2. Monitoring disease course and response to therapy 
Several reports link the detection of minimal residual disease in bone marrow during therapy 
to outcome in high-risk neuroblastoma patients. Saarinen and coworkers used a sensitive 
immunologic assay to monitor in vivo bone marrow purging in children with high-risk 
neuroblastoma. The purging efficacy during the first 3 months after diagnosis was a strong 
prognostic factor reflecting tumor responsiveness to therapy.208 Seeger and colleagues 
evaluated bone marrow samples from 466 children with high-risk metastatic neuroblastoma 
and reported that patients with more than 100 tumor cells per 105 nucleated bone marrow 
cells after three to four cycles of chemotherapy had virtually no chance of survival.205 Fukuda 
et al. published similar results.203,209 The persistence of MRD in bone marrow, four months 
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after the start of chemotherapy, was a poor prognostic parameter in high-risk 
neuroblastoma.203,209 Tchirkov and coworkers used tyrosine hydroxylase (TH) real-time RT-
PCR to study residual disease in bone marrow. The overall survival for patients with more 
than 1000 TH copies in bone marrow after initial chemotherapy was significantly worse.210 
Cheung and colleagues evaluated the clinical relevance of micrometastases in bone marrow 
at the end of treatment.211,212 Their studies showed that detection of GAGE or GD2 
synthetase transcripts in bone marrow, 24 months after completion of intensive therapy 
combined with anti-GD2 antibody immunotherapy, correlated with poor event-free survival. 
The detection of residual neuroblastoma cells in peripheral blood from clinically disease-free 
children is also associated with rapidly progressing disease and high relapse rate.206 
Preliminary studies have shown that neuroblastoma cells can be detected in peripheral blood 
up to 11 months before urinary catecholamine concentrations increase and clinical relapse 
occurs.206 Whether treatment of this low-level disease will offer a survival advantage remains 
unclear.  
 
3.3. Screening of autologous stem cell preparations 
High-dose chemotherapy and subsequent hematopoietic rescue are widely used in the 
treatment of high-risk neuroblastoma patients. Despite this intensive therapy, many children 
relapse. The clinical significance of re-infusing neuroblastoma cells during transplantation 
procedures has been a matter of debate. However, recent studies have shown that 
circulating neuroblastoma cells are highly colonogenic and, if re-infused, could lead to 
system recurrence.199,201,213 In addition, Tchirkov and colleagues found a relationship 
between increased levels of TH transcripts in peripheral blood stem cell (PBSC) harvests 
and reduced survival.210 A similar tendency was observed by Burchill and coworkers.214 The 
correlation between tumor cell detection in PBSC harvests and poor post-transplant clinical 
outcome supports a role for re-infused tumor cells in relapse. Consequently, the use of 
purged PBSC collections is believed to reduce the risk of relapse post-transplant. However, it 
remains unclear whether such procedures would offer a clinical advantage. 
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4. Discussion and future perspectives 
Conventional cytomorphology is still the only accepted technique for the detection of 
disseminated neuroblastoma cells in bone marrow, peripheral blood and PBSC harvests. 
This method is informative at diagnosis or relapse when overt metastases are present. 
However, it cannot be used to detect occult neuroblastoma cells in clinical samples collected 
during therapy or follow up because of its limited sensitivity (at the best 1.10-3).113 
Consequently, sensitive methods for the detection of rare neuroblastoma cells and the 
evaluation of their clinical significance are urgently needed. Assays based on 
immunocytochemistry, flow cytometry and real-time quantitative RT-PCR were developed 
and evaluated (reviewed in Paper 7).  
 
In collaboration with the SIOPEN Bone Marrow Subcommittee, we developed, optimized and 
standardized an immunocytochemical assay, formulated morphological and immunological 
criteria and designed a work flow (Paper 4). Four important improvements were achieved: 1) 
a sensitivity of 10-6 was reached, 2) the concordance between the different observers, with 
regard to staining and evaluation of results, increased significantly, 3) the range between the 
highest and lowest reported result was reduced by half and 4) discordant results were only 
found in samples with less than 10 CPC’s per 1.106 mononuclear cells. We describe the first 
internationally standardized protocol for detection and quantification of occult neuroblastoma 
cells by immunocytochemistry. Our method is a valuable tool for multicenter studies 
evaluating the clinical significance of minimal residual disease in neuroblastoma.  
 
In paper 5, two four-color flow cytometric assays using different combinations of CD9, CD81, 
CD56, CD45 and anti-GD2 disialoganglioside are described. The sensitivity of both tests was 
assessed using spiking experiments and the results were compared to those of an 
immunocytochemical reference assay. The flow cytometric assays were less sensitive than 
the immunocytochemical test which was considered to be the gold standard. However, as 
few as one neuroblastoma cell in 104 to 105 mononuclear cells could be detected. Since 
Seeger et al. reported that a sensitivity of 0.1% after three to four cycles of therapy most 
likely represents the clinically useful threshold,205 we still believe that flow cytometry can be 
used to study MRD in neuroblastoma. 
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Within the framework of this thesis, disseminated neuroblastoma cells were also detected by 
means of real-time quantitative RT-PCR (QPCR) (Paper 6). The expression of three different 
genes (tyrosine hydroxylase, GALGT and ELAVL4) was evaluated. We were able to detect 
ELAVL4 and TH transcripts in clinical samples containing only one neuroblastoma cell per 
106 mononuclear cells whereas no GALGT transcripts were found in samples containing up 
to 100 neuroblastoma cells per 106 mononuclear cells. The potential prognostic value of TH, 
GALGT and ELAVL4 QPCR was assessed by analyzing subsequent samples from stage 4 
patients. Preliminary results indicate that persistence of high ELAVL4 expression is 
associated with unfavorable outcome. However, further studies are needed to confirm these 
results. 
 
Several research groups found a relationship between sensitive detection of disseminated 
neuroblastoma cells in peripheral blood, bone marrow and PBSC harvests during or after 
therapy and unfavorable outcome.196,203-211,214-216 On the basis of these data, one might be 
tempted to use the detection of residual neuroblastoma cells during or after treatment as a 
prognostic factor to identify patients at risk for relapse. However, prudence is called for since 
therapies used after MRD detection may decrease the significance of neuroblastoma 
micrometastases. Indeed, Seeger and coworkers reported that residual neuroblastoma cells 
detected in bone marrow harvested for autologous hematopoietic stem cell transplantation 
(AHSCT) in patients who were not treated with the differentiation inducer 13-cis retinoic acid 
(13-cis-RA) correlated with poor EFS. However, this was not the case for patients 
randomized to receive 13-cis-RA. Other differences in treatment regimens such as purging of 
stem cell harvests could also influence the clinical significance of MRD detected during 
induction therapy. By contrast, detection of tumor cells in peripheral blood or bone marrow 
after completion of therapy may be less influenced by differences in therapeutic approach. 
However, the prognostic value of neuroblastoma micrometastases in post-treatment samples 
from patients treated with 13-cis-RA could differ from the clinical relevance of residual tumor 
cells in samples from children not treated with this differentiation inducer. Viable but 
terminally differentiated non-proliferating tumor cells could persist in bone marrow or 
peripheral blood for months to years after therapy without leading to progressive disease.  
 
Large and well controlled clinical studies are indispensable to determine the prognostic 
significance of disseminated neuroblastoma cells in bone marrow, peripheral blood or PBSC 
collections. MRD evaluation before, during and after therapy is an integral part of the ongoing 
high risk study of the International Society of Pediatric Oncology European Neuroblastoma 
(SIOPEN) group. Bone marrow, peripheral blood and PBSC samples, collected at various 
time points during therapy, will be analyzed by immunocytology and RT-PCR. The large 
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number of uniformly treated patients will provide the statistical power needed to define the 
prognostic value of MRD in neuroblastoma. However, large cooperative studies can only 
reach reliable conclusions if all involved laboratories use standardized detection techniques.  
 
In conclusion, accurate detection of disseminated tumor cells will improve staging, risk 
assessment, therapy stratification and monitoring of therapeutic response in neuroblastoma 
patients. Moreover, the more sensitive and specific detection of micrometastases may 
ultimately lead to a redefinition of important clinical terms such as ‘disease free’ and 
‘relapse’. We believe large multicenter, quality controlled, prospective clinical studies are 
indispensable to determine the clinical usefulness of MRD detection in neuroblastoma. Such 
studies will generate data which will ultimately lead to an improved outcome for children. 
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Summary 
Well designed multimodal treatment regimens have led to a significant improvement in long-
term event-free survival of children diagnosed with cancer. However, a substantial number of 
patients relapses and cannot be cured with modern therapy. The identification of features 
predicting a patient’s response to therapy has been a continuing goal of researchers working 
in the field of pediatric hematology-oncology. These prognostic parameters are used for risk 
assessment and therapy stratification: low risk patients are treated with less intensive and 
toxic chemotherapy, whereas high risk patients receive a more aggressive treatment. 
Recently, two approaches have become popular: 1) screening for transmembrane protein-
mediated multidrug resistance (MDR) in childhood ALL and 2) minimal residual disease 
(MRD) analysis in neuroblastoma. 
 
Intrinsic or acquired resistance, mediated by transmembrane transport proteins, is one of the 
most important causes of treatment failure in childhood ALL. Several multidrug resistance-
related drug efflux pumps have been characterized (e.g. P-glycoprotein, multidrug 
resistance-associated protein, lung resistance protein and breast cancer resistance protein) 
but their clinical relevance in childhood ALL remains controversial. The lack in standardized 
detection techniques hampers the comparison of data. Moreover, most assays are not 
sensitive enough to detect low-level resistant cells. Consequently, one of our major goals 
was the development, evaluation and optimization of a more sensitive and specific detection 
technique for the assessment of P-glycoprotein activity. In addition, the clinical relevance of 
P-glycoprotein expression and activity in childhood ALL was evaluated in a prospective study 
and current knowledge about the clinical relevance and prognostic value of multidrug 
resistance-related proteins in pediatric ALL patients was summarized. Several researchers 
found a relationship between P-gp, LRP, BCRP, and MRP3 expression and/or activity and an 
unfavorable prognosis in childhood ALL. However, larger multicenter studies are needed to 
confirm these results. 
 
Reliable detection of neuroblastoma cells in bone marrow and peripheral blood is crucial for 
correct clinical staging and risk assessment at diagnosis and monitoring therapeutic 
response during treatment. Moreover, screening of autologous stem cell preparations is 
crucial since the re-infusion of contaminated stem cell products could lead to systemic 
recurrence. Conventional cytomorphological screening of bone marrow aspirates and 
biopsies is only informative at diagnosis or relapse when overt metastases are present but it 
cannot be used to detect occult neuroblastoma cells in clinical samples collected during 
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therapy or follow up because of its limited sensitivity. Consequently, sensitive methods for 
the detection of rare neuroblastoma cells and the evaluation of their clinical significance are 
urgently needed. As part of this study, sensitive and specific assays based on 
immunocytochemistry, flow cytometry and real-time quantitative RT-PCR were developed, 
evaluated and standardized. In addition, data on clinical importance of disseminated disease 
was reviewed. Several research groups found a relationship between sensitive detection of 
disseminated neuroblastoma cells in peripheral blood, bone marrow and PBSC harvests 
during or after therapy and unfavorable outcome. However, international, quality controlled, 
prospective clinical studies are indispensable to confirm these preliminary results. 
 
In conclusion, the detection techniques developed within the framework of this thesis allow 
the accurate assessment of multidrug resistance and minimal residual disease in childhood 
malignancies. This will improve risk classification and therapy stratification and may 
ultimately result in increased long term survival for children with cancer. In addition, an 
overview of the clinical relevance of the above mentioned prognostic parameters is given. 
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Samenvatting 
Door de ontwikkeling van efficiëntere behandelingsschema’s is de lange termijn overleving 
van kinderen met kanker significant verbeterd. Toch volstaan de beschikbare therapeutische 
middelen niet om alle patiëntjes te genezen. Men is op zoek naar klinische, biologische en/of 
genetische prognostische parameters om kinderen met kanker in verschillende risicogroepen 
in te delen. Patiëntjes met goede prognostische eigenschappen worden minder intensief 
behandeld terwijl kinderen met ongunstige prognostische factoren agressievere therapie 
ontvangen. Recent werden twee nieuwe prognostische parameters beschreven. Enerzijds 
zou de expressie en activiteit van resistentie-gerelateerde transporteiwitten in leukemische 
cellen met een ongunstige prognose gepaard gaan. Anderzijds zou er een verband bestaan 
tussen de detectie van residuele neuroblastoomcellen in beenmerg (afgenomen tijdens de 
behandeling) en een verhoogde kans op herval. 
 
Intrinsieke of verworven chemotherapieresistentie is één van de meest belangrijke oorzaken 
van therapeutisch falen bij kinderen met ALL. Er kunnen verschillende mechanismen 
aanleiding geven tot multidrug resistentie (MDR), maar cellulaire resistentie, veroorzaakt 
door overexpressie van transmembranaire transporteiwitten, is het best bestudeerd. Deze 
transporteiwitten pompen chemotherapeutica uit de cel en verminderen zo de intracellulaire 
toxiciteit. Er zijn verschillende MDR-pompen beschreven (o.a. P-gp, MRP1, BCRP en LRP) 
maar hun klinisch en prognostisch belang bij ALL patiëntjes blijft onduidelijk ondanks 
diepgaand onderzoek. Door een gebrek aan gestandaardiseerde detectietechnieken is het 
moeilijk om de resultaten van de verschillende studies met elkaar te vergelijken. Bovendien 
zijn de gebruikte testen vaak niet gevoelig genoeg om weinig resistente tumorcellen op te 
sporen. Daarom werd er in het kader van deze thesis een nieuwe, gevoelige en specifieke 
techniek ontwikkeld om de P-gp activiteit te bepalen. Het klinische belang van P-pg 
expressie en activiteit bij kinderen met ALL werd in een prospectieve studie geëvalueerd en 
de bestaande informatie over het klinische en prognostische belang van de andere multidrug 
resistentie eiwitten werd samengevat. Verschillende onderzoekers vonden een verband 
tussen P-gp, LRP, BCRP en MRP3 expressie en/of activiteit en een ongunstige prognose bij 
kinderen met ALL. Verder onderzoek zal uitwijzen of deze resultaten bevestigd kunnen 
worden.  
 
De betrouwbare detectie van tumorcellen in beenmerg van neuroblastoompatiënten is zeer 
belangrijk in het kader van een correcte stagering en risico-evaluatie op het moment van 
diagnose en de bepaling van de therapeutische respons tijdens de behandeling. Daarnaast 
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is ook het screenen van autologe stamcelcollectes van belang omdat de reïnfusie van 
tumorcellen aanleiding kan geven tot herval. De cytomorfologische beoordeling van 
beenmerg uitstrijkjes is enkel informatief bij diagnose of herval wanneer het beenmerg 
massaal ingenomen is. Door een gebrek aan gevoeligheid kan deze techniek echter niet 
gebruikt worden om residuele tumorcellen op te sporen tijdens de therapie. Meer gevoelige 
en specifieke detectietechnieken zijn dan ook dringend nodig. Wij ontwikkelden en 
standaardiseerden nieuwe specifieke en gevoelige methodes op basis van 
immunocytochemie, flowcytometrie en ‘real-time’ kwantitatieve RT-PCR. Daarnaast werd het 
klinische belang van minimale residuele ziekte bij kinderen met neuroblastoom bestudeerd. 
Verschillende onderzoekers toonden aan dat residuele ziekte met een verhoogde kan op 
herval geassocieerd is. Internationale, gestandaardiseerde studies zijn echter nodig om deze 
preliminaire resultaten te bevestigen. 
 
Met behulp van de detectietechnieken die in het kader van deze thesis ontwikkeld werden, 
kan het belang van multidrug resistentie en minimale residuele ziekte bij kinderen met kanker 
nauwkeuriger bepaald worden. Dit kan tot een verbeterde risico-evaluatie en 
therapiestratificatie leiden wat uiteindelijk moet resulteren in een verbeterde lange termijn 
overleving voor kinderen met kanker.  
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Résumé 
Grâce au développement récent de schémas thérapeutiques combinés, la survie à long 
terme des enfants atteints de cancer s’est considérablement améliorée. Cependant, même 
les thérapies actuelles ne permettent pas encore la guérison d’un nombre significatif de 
patients en rechute. La recherche de facteurs biologiques et génétiques prédictifs d’une 
réponse au traitement représente un objectif majeur pour les pédiatres oncologues. 
L’identification de marqueurs à haute valeur pronostique permet d’orienter le traitement et de 
classer plus précisément les patients dans différents groupes de pronostic. Ainsi un patient 
appartenant à un groupe de risque faible bénéficiera d’un traitement peu agressif et moins 
toxique, alors qu’un patient avec une tumeur présentant des marqueurs de pronostic 
défavorable recevra d’emblée un traitement intensif. Deux approches sont actuellement 
privilégiées: 1) La recherche de la protéine transmembranaire (P-gp) responsable de la 
chimio-résistance multiple (MDR) chez les enfants atteints de LLA, et 2) la détection de la 
maladie résiduelle minime chez les patients atteints de neuroblastome.  
 
La chimio-résistance, intrinsèque ou acquise, en particulier celle causée par la surexpression 
des protéines de transport transmembranaire, est l’une des causes majeures de l’échec 
thérapeutique chez les enfants souffrant de LLA. Plusieurs mécanismes de reflux conduisant 
à une résistance multiple aux drogues ont été décrits (entre autres P-gp, MRP1, BCRP et 
LRP), mais leur signification clinique chez les patients avec LLA est encore controversée. 
L’absence de standardisation des techniques de détection ne permet pas la comparaison 
des différentes études. De plus, la sensibilité des méthodes actuelles est encore insuffisante 
pour détecter de rares cellules tumorales à faible niveau de résistance. C’est pourquoi un 
objectif majeur de ce travail a été le développement, l’évaluation et l’optimisation d’une 
méthode sensible et spécifique de mesure de l’activité des P–gp. Sa relevance clinique chez 
les enfants souffrant de LLA a été évaluée dans une étude prospective et une synthèse de 
l’état des connaissances actuelles sur la valeur des autres protéines de chimio-résistance 
multiple a été réalisée. Plusieurs études ont montré un lien entre l’expression et/ou l’activité 
de P-gp, LRP, BCRP et MRP3 et une évolution défavorable de la maladie chez les enfants 
souffrant de LLA. Cependant des investigations plus poussées doivent encore confirmer ces 
résultats. 
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La détection fiable d’une infiltration médullaire par des cellules de neuroblastome représente 
au diagnostic une donnée essentielle pour établir le bilan d’extension et évaluer le pronostic, 
et ensuite pour mesurer la réponse au traitement. De plus le screening des préparations 
d’aphérèse est indispensable afin d’assurer une réinfusion de cellules souches exempte de 
cellules tumorales, qui dans le cas contraire pourrait conduire à une rechute. L’analyse 
cytomorphologique classique de la moelle osseuse n’est informative que dans les cas 
d’invasion massive de la moelle au diagnostic ou lors de rechute. En revanche, le manque 
de sensibilité de cette technique ne permet pas la détection de micrométastases ou de la 
maladie résiduelle minime. Il est donc urgent de disposer de méthodes sensibles et 
spécifiques. Nous avons développé et standardisé des analyses sensibles faisant appel à 
des techniques d’immunocytochimie, de cytométrie de flux, de PCR quantitative en real-time. 
En plus, les résultats sur la valeur clinique des micrométastases chez des enfants souffrant 
de neuroblastome ont été analysés. En effet, plusieurs chercheurs ont démontré qu’une 
maladie résiduelle minime pouvait être associée à une probabilité élevée de rechute. Des 
études internationales et standardisées seront nécessaires pour confirmer ces résultats 
préliminaires. 
 
En conclusion, les méthodes de détection développées dans le cadre de cette thèse ont 
permis la mise en évidence précise et sensible des phénomènes de chimio-résistance 
multiple et de maladie résiduelle minime chez les enfants atteints de cancer. Il pourrait en 
résulter une meilleure évaluation du risque évolutif et une anticipation thérapeutique avec 
une amélioration de la survie à long terme chez les enfants atteints de cancer. 
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Abbreviations 
13-cis-RA: 13-cis retinoic acid 
ABC: ATP-binding cassette 
AHSCT: autologous hematopoietic stem cell transplantation 
ALL: acute lymphoblastic leukemia 
AML: acute myeloid leukemia 
B-ALL: precursor B-cell lymphoblastic leukemia 
BCRP: breast cancer resistance protein 
CD: cluster of differentiation 
CNS: central nervous system 
CPC: criteria positive cell 
CT-scan: computed tomography scan  
c: cytoplasmic 
del: deletion 
dmin: double minute chromosomes 
DNA: deoxyribonucleic acid 
EFS: event-free survival 
FAB: French-American-British 
GALGT: GD2 synthetase (β1,4-N-acetylgalactosaminyltransferase) 
HSR: homogeneously staining regions 
HVA: homovanillic acid 
INPC: International Neuroblastoma Pathology Committee 
INSS: International Neuroblastoma Staging System 
JC-1: 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethilbenzimidazolcarbocyanine iodide 
LDH: lactate dehydrogenase 
LOH: loss of heterozygosity 
LRP: lung resistance protein 
Mb: megabases  
MDR: multidrug resistance 
MIBG-scan: metaiodobenzylguanidine scan 
MKI: mitosis-karyorrhexis index  
MRD: minimal residual disease 
MRI-scan: magnetic resonance imaging scan 
mRNA: messenger RNA 
MRP: multidrug resistance-associated protein 
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NAG: neuroblastoma amplified gene 
NC: negative cell 
NCIC: not convincingly interpretable cell 
PAS: periodic acid Schiff 
PBSC: peripheral blood stem cell 
P-gp: P-glycoprotein 
QPCR: real-time quantitative RT-PCR 
rho123: rhodamine 123 
RNA: ribonucleic acid 
RT-PCR: reverse transcriptase-polymerase chain reaction 
SIOPEN: International Society of Pediatric Oncology European Neuroblastoma group 
sP-gp: sister of P-glycoprotein 
T-ALL: precursor T-cell lymphoblastic leukemia 
TAP: transporter associated with antigen processing 
TCR: T cell receptor 
TdT: terminal deoxynucleotidyl transferase 
TH: tyrosine hydroxylase 
VMA: vanillylmandelic acid 
WHO: World Health Organization 
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ook nog andere dingen belangrijk waren in het leven.  
 
Allemaal heel erg bedankt! 
 
Katrien 
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